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Abstract of this thesis 
 
Background - The natural history, predictors and outcomes of stroke 
recurrence after first-ever stroke have been insufficiently investigated. The 
available evidence shows great variation and does not provide a consensus of 
key predictors of stroke recurrence or a critical time-period for stroke 
recurrence occurring after initial stroke. This thesis uses data collected from 
the population-based South London Stroke Register to estimate the natural 
history of stroke recurrence after first-ever stroke.  
 
Methods - Data were collected over 12 years from all individuals known to 
have had an initial and first recurrent stroke from the South London Stroke 
Register. The cumulative risk and predictors of stroke recurrence up to 12 
years after first stroke were identified using survival analyses, taking into 
account the effect of temporal changes in stroke management. The effect of 
stroke recurrence on risk of death after first stroke was estimated up to 15 
years after initial stroke. A systematic review and meta-analysis of studies of 
the risk and cumulative risk of stroke recurrence after first stroke was also 
conducted.  
 
Results - The risk of stroke recurrence was estimated to be up to 25% at 12 
years after first stroke. Cardiovascular risk factors were found to be important 
predictors of stroke recurrence, however differences in risk of recurrence were 
noted between the aetiological subtypes. Stroke recurrence was 
demonstrated to increase risk of death at all time-points up to 15 years after 
first stroke.  
 
Conclusions – The risk of stroke recurrence is considerable and is associated 
with increased risk of death up to 15 years after first stroke. Further research 
is needed to examine the effect of secondary prevention on risk of recurrence. 





biggest increase in risk of death identifying a potentially important time-period 
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Chapter 1 Introduction 
Stroke is the second leading cause of global mortality and the third largest 
cause of disability worldwide [1, 2]. Whilst the impact of stroke on individuals 
and societies is undeniable, evidence from population-based studies on long-
term outcomes after stroke remain relatively rare[3]. By using the population-
based South London Stroke register (SLSR) as a sampling frame, this thesis 
will explore the natural history of stroke recurrence. Stroke recurrence is 
broadly defined as an individual’s second stroke using criteria discussed later 
in this thesis. 
 
This chapter provides the background for this thesis and sets out the concepts 
and ideas to be considered. It begins by describing the incidence of stroke 
from previous literature and presenting the outcomes experienced after first 
stroke, before focussing on stroke recurrence, the factors found to be 
important in predicting recurrence in previous literature, and how secondary 
prevention medication may have a role in reducing risk. The chapter 
concludes by outlining questions as yet unanswered by previous literature and 
explaining the objectives and hypothesis of this thesis.  
 1.1 The incidence of stroke 
The World Health Organisation (WHO) estimated in 2002 (still the most recent 
published estimates) that 15.3 million people had a stroke worldwide, with 
more than a third, 5.5 million, resulting in death. Of the 57 million deaths 
worldwide in 2002, stroke accounted for nearly 10%[4]. Population projections 
for Europe suggest that the proportion of the population aged 65 and over will 
increase from 20% to 35% by 2050, and during the same time period, the total 
European population is expected to decrease from 728 million to 705 
million[5].  It is predicted that this demographic shift will increase the number 
of acute stroke episodes from 1.1 to more than 1.5 million per year by 2025[6] 





million disability-adjusted life years (DALYs) globally in 1990 to 61 million 
DALYs by 2020[7]. 
 
However, data suggest that stroke incidence rates are not increasing in all 
countries and equally amongst all populations. Both data collected in men and 
women aged 35 to 64 years for the WHO MONICA Project, and population-
based stroke studies, demonstrate a widening gap between high-income 
countries with low and declining stroke incidence and mortality rates, and in 
middle and low-income countries where stroke incidence and mortality is high 
and increasing[8-10] 
 
Within the United Kingdom approximately 152000 strokes occur each year, 
including 30000 recurrent or second strokes. In 2010, stroke accounted for 
50000 deaths in the UK (7% of all deaths in men and 10% of all deaths in 
women) [11]. Analyses conducted by Murray et al of the UK specific findings 
from the Global Burden of Disease Study 2010 showed that stroke remains 
the third highest cause of years of life lost across all ages in the UK, and a 
significant cause of both premature mortality and excess death when 
compared to other nations studied[12].  
 
In 1999, Stewart et al reported age- and sex-adjusted stroke incidence rates 
of 1.25 per 1000 population per year in the geographically defined area 
covered by the South London Stroke Register (SLSR). They noted 
significantly higher incidence rates in black compared to white people with a 
black to white age-adjusted incidence rate ratio of 2.21. Their analyses 
revealed that in people aged 35-64, increasing age, male sex, black ethnic 
group and lower social class were independently associated with an 
increased incidence of stroke in South London[13]. More recently, SLSR 
analyses reported by Heuschmann et al demonstrated a total stroke incidence 





women from 1.20 to 0.91 per 1000 population per year, over the 10 year study 
period between 1995-2004[14].  
 
Decreasing trends in stroke incidence have also been reported by the other 
population-based stroke study in the United Kingdom. Stroke incidence rates 
in Oxfordshire from 1981 to 1984 and 2002 to 2004 were compared by the 
Oxford Vascular Study (OXVASC) in collaboration with the original 
investigators of the Oxfordshire Community Stroke Project (OCSP) There was 
little change reported in either the ethnic mix of the 93% white population or in 
the organisation of primary health-care during the interim period[15]. Despite 
a pre-study prediction of a 28% increase in first-ever strokes to account for 
the higher proportion of people aged over 75 years compared to the original 
study population, the observed number of strokes recorded decreased in both 
men and women. Age- and sex- adjusted incidence of first-ever stroke fell by 
29% from 2.27 to 1.62 per 1000 population per year between the studies, and 
significant reductions were reported in the incidence of both disabling and 
fatal strokes[15]. This is consistent with decreasing trends in stroke incidence 
observed in the Global Burden of Disease analyses[12, 15]. 
 1.2 The classification of stroke 
It is widely accepted that stroke is not a single disorder but a heterogeneous 
collection of diseases, with approximately 85% of strokes due to cerebral 
infarction (ischaemic stroke), 10% due to primary haemorrhage (PICH) and 
5% due to subarachnoid haemorrhage (SAH)[16]. Knowledge of the pathology 
and aetiology of a stroke can be important in order to understand why a stroke 
has occurred and to guide treatment choices, for example, the use of 
emergency thrombolysis to treat acute ischaemic stroke.   1.2.1  Ischaemic stroke 
Ischaemic strokes occur due to an obstruction within a blood vessel supplying 





vessel walls. This can lead to the formation of a cerebral thrombosis at the 
site of the obstruction, an embolus which is carried to the brain inside the 
blood vessel, or the infarction of the small blood vessels deep inside the 
brain[17].  
 
The estimated worldwide 30-day case fatality rate after first ischemic 
stroke ranges from 16 to 23% although wide variation has been 
reported in different countries and between different stroke subtypes[10, 
18] 
 
The two main classifications for ischaemic stroke used widely are the Oxford 
Community Stroke Project (OCSP) classification and the Trial of Org 10172 in 
Acute Stroke (TOAST) classification[19, 20]. The OCSP classification is a 
clinical classification used to allocate ischaemic strokes to one of four 
subtypes depending on the clinical signs and symptoms displayed at the time 
of maximum impairment after stroke. The four subtypes are: total anterior 
circulation stroke (TACI); partial anterior circulation stroke (PACI); lacunar 
infarct (LACI); and posterior circulation stroke (POCI). Details relating to how 
the subtypes are defined for the context of this thesis are discussed later in 
this thesis, however features of the four subtypes are summarised in Figure 1.  
 
The TOAST classification divides ischaemic strokes into five main subtypes 
on the basis of probable or possible stroke aetiology using clinical features 
and the results of diagnostic tests. The five subtypes are: 1) large artery 
atherosclerosis, 2) cardioembolism, 3) small artery occlusion, 4) stroke of 
other determined aetiology, and 5) stroke of undetermined aetiology[20]. The 







OCSP classification subtype Clinical features 
Total Anterior Circulation Infarct (TACI) A combination of: 
x A new higher cerebral dysfunction 
(e.g., dysphasia, dyscalculia, 
visuospatial disorder); and  
x Homonymous visual field defect; and 
x Ipsilateral motor and/or sensory deficit 
of at least two areas of the face, arm 
and leg. 
Partial Anterior Circulation Infarct (PACI) Two of the three components of the TACI 
syndrome, with: 
x Higher cerebral dysfunction alone, or  
x A motor/sensory deficit more 
restricted than those classified as 
LACI  
Lacunar Infarct (LACI) x A pure motor stroke; 
x A pure sensory stroke; 
x A sensori-motor stroke; or  
Ataxic hemiparesis.  
x Acute focal movement disorders 
should also be considered with in this 
group.  
Posterior Circulation Infarct (POCI) Presentation with any of:  
x Ipsilateral cranial nerve palsy with 
contralateral motor and/or sensory 
deficit; bilateral motor and/or sensory 
deficit;  
x A disorder of conjugate eye 
movement; 
x Cerebellar dysfunction without 
ipsilateral long-tract deficit (i.e., ataxic 
hemiparesis); or  
x An isolated homonymous visual field 
defect. 





 1.2.2 Primary intracerebral haemorrhage (PICH) 
Primary intracerebral haemorrhage, or bleeding into the brain parenchyma is 
widely associated with poorer outcomes after stroke compared to the other 
stroke subtypes[21, 22]. The 30 day mortality for PICH has been reported to 
be 30–55%, with half the deaths occurring in the acute phase, especially in 
the first 48 hours[23-25]. Complications of ICH also associated with poor 
outcome may include oedema, haematoma expansion or intra-ventricular 
extension with hydrocephalus, seizures and raised blood pressure[26].  
 1.2.3 Subarachnoid haemorrhage (SAH) 
An SAH is a haemorrhage from a cerebral blood vessel, aneurysm or vascular 
malformation into the space between the arachnoid and pial layers of the 
brain. It is characterised by sudden onset headache, and vomiting, and may 
occur with or without loss of consciousness. 10–15% of those affected die 
before reaching hospital and 25% die within 24 hours of the bleed. Overall 
survival is about 50%, half of whom have residual disability and most of whom 
experience long-term effects of fatigue and cognitive symptoms[16]. 
 1.3 Outcomes after first stroke 
Knowledge of a patient’s long-term prognosis for survival after a stroke is 
important to both patients and their clinicians. Prognostic information can help 
aid the selection of appropriate treatments for the patient and facilitate the 
provision of accurate information to the patient and their family [27].  
 
Research from the Oxford Community Stroke Project (OCSP) found the 30 
day all-stroke case fatality rate after first stroke to be 18%, with patients who 
survived at least 30 days having an average annual risk of mortality of 9.1%, 
over two times the risk of the general population[21, 28]. Adjusted mortality 





37% from 0.44 per 1000 population (95%CI 0.35-0.54) during 1981-84 to 0.24 
per 1000 population (95%CI 0.20-0.37) during 2002-2004. However, the 30 
day case fatality recorded over this period remained the same: 17.2% in 
2002-04 compared to 17.8 in 1981-84[15]. In South London, survival after first 
stroke was shown to improve significantly over a 16 year period between 
1995 and 2010. In multivariable analyses, having had a recent stroke, being 
of black Caribbean/black African ethnicity, and stroke unit admission were 
found to be associated with better survival[29].  
 
The impact of a stroke on the life of an individual is known to be an important 
predictor of outcome after first stroke. Often this can be taken to mean solely 
physical disability or stroke severity, however it has been known for over 20 
years that social and psychological challenges can inhibit recovery after 
stroke[30]. The International Classification of Functioning, Disability and 
Health (ICF) was defined by the World Health Organisation (WHO) in 2001 as 
an attempt to provide a unified and standard language for defining health and 
health-related outcomes, taking into account all aspects of an individual’s life, 
including their functional status and ability to participate in day-to-day 
activities[31]. After a stroke, patients and their carers are often faced with a 
multitude of physical, social and psychological challenges. Fifty percent of 
stroke survivors are left permanently disabled and requiring care either from 
relatives, friends or the community [32].  
 
There are two main scales widely used to measure levels of disability and 
impairment after stroke. The modified Rankin scale has been reported to 
portray handicap, i.e. the disadvantage due to disability or impairment, by 
measuring an individual’s functional independence. This contrasts with the 
Barthel Index, which estimates an individual’s functional status through the 
ability to perform activities of daily living[33]. The scales are often used 
together or individually at regularly recorded intervals allowing functional 






A recent study by the Framingham Heart Study group, found that despite no 
significant difference in stroke subtype, severity and case-fatality rates, 
women were likely to be significantly more disabled. Disability was defined in 
the study using the modified Rankin score measuring functional 
independence, both at the time of stroke and during the acute phase (the first 
14 days after stroke onset). This was found particularly in activities of 
dressing, grooming, and transfer from bed to chair. At three to six months 
after first stroke, women remained more disabled than men, and were 3.5 
times more likely to be institutionalised[34].  
 
Functional status, as defined using the Barthel Index, has been shown to be 
associated with quality of life after first stroke[35]. In a population-based study 
by Dhamoon et al in Northern Manhattan, USA, quality of life was shown to 
decline annually up to 5 years after stroke among survivors free of stroke 
recurrence or myocardial infarction and independent of other risk factors[35].  
 
In analyses estimating disability, cognition and psychological outcomes up to 
10 years after initial stroke between 1995 and 2006, Wolfe et al found that 
20%–30% of survivors had a poor outcome over 10 years of follow-up. The 
highest rates of disability were observed 7 days after first stroke and remained 
at a rate of approximately 110 per 1000 stroke survivors up to 10 years. Rates 
of inactivity and cognitive impairment both declined up to 1 year thereafter 
remaining stable until eight years after stroke. Increased age was associated 
with higher rates of disability, inactivity, and cognitive impairment[3].          
                                  
The long-term prognosis for recurrence-free survival is also of key 
importance[27]. Stroke survivors remain at increased risk of further strokes 
compared to the general population[36]. These recurrent strokes are more 
likely to be disabling or fatal than first strokes, yet studies show considerable 
variation in estimates of the cumulative risk of stroke recurrence in the early 





predict an individual’s risk of second stroke[37]. Differences in the reported 
risk of stroke recurrence and potential reasons for this shall be discussed 
further in Chapter 4. 
 1.4 Predictors of stroke recurrence 
The lack of consensus regarding the prognostic indicators of stroke 
recurrence or second stroke, make it difficult for accurate identification of 
those at high risk of stroke recurrence particularly in the first weeks to months 
after first stroke [38, 39]. Chandratheva et al, on behalf of the Oxford Vascular 
Study, investigated the prognostic value of three widely-used validated 
prognostic scores: the ABCD(2) score, the Essen Stroke Risk Score and the 
Stroke Prognosis Instrument II on the 90 day risk of stroke recurrence. They 
found that the predictive power of the ABCD(2) score, which has a primary 
use predicting the risk of stroke after transient ischaemic attack, was at best 
modest in patients with a minor stroke. Neither the Essen Stroke Risk score 
nor the Stroke Prognosis Instrument II predicted stroke recurrence up to 90 
days[39]. 
 
Even in the longer term problems with prognostic scores exist. The Essen 
Stroke Risk Score (ESRS), derived using data from a subset of ischaemic 
stroke patients in the Clopidogrel versus Aspirin in Patients at Risk of 
Ischemic Events (CAPRIE) trial, was shown to be predictive of recurrence at 1 
year after first stroke, with a stepwise increase in risk demonstrated for every 
point increase in risk score[40]. However as the score predicts cardiovascular 
outcome rather than stroke recurrence, participants were considered to have 
had an ‘initial event’ if they had (1) symptomatic coronary artery disease; (2) 
cerebrovascular disease (ischemic stroke or TIA); (3) peripheral arterial 
disease; or (4) at least 3 predefined atherothrombotic risk factors. 
Furthermore, patients already in a clinical trial, hospitalized patients, those 
aged under 45 years age and those considered to have difficulty returning for 






There remains a clear need for an accurate predictive model to estimate the 
risk of stroke recurrence in the short and long-term after first stroke. However, 
in order for this to be possible, identification of the factors important in stroke 
recurrence are first needed. 
 
Despite being a major cause of mortality and morbidity, stroke remains largely 
preventable[41]. Studies have identified modifiable and non-modifiable risk 
factors associated with first stroke, which are summarised in Table 1.  
Non-modifiable risk factors Modifiable risk factors 
Age  Hypertension 
Sex Diabetes 
Ethnicity/race Hyperlipidaemia 
Family history of stroke Atrial fibrillation 
 Cigarette smoking 
 Asymptomatic carotid stenosis 
 Obesity 
 Physical inactivity 
Table 1. Risk factors for first stroke 
 
To date, little consensus has been reached between studies as to which of 
these risk factors are important in predicting stroke recurrence. This shall be 
explored further in Chapter 3 of this thesis. Furthermore few population-based 
studies have looked at patterns of the pathological and aetiological stroke 
subtypes between first and second stroke during long-term follow-up i.e. 10 
years and beyond. There is little evidence to indicate that if the subtype of a 
patient’s first stroke is known, this can be used to predict the subtype of 
further strokes. This shall be discussed in Chapter 5 of this thesis.  
 1.5 The use of secondary prevention medication 
Patients with a stroke recurrence are known to have, on average, poorer 
survival outcomes compared to those with a first stroke only. This was 





month survival after first and recurrent stroke in the USA. They found survival 
from first stroke to consistently better than that for recurrent stroke (for 
example, the 2-year survival from first stroke for men aged 65 to 69 years was 
66.5% after first stroke compared with 51.1% after recurrent stroke; p<0.001 
by log-rank test and 68.0% versus 53.5% (p<0.001) for women of the same 
age). Overall 2 year survival was reported to be 48% after first stroke versus 
56.7% (p<0.001) after stroke recurrence [42]. It therefore seems reasonable 
to hypothesise that appropriate secondary prevention needs to be 
implemented as soon as possible, and maintained beyond the first weeks and 
months after first stroke.  
 
This is consistent with the National Clinical Guidelines for Stroke published by 
the Royal College of Physicians in 2012, however the number of trials 
supporting this hypothesis are fewer than for primary prevention[43, 44]. The 
non-randomised Early use of eXisting PREventive Strategies for Stroke 
(EXPRESS) study conducted by the Oxford Vascular Study group 
demonstrated that urgent assessment and treatment after TIA or minor stroke 
resulted in an 80% reduction in 90 day risk of recurrent stroke (adjusted 
hazard ratio 0·20, 95% CI 0·08–0·49; p=0·0001)[45].  
 
However, secondary prevention has been shown in randomised controlled 
trial settings not merely to reduce the risk of recurrence, but to also have a 
role in reducing the overall cardiovascular disease burden by lowering 
mortality and morbidity rates[46]. Less evidence has been provided using 
population cohorts. It is notable that the studies mentioned below define a TIA 
as an initial cerebrovascular event rather than, as it will be defined later for the 






1.5.1 Anti-hypertensive medication 
In 1999, Hankey and Warlow reported that in a population of 1 million about 
12000 would have had a previous stroke or TIA and 6000 (or 50%) of these 
will be hypertensive[47]. Since this time, many studies have investigated the 
effect of anti-hypertensive drugs in the secondary prevention of stroke. The 
key findings of two important studies are summarised below.  
The HOPE study investigated the effect of ramipril in patients who were at 
high risk of cardiovascular events. Eleven percent of their included patients 
had a prior stroke, and this group showed a non-significant 17% relative risk 
reduction in stroke recurrence during the study period[48]. PROGRESS was a 
randomised trial of a perindopril-based blood pressure lowering regimen 
among 6105 individuals with a previous stroke or TIA. Patients were randomly 
assigned to either an active treatment group or placebo. After 4 years of 
follow-up, the risk of stroke was reduced by approximately 25% in both 
hypertensive and non-hypertensive subgroups[49]. More in depth analyses of 
ischaemic stroke subtypes, showed a significant benefit of active treatment 
with the combination of perindopril and indapamide in reducing 
atherosclerotic, lacunar and haemorrhagic strokes (relative risk reduction 
39%, 23% and 50% respectively) with no effect noted on strokes of a cardio-
embolic subtype[49]. 
 1.5.2 Antiplatelet agents 
Antiplatelet treatments such as aspirin, dipyridamole and clopidogrel have 
been shown to reduce the risk of recurrent stroke in clinical trials. The 
Antithrombotic Trialists Collaboration compared aspirin to placebo in a meta-
analysis combining the results of 21 trials of people with a past history of 
stroke or TIA. The group reported a 2 year risk of 17.8% for those treated with 
antiplatelets and 21.4% for controls, therefore reporting a 22% odds reduction 
for non-fatal stroke or myocardial infarction or vascular death. The meta-
analysis found that the risk reduction was the same regardless of whether a 





follow-up meta-analysis in 2009 by the same research group demonstrated a 
continued 20% risk reduction in stroke in patients taking aspirin compared to 
placebo[51]. 
 1.5.2.1 Aspirin and dipyridamole 
The results of the second European Stroke Prevention Study (ESPS-2) 
indicated that in the prevention of stroke after TIA or minor stroke, 200mg of 
extended-release dipyridamole taken twice a day was as effective as 25 mg of 
aspirin taken twice a day, with the combination of the two being even better 
than either drug alone. The relative risk reduction of stroke or death was 13% 
for aspirin, 15% for dipyridamole and 24% for the combination of the two 
drugs[52]. This was confirmed by the ESPRIT study which found an absolute 
risk reduction of 1% a year in a primary outcome measure (comprised of 
death from all vascular causes, non-fatal stroke, non-fatal myocardial 
infarction or a major bleeding episode) in patients on aspirin and dipyridamole 
compared to aspirin alone[53]. 
 1.5.2.2 Clopidogrel 
As mentioned previously, the CAPRIE trial investigated the effect of 
clopidogrel compared to aspirin in patients with ischaemic stroke, myocardial 
infarction or peripheral vascular disease. They found that among the stroke 
sub-group, there was a 7.3% relative risk reduction of stroke, myocardial 
infarction or death[54]. The MATCH trial was conducted to investigate 
whether it was safe and more effective to add aspirin 75mg per day to 
clopidogrel 75mg per day in patients with recent TIA or ischaemic stroke who 
were at high risk of recurrent vascular events[55]. The study reported a 
benefit of 10 fewer recurrent ischaemic events per 1000 patients. However, 
there were three times as many life-threatening haemorrhages reported in the 







The oral anticoagulant warfarin, has been demonstrated to reduce the risk of 
cardio-embolic stroke, however it conveys no benefit compared to aspirin in 
patients with non-cardioembolic stroke[56].In patients with atrial fibrillation, the 
European Atrial Fibrillation Trial demonstrated that the use of warfarin therapy 
was associated with a risk reduction of 67% (from 12% to 4%) in patients with 
a previous TIA or minor stroke. The study also found an advantage in using 
warfarin over aspirin in these patients and clearly demonstrated that providing 
there is no known contraindication to its use, warfarin should be the treatment 
of choice[57]. 
 1.5.4 Carotid revascularisation 
Carotid endarterectomy has been shown to reduce the risk of recurrent stroke 
in patients with symptomatic stenosis, showing greater benefit in patients with 
a greater degree of stenosis until the vessel collapses and is occluded[58]. 
The North American Symptomatic Carotid Endarterectomy Trial (NASCET) 
studied patients with a TIA or minor stroke and an ipsilateral carotid stenosis 
of 70% or more. The study found a 2 year risk of ipsilateral stroke was 9% in 
the endarterectomy group compared to 26% in those who were medically 
managed, and the trial was stopped early due to the significant benefit seen in 
the endarterectomy group[59]. However, the NASCET group found that the 
risk reduction was less in patients who have less severe carotid stenosis (50-
69%). This was also found by the European Carotid Surgery Trial (ECST) who 
showed carotid endarterectomy to be of benefit for those with a high-grade 
carotid stenosis, defined as a 70-99% stenosis, but no benefit of surgery for 
those with a mild (0-29%) stenosis[60]. 
 
The treatment of carotid disease with angioplasty and stent placement has 
had mixed results when compared to the more traditional endarterectomy. 





differences in risk of death due to stroke between the angioplasty and 
endarterectomy groups[61]. The Stenting and Angioplasty with Protection in 
Patients at High Risk of Endarterectomy (SAPPHIRE) study which included 
enrolled patients with a history of cardiac disease, showed the angioplasty 
group to have a better 30 day outcome, with stroke or death occurring in 4.5% 
compared to 6.6% of the endarterectomy group[62]. However, the largest trial 
comparing these procedures, the International Carotid Stenting Study (ICSS) 
reported twice the risk of stroke in the endovascular treatment group, 
compared to patients who underwent an endarterectomy (ICSS)[63]. Clearly 
more evidence is needed to necessitate a widespread change in practice from 
the traditional endarterectomy, to endovascular procedures in patients with no 
contra-indications[63].  
  1.5.5 Lipid-lowering agents 
Studies indicate that lipid-lowering agents, traditionally used in patients with 
coronary artery disease, may be effective in independently reducing the risk of 
stroke recurrence. The Stroke Prevention by Aggressive Reduction of 
Cholesterol Levels (SPARCL) study was conducted to investigate the effect of 
aggressive atorvastatin therapy (80mg/day) on patients who had a previous 
TIA or stroke, had a low-density lipoprotein (LDL) level between 100 mg/dl 
and 190 mg/dl (2.58-4.91mmol/l) and had no evidence of coronary artery 
disease[64]. Patients were followed up for 6 years and a 16% risk reduction in 
time to stroke was demonstrated in the atorvastatin group, compared to the 
control group. A 23% risk reduction in the secondary end point of time to 
stroke or TIA and a 35% reduction in coronary events, were also noted. 
However, in this study, a 66% increased risk of intra-cerebral haemorrhage 
was found in the atorvastatin group. The mechanism for this is as yet 
undefined, and whilst the overall benefit in terms of stroke risk reduction is 







Most studies investigating the risk of glycaemic control in patients with 
diabetes mellitus have looked at primary rather than secondary prevention[65, 
66]. However, pioglitazone, one of the insulin sensitiser thiazolidinediones 
was shown to reduce insulin resistance in diabetic patients with a recent 
stroke or TIA[67]. The safety profile of the thazolidinediones have come under 
scrutiny in recent years with the withdrawal of rosaglitazone for increasing 
cardiovascular risk, although pioglitazone was not implicated at this time[68].  
 
There are no published studies specifically reporting the role of smoking 
cessation, abstinence from alcohol, weight reduction measures, or physical 
activity in risk reduction for stroke recurrence.  
 1.6 Problems with the use of secondary prevention 
Despite the evidence mounting for the use of secondary prevention to reduce 
the risk of recurrent stroke, it is apparent that not all patients who would 
benefit from these medications, receive or take them. A national cross-
sectional study of nursing homes in the United States found that when 
adjusted for age, sex and physical function, black stroke survivors were 20% 
less likely to receive any form of anticoagulant or antiplatelet therapy 
compared to white survivors[69]. The study also noted that the use of any 
treatment was lower for Hispanics (45.5%), non-Hispanic blacks (49.4%) and 
Asian-Pacific Islanders (38.9%) than for whites (54.3%), although they were 
higher amongst the Native American population (58.0%). This is despite long-
standing evidence that the black and Hispanic population have an increased 
risk of stroke recurrence compared to the white population[70].  
 
Problems in initiating secondary preventive strategies include patient 
compliance due to undesired side-effects, poor understanding, financial 
constraints and poor motivation, as well as inadequate communication and a 






The second national health and nutrition examination survey (NHANES) 
mortality follow-up study demonstrated a stepwise increase in cardiovascular 
disease mortality for patients with a previous history of myocardial infarction 
or stroke with increasing numbers of inadequately controlled risk factors. For 
patients with a previous history of MI or stroke the relative risk of 
cardiovascular death was reported as 2.6 (95% CI 1.3-5.1) times the general 
population if all investigated risk factors were adequately controlled, 
increasing to 4.3 (2.9-6.3) times with one inadequately controlled risk factor, 
and 5.7 times the risk of death with two inadequately controlled risk factors. 
This equates to 5.7 years of life lost compared to the age-matched general 
population even if all risk factors are controlled, increasing to 7.5 years and 
8.9 years lost with one and two inadequately controlled risk factors 
respectively [73]. 
 
Knowing an individual’s risk of stroke recurrence, based on their personal risk 
factor profile may provide a stroke survivor with the impetus for risk factor 
modification[74]. It may also help health professionals to identify those at 
increased risk, possibly from multiple borderline risk factors which individually 
may seemingly not be cause for concern. This is critical in identifying and 
targeting specific risk factors important for an individual at the crucial time-
point after first stroke, therefore reducing the risk of stroke recurrence at an 
individual patient level. 
 1.7 Unanswered questions 
Despite the previous research conducted on stroke recurrence, many 
questions remain as yet unanswered. In particular: 
x What is the risk of stroke recurrence for an individual at different time 
points after first stroke?  
x Which risk factors are important in predicting stroke recurrence for an 
individual? 
 Are the important risk factors for stroke recurrence different up to 1 





 Is targeted use of secondary prevention likely to reduce the risk of 
stroke recurrence in high-risk individuals?  
 What is the effect of stroke recurrence on other outcomes, for example 
the risk of death after first stroke? 
 Is risk of death dependent on the time-point at which stroke recurrence 
occurs? 
 1.8 Hypothesis 
This thesis hypothesises that: 
x the natural history of stroke recurrence can be estimated, and 
predictors of stroke recurrence can be identified at different time points 
up to 12 years after first-ever stroke.  
x the treatment of modifiable predictors of stroke recurrence, at the 
appropriate time point after stroke recurrence will reduce the risk of 
stroke recurrence.  
x stroke recurrence has an effect on risk of death after first-ever stroke. 
 1.9 Objectives of thesis 
This thesis will use data collected from the South London Stroke Register, to 
estimate the natural history of stroke recurrence after first-ever stroke. 
Predictors for stroke recurrence will then be identified from variables including 
socio-demographic factors, risk factors diagnosed at the time of initial stroke, 
patterns in stroke subtype, and stroke severity markers, taking into account 
the effect of temporal changes in stroke management, e.g. the use of 
secondary prevention medication. 
 
This shall be addressed through the analysis of data collected over a period of 
12 years from all individuals known to have had an initial and first recurrent 





stroke register situated in a geographically defined area of South London. The 
objectives of this thesis are: 
1. To estimate the cumulative risk of stroke recurrence at different time-
points up to 12 years after first-ever stroke from existing literature and 
from a population-based stroke register. 
2. To identify factors which predict the risk of stroke recurrence, from 
variables including socio-demographic factors, risk factors diagnosed 
at the time of initial stroke, patterns in stroke subtype, and stroke 
severity markers, at different time-points up to 12 years after first-ever 
stroke. 
3. To investigate the association of temporal changes in stroke 
management, e.g. the use of secondary prevention medication at 
different time-points after initial stroke, on the risk of stroke recurrence.  
4. To estimate the association between stroke recurrence and the risk of 
death up to 15 years after first-ever stroke. 
 1.10 Summary 
This chapter has highlighted gaps in current literature related to stroke 
recurrence, and demonstrated the need to explore the natural history of stroke 
recurrence further and to identify predictors. It seems logical to hypothesise 
that appropriate secondary prevention medication should reduce the risk of 
stroke recurrence by targeting important risk factors. 
The next chapter outlines the South London Stroke Register which is the 
sampling frame from which the analyses presented in this thesis were 
conducted. The methods used in both the literature review searches, and for 





Chapter 2.  Methods 
This chapter builds on the background laid out in Chapter 1 of this thesis. It 
outlines the rationale for using a population-based register as a sampling 
frame to measure the impact of stroke, and describes the characteristics of 
the South London Stroke Register, which shall be used to fulfil the objectives 
described in the previous chapter. The search strategies and methods used to 
review the literature and conduct the meta-analysis are then described. 
Finally, the general statistical methods used in the analyses for this thesis 
shall be outlined.  
 2.1 Population-based stroke registers 
The measurement of the overall health status of a population is an important 
public health issue, and it is essential that methods used to measure the 
impact of illness fully reflect the effect of disease on the whole of the 
population being studied. Whilst hospital-based studies measuring outcome 
after chronic disease may have access to a readily available cohort of patients 
with the condition of interest to the researchers, many are restricted to 
selected patients, such as those admitted to hospital or referred to 
rehabilitation services.  
 
There are several major disadvantages to the use of hospital-based studies or 
registers to assess outcome after stroke due to distortion of the true clinical 
course and prognosis by selection bias. A key disadvantage is the degree to 
which the case-mix of hospital-based studies can be representative of stroke 
patients as a whole, and therefore how far information obtained can be 
extrapolated to other groups of patients. Or particular concern is the inclusion 
of both severely ill patients and those with mild stroke symptoms, both of 
whom may not be admitted to hospital for a variety of reasons[75]. This will be 
discussed in more detail as part of the systematic review in Chapter 4. Non-





reliable denominator, therefore precluding the calculation of incidence 
rates[76].  
 
In 1987, Malmgren and colleagues, reviewed 65 studies of stroke incidence 
from around the world and found that only nine studies met a set of 
standardised criteria sufficiently to allow comparison with each other[77]. 
These criteria have been updated by Bonita in 1995, and Sudlow and Warlow 
in 1996 to produce an updated set of criteria for comparable studies of stroke 
incidence[75][72]. 
 
 These criteria are summarised in Table 2. 
 
Standard definitions 
x WHO definitions of stroke 
x First-ever-in-a-lifetime stroke data available, even if unpublished 
 
Standard methods 
x Complete, community-based case ascertainment 
x Prospective study design, ideally with ‘hot pursuit’’ of cases 
x Large, well-defined, stable population 
x Reliable method for estimating population denominator 
 
Standard data 
x Separate whole years of data available, even if unpublished 
x Data for men and women separately available, even if unpublished 
x Include ages up to and over 85 years if possible 
x Standard mid-decade age-bands) e.g.. 55-64 years) available, even if unpublished 
x Data preferably available in 5-year age bands 






2.2 The South London Stroke Register (SLSR)  
 
The SLSR is a prospective, longitudinal, population-based stroke register 
recording first-ever strokes in patients of all age groups in a defined area of 
South London. Since 1 January 1995, the SLSR has been monitoring 
incidence rates, cause, risk factors and long-term outcomes after stroke[13].  
 
The SLSR provides a good sampling frame for this thesis as it provides long-
term longitudinal data from a population-based setting, using overlapping 
notification sources and capture-recapture techniques in order to maximise 
completeness of case ascertainment[14]. Follow-up data are collected at 
multiple time-points making it possible to conduct longitudinal comparisons of 
stroke outcomes over time. Therefore it is possible to use the SLSR to 
describe the natural history of stroke recurrence as well as to assess the 
development of risk factors for stroke recurrence over time.  
 
The SLSR has all the criteria listed in Table 2 as essential for a population-
based stroke register[75]. These include: 
x a clear and concise implementation plan and SLSR manual to ensure 
quality control of the data;  
x ‘hot pursuit’ of cases to maximise case ascertainment; 
x multiple overlapping sources of notification to maximise completeness 
of case ascertainment; 
x commitment from local medical practitioners including local hospital 
consultants and general practitioners, regarding case notification; 
x effective methods of data collection and processing 
x adequate safeguarding procedures to ensure confidentiality of 






As with any long-term disease register, there are certain limitations which 
need to be acknowledged: 
x It is highly likely that despite overlapping notification sources and ‘hot-
pursuit’ techniques, there are cases that will not be identified by the 
SLSR, including those who had a stroke whilst away from home, and 
those who sustained minor strokes and may not have sought help from 
either their general practitioner or secondary care services[13].  
 
x Although population denominator data was derived from census data 
from the Office for National Statistics (ONS), the area of South London 
in which the SLSR is situated has a highly transient population. 
Southwark in particular was cited as one of the ten London boroughs 
with the highest levels of population mobility between 1991 and 
2001[78]. For this reason, population growth, mobility and cross 
boundary effects are difficult to estimate within this area and may 
influence results derived from the SLSR.  
 
x Due to the length of follow-up undertaken at the SLSR (currently in its 
19th year), is it inevitable that there will be missing data due to reasons 
including retrospective registrations, loss to follow-up, refusal by the 
patient or carer, or a basic lack of known data available to the SLSR. 
The methods of limiting and handling of missing data used in this thesis 
are discussed in Section 2.5. 
 
x As a practical consideration of note, issues with the continuity of data 
collection due to the long duration of the SLSR are inevitable. This is 
due to changeover of staff at the SLSR over time, and changes to the 
data collected by the register over the last 19 years. The methods used 





2.5, however the regularly updated SLSR manual is a useful aid to 
overcome these limitations to a certain degree.  
 2.2.1 The SLSR population 
The SLSR records first stroke in patients of all age groups living within a 
defined area corresponding to 22 wards of Lambeth and Southwark . The total 
source population was 271817 with 63% white, 28% black and 9% of other 
ethnic groups at the time of Census 2001[79].   
 
 In 2004 the boundaries of the SLSR area were changed to reflect boundaries 
of electoral wards as defined at that time. The new area consisted of 310,026 
persons at the time of the 2001 census, 14.1% more than the old area, 
estimated to have a population of 271,817 in 2001. Between 2001 and 2011 
the population of the new area increased by 15.3%, with the largest increases 
occurring among 45 to 59 year olds (44% increase), Asian (51% increase) 
and other (232% increase) ethnic groups  
 
 
At the time of the 2011 census the SLSR source population consisted of 
357,308 individuals of which 56% were of white ethnicity, 25% Black (14% 
Black African, 7% black Caribbean, 4 % Black Other), 6% Asian and 12% 
other ethnic group. [80].  Table 3 shows the ethnicity breakdown for the SLSR 
area. It is notable that the proportion of the study population who were of a 
Black Caribbean ethnicity, declined through throughout the study period, 











  1991 2001 (new boundaries) 2011 
 
Total (%) Total (%) Total (%) 
All white 167834 (72.6) 194177 (62.3) 200890 (56.2) 
Black African 17477 (7.5) 46104 (14.9) 50556 (14.1) 
Black Carribean 25809 (11.0) 29011 (9.4) 25087 (7.0) 
Black other 6213 (2.7) 13498 (4.4) 15315 (4.3) 
Asian*  (In ‘Other’ in 1991) 13880 (4.5) 21023 (5.9) 
Other 




Table 3: Ethnicity breakdown for SLSR area in the 1991, 2001 and 2011 census 
 2.2.2 Case ascertainment  
The SLSR utilises multiple overlapping referral sources to ensure notification 
of all patients with a suspected diagnosis of first or recurrent stroke[13]. ‘Hot 
pursuit’ is used to detect stroke cases, i.e. SLSR staff actively pursue 
potential stroke cases, rather than waiting passively for referrals to the 
register from notification sources. Patients identified by any notification 
source, are investigated for eligibility of study inclusion. Hospital surveillance 
of admissions for stroke include teaching hospitals both within and outside the 
study area. For identifying patients not admitted to hospital, all general 
practitioners (GPs) and community therapists within and on the borders of the 
study area are contacted regularly and asked to notify all potential stroke 
patients to the SLSR[13]. Completeness of case ascertainment was estimated 
to be between 75-84% over the 10 year period from 1995-2004[14]. The 
sources of notification include: 
 
x Research team/ward checks 
Telephone contact is made twice-weekly with all wards at St. Thomas 





the wards at St. George’s Hospital, University Hospital Lewisham and the 
National Hospital for Neurology and Neurosurgery at Queen Square. SLSR 
staff also regularly visit the hospital wards where stroke patients are most 
likely to be admitted, such as stroke units, neurosurgery wards, medical 
admissions units, and rehabilitation wards in order to identify any patients 
suitable for admission to the SLSR.  
 
x Hospital staff 
Consultants, junior doctors and nursing staff, particularly those working in 
stroke medicine, neurology or neurosurgery, elderly care medicine or general 
medicine are encouraged to notify any patients they may see in their clinical 
practice, both as in-patients and out-patients.  
 
x Radiology electronic records 
The results of CT and MRI scans of the brain conducted at Guy’s and St. 
Thomas’, King’s College Hospital and St. Georges Hospital are viewed 
electronically by a Research Registrar to identify any potential strokes cases. 
Once screened, the relevant notes are retrieved for possible stroke diagnosis. 
Cases where a diagnosis of stroke is possible but unclear are discussed with 
a Stroke Consultant before a final decision whether to proceed with stroke 
registration, or not, is made.  
 
x Accident and Emergency (A&E) records 
These records, in particular those of hospital admissions maintained by Bed 
Managers at St. Thomas’ Hospital and King’s College Hospital, are regularly 
checked for any stroke cases admitted to hospital. A&E records can also be 
particularly useful for identifying stroke patients who died very soon after 
admission to hospital, as well as patients presenting to hospital with very 






x Bereavement records 
Records in the bereavement office at St. Thomas’ and King’s College 
Hospitals are regularly checked for the mention of stroke on any part of the 
death certificate. The notes of all patients where stroke is mentioned are then 
examined to identify any suitable cases not previously known to the SLSR.  
 
x General Practitioner and practice staff 
GP surgeries notify the SLSR of any relevant stroke cases by telephone, 
electronic mail or by post. In order to make local GPs aware of the SLSR and 
keep them informed of any changes to the register, all GPs are sent a 
newsletter from the SLSR every three months. SLSR staff also request 
consent from stroke patients or their carers to report all incident cases back to 
the patient’s own GP to keep them as informed as possible.  
 
x Community therapists 
Therapists from the local community hospitals (Lambeth Community Care 
Centre and Pulross) notify the SLSR of any stroke cases referred to them. 
Regular newsletters are also sent to keep the community therapists up to date 
about the SLSR. 
 
x Office for National Statistics (ONS) 
An updated list is sent every six months to the ONS of all patients on the 
SLSR who were alive, or who were known to have died but for whom there 
was no death record reviewed by SLSR staff. The ONS inform the SLSR on a 
quarterly basis of any of these patients who have died. The ONS also provide 
death certificate data which can be reviewed by SLSR staff to ascertain the 





useful to ascertain stroke recurrence prior to death in patients known to the 
SLSR. 
 2.2.3 Data collection 
Specially trained fieldworkers collect all reported data prospectively. Initial 
assessments are performed within 72 hours of onset of stroke symptoms 
wherever possible. Data are collected from patients, their relatives, friends, 
carers, and where necessary from their medical notes or general practitioner 
allowing pre-stroke information to be collected for even the most dysphasic, 
confused or unwell patients. Difficult cases are discussed with senior stroke 
physicians prior to registration, and all registered cases are reviewed on a 
monthly basis in order to monitor inter-observer validity and to ensure that the 
stroke subtypes recorded are appropriate. The information collected on initial 
assessment includes patient demography, stroke risk factors, indicators of 
stroke severity, and stroke subtypes according to pathological and aetiological 
classification.  
 
After the initial interview, patients registered at the SLSR are followed up at 
three months, one year, and then annually post-initial stroke. In all but very 
few cases, these assessments are carried out by a field-worker by face-to-
face interview with the patient and/or their carers. However in order to follow-
up patients who may not be able to be visited by fieldworkers, e.g. those who 
move far away from the study area either after initial stroke or during the 
follow-up period, both postal and telephone versions of the follow-up 
questionnaire have been designed. The follow-up questionnaires are 
standardised into an easy-to-read format to enable patients to fill in the 
questions themselves. Questionnaires for each time point are identical to 






2.2.4 Ethical approval 
Informed consent to participate in the SLSR is obtained from all recruited 
patients, or assent from their designated next of kin if the patient is unable to 
consent themselves. The design of the SLSR is approved by the NHS 
Research Ethics Committees of Guy’s and St Thomas’ NHS Foundation Trust 
(REC number: EC01/020), King’s College Hospital Foundation Trust, St 
George’s University Hospital, National Hospital for Neurology and 
Neurosurgery, and Westminster Hospital.  
 2.3 Variable definition 
All explanatory and response variables used in this thesis are defined fully in 
the later chapters, however a brief summary of the variables used is given 
below. 
 2.3.1 Defining stroke and stroke recurrence 
For the purposes of the original analyses conducted in this thesis, a stroke 
has been defined according to the World Health Organisation (WHO) criteria 
as: 
‘Rapidly developing clinical signs of focal (or global) neurological deficit lasting 
more than 24 hours or leading to death, with no apparent cause other than 
that of vascular origin’[81].  
 
A stroke recurrence has been defined in the same way as for an initial stroke, 
however in addition for a diagnosis of a recurrence to be made, the presence 
of a new neurological deficit, or deterioration of a previous deficit not due to 
oedema, haemorrhagic transformation, or intercurrent illness is required. Only 
recurrences 21 days after the initial event, or if earlier, clearly in a different 





in these circumstances shall be included in the analyses conducted in this 
thesis. Differences in the definitions of stroke recurrence used in studies shall 
be discussed further in Chapter 4, later in this thesis. 
 2.3.2 Classifications of stroke subtype 
The main pathological and aetiological subtypes widely used to classify stroke 
were described earlier in this thesis in Section 1.2. The pathological subtype 
of stroke will be classified using the broad categories of the Oxfordshire 
Community Stroke Project (OCSP) classification as cerebral infarction (CI), 
primary intracerebral haemorrhage (PICH), subarachnoid haemorrhage (SAH) 
or undefined (UND)[19]. Classification is based on results from at least one of 
the following: brain imaging performed within 30 days of stroke (computerised 
tomography or magnetic resonance imaging), analysis of cerebrospinal fluid 
(in all living patients with subarachnoid haemorrhage in whom brain imaging 
was not diagnostic) or necropsy examination.  
 
The aetiological classification of ischaemic strokes will use a classification 
system based on the Trial of Org 10172 in Acute Stroke Treatment (TOAST) 
criteria[20], modified in order to improve the rate of determined aetiology and 
to account for expected differences in stroke subtype for the local black 
population[82]. A summary of the modified TOAST criteria is shown in Table 
4. 
 
Stroke subtypes include extracranial large artery atherosclerosis (LAAec), 
intracranial large artery atherosclerosis (LAAic), high-risk cardioembolism 
(CE-h), medium-risk cardioembolism (CE-m), small vessel occlusion (SVO), 
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2.3.3 Case ascertainment of stroke recurrence 
Stroke recurrence was ascertained in the same way as for initial stroke, by use of 
the referral sources discussed in Section 2.2.2. In addition all patients followed up 
annually by the SLSR were asked the following screening questions to ascertain 
if they had had a recurrence: 
x Have you had another stroke since your last follow up visit or since your 
first stroke? 
x Have you experienced any of the following symptoms: new visual 
problems, new speech problems, or new weakness of your arms and legs, 
since your last follow-up visit or since your first stroke? 
 
If the patient was found to have had a stroke recurrence, according to the criteria 
defined in Section 2.3.1, a form documenting details of the stroke recurrence was 
completed by the fieldworker. Registration of first stroke recurrence was 
performed in the same way as the initial stroke 
 2.3.4 The main explanatory variables used in this thesis 
Potential predictors of stroke recurrence were identified through review of the 
literature and the following variables were selected: 
 
Demographic factors included age (categorised as <65, 65-74, ≥75), gender, 
ethnicity (categorised as white, black and other) and socio-economic status. 
Socioeconomic status categories were grouped into non-manual (I, II, and III non-
manual) or manual (III manual, IV, and V) or economically inactive, according to 
the patient’s current (or for the retired and others not currently working, the most 






Information about co-morbidities, obtained from the initial questionnaire or from 
GP records, included history of transient ischaemic attack (TIA), ischaemic heart 
disease, atrial fibrillation (AF), hypertension, diabetes mellitus and smoking. 
Smoking status was recorded as current smoker or non- or ex-smoker. 
 
Stroke severity was defined as the presence of neurological deficit during the 
acute phase of the initial stroke. The level of consciousness was assessed using 
the Glasgow Coma Scale (GCS) dichotomized into GCS <13 (impaired 
consciousness) and GCS≥13[84]. 
 
Classification of pathological stroke subtype was categorised into ischaemic 
stroke, PICH or SAH based on results from at least one of the following: brain 
imaging (CT or MRI scan) and post-mortem studies. 
 
A range of indicators of the processes of care after an acute stroke, suggested to 
be useful proxy measures for the overall quality of stroke care, were 
examined[16]. Patients were classified as (1) not admitted to hospital; (2) 
admitted to stroke unit; (3) admitted to general medical ward/intensive care; and 
(4) unknown.  
 2.4 My personal contribution and experience at the SLSR 
I worked for four years (2007-2011) as a Clinical Research Fellow on the SLSR. 
During this time, my position has been split between working as a member of the 
SLSR team, and my involvement in the research project from which the work 
contributing to this thesis is derived. I gained practical understanding of general 
research methodology, as well as first-hand experience of the benefits and 





 I confirmed the diagnosis of new stroke cases referred to the register and 
discussed any difficult cases with senior stroke physicians before 
completing the initial assessment forms.  
 
 I identified stroke cases by visiting medical wards, elderly care wards, 
stroke units and the bereavement offices of Guy’s and St. Thomas’, King’s 
College Hospital, and St. George’s Hospital.  
 
 I gained experience in interpreting CT and MRI brain scans and benefitted 
from one-to-one review of these radiological assessments with expert 
stroke physicians. I also attended multi-disciplinary team meetings on the 
stroke unit, and participated in stroke clinics. 
 
 I conducted three-monthly and annual follow-up assessments of patients 
by both face to face and telephone interviews. This allowed me to better 
understand many of the long-term challenges faced by stroke survivors in 
the community.  
 
 I participated in the re-design of the initial and recurrence assessment 
questionnaires. The regular review of the questionnaires allows the SLSR 
to optimise the questions being asked of register participants and tailor the 
questionnaire to match current research aims. This also stops the 
questionnaire getting too long, an important factor for ensuring the 
maximum response rate.  
 
 I learned the principles of epidemiology and statistics, including data entry, 
collection, analysis and interpretation. The analyses undertaken in this 
thesis use three statistical packages ‘SPSS’, ‘STATA’ and ‘SAS’. This is 





packages and learned to conduct all the univariate and multivariable 
analyses described in this thesis. This includes both time-dependent and 
non-time-dependent survival analyses.  
 
 I have presented findings from this thesis in the form of oral and poster 
presentations at national and international stroke conferences, have 
written papers in peer-reviewed journals, contributed to book chapters, and 
lectured both medical students, doctors, other researchers and PhD 
students about stroke epidemiology, stroke recurrence and the use of 
secondary prevention.  
 2.5 Handling missing data 
Due to the length of follow-up of patients undertaken at the SLSR, there will 
invariably be missing data. Data may be missing completely at random (MCAR), 
missing at random (MAR) or missing not at random (NMAR)[85]. If data are 
MCAR or MAR, they can be analysed as normal, (using maximum likelihood 
methods) and should give unbiased results, providing all variables associated 
with a chance of missing a measurement are included in the model[85]. However 
this is not true of NMAR data, and any analyses conducted using this data may 
be biased. 
 
Within the SLSR, reasons for missing data during follow-up include retrospective 
registrations; patients lost to follow up either for a specific time interval i.e. 
missing their two year follow-up only, or indefinitely; or very rarely, due to refusal 
but the patient or their carers. The analyses conducted in Chapter 3 of this thesis, 
used data collected at the time of initial stroke and subsequent follow-up 
assessments, for initial strokes registered with the SLSR from 1995-2005. 
During this thesis, analyses were not specifically undertaken to assess whether 
loss to follow-up was uninformative with regards to stroke recurrence, i.e. whether 





follow-up. However in as yet unpublished work looking at predictors of being lost 
to follow-up within the SLSR population, no differences in odds were reported 
between the ethnic groups.  
 
Whilst data has been collected on both initial and recurrent stroke by the SLSR 
since 1995, it became evident that in order to have sufficient long-term data 
needed for the more complex analyses later in this thesis, the original data 
sources would need to be reviewed. Therefore I also undertook different 
measures specifically related to maximising the completeness of available data 
related to patients with a stroke recurrence: 
 
 I conducted a review of the data related specifically to stroke recurrence 
collected by the SLSR since January 1995. The purpose of this review was 
to primarily access the medical records, including those transferred to 
microfiche for storage, of all patients who were known to the SLSR as 
having had a stroke recurrence. This allowed the information previously 
obtained on SLSR recurrence forms to be verified, and any additional 
information identified to be available for use in subsequent analyses. 
 
 Both the pathological OCSP and aetiological TOAST classifications have 
been introduced since the start of the SLSR in 1995, therefore, as part of 
the medical notes review, I classified both the initial and first recurrence 
stroke event according to the OCSP and TOAST criteria. These 
classifications were then verified with a senior stroke physician. Both the 
OCSP and TOAST classifications have previously been validated to be 
applied retrospectively as well as for prospective use[15].  
 
 Finally, in order to ensure that all possible cases of stroke recurrence were 
included known to the SLSR and therefore included in the analyses, I 





Statistics (ONS). The ONS sent quarterly data to the SLSR stating the 
cause of death of patients registered with the SLSR since 1995. I 
designed, and having conducted a pilot study to check sensitivity, applied 
an algorithm (Appendix 3) using the ICD-9 or ICD-10 codes (International 
classification of diseases, 9th revision or 10th revision) to identify any 
further patients who may have had a stroke recurrence prior to death. The 
notes of these patients were then reviewed in order to ascertain clinically 
whether a further stroke had occurred, and if appropriate the stroke 
recurrence is registered.  
 
These measures outlined above contributed towards the development of a an 
updated dataset which was used to conduct the analyses described in Chapters 5 
and 6 of this thesis.  
 2.6 Search strategies used for systematic review of the literature 
A comprehensive search of the literature was conducted using Ovid Medline 
(1950-December 2009), EMBASE (1950-December 2009) and the Web of 
Science. These databases were searched by use of both the medical subject 
heading (MESH) terms and free text, combining terms for stroke (stroke OR 
cerebrovascular disease OR cerebrovascular accident) AND stroke recurrence 
(recurren*). 
 
In addition, the reference lists of all identified studies and the contents pages of 
relevant peer-reviewed journals, as well as abstracts from national and 
international conferences related to stroke were hand-searched in order to 
identify studies not previously identified by the electronic searches. All searches 
included studies published up to the end of December 2009. These literature 
searches were updated to include articles published before January 11th 2014 for 






2.7 Statistical methods 2.7.1 Survival analysis 
Survival analysis is the method for analysing data where the outcome variable is 
the time until the occurrence of an event of interest. It is otherwise known as 
‘time-to-event analysis’. The event can be death or the occurrence of a disease, 
and can be measured in days or weeks or even hours[86].   
 
Observations are censored when information about survival time are incomplete, 
for example if subjects do not experience the event during the follow-up period; if 
they die prior to the end of the study (provided the study is not estimating the time 
to death); or if they drop out of the study before the end of the study period.  
 
Survival methods incorporate information from both censored and uncensored 
observations in estimating important model parameters. The dependent variable 
in survival analysis is composed of two parts: one is the time to event and the 
other is the event status, which records if the event of interest occurred or not. 
Two functions which are dependent on time (the survival and hazard functions) 
can then be estimated. The survival and hazard functions are key concepts in 
survival analysis for describing the distribution of event times. The survival 
function gives, for every time, the probability of surviving (or not experiencing the 
event) up to that time. The hazard function gives the potential that the event will 
occur, per time unit, given that an individual has survived up to the specified time.  
 
A number of models are available to analyse the relationship of a set of predictor 
variables with the survival time. Methods include parametric, nonparametric and 
semi-parametric approaches[87]. 
 
Parametric methods assume that the underlying distribution of the survival times 





lognormal distributions. The distribution of survival times and changes in the 
distribution due to the addition of covariates or predictors are analysed. Model 
parameters in these settings are usually estimated using an appropriate 
estimation of maximum likelihood, that is, by estimating the value which makes 
the observed values most probable. 
 
A nonparametric estimator of the survival function, the Kaplan Meier method is 
widely used to estimate and graph survival probabilities as a function of time and 
in particular to obtain univariate descriptive statistics for survival data. To test for 
overall differences between estimated survival curves of two or more groups of 
subjects, the log-rank test can be used to compare the Kaplan-Meier curves 
estimated for each group of subjects. 
 
The semi-parametric Cox proportional hazards regression model is used to test 
for differences in survival times of two or more groups of interest, while allowing 
adjustment for covariates of interest. 
 
The Cox model describes the relation between the event incidence, as expressed 
by the hazard function and a set of covariates and which mathematically is written 
as: 
h(t) = h0 (t) x exp {b1x1 + b2x2 + ... + bpxp} 
where the hazard function h(t) is dependent on (or determined by) a set of p 
covariates (x1, x2, ... xp), whose impact is measured by the size of the respective 
coefficients (b1, b2 ...  bp). The term h0 is called the baseline hazard, and is the 
value of the hazard if all the xi are equal to zero. The ‘t’ in h(t) indicates that the 
hazard may (and probably will) vary over time.  
 
While a non-linear relationship between the hazard function and the predictors is 





in the setting where the predictor variables do not vary over time. This 
assumption is called the proportional hazards assumption and checking if this 
assumption is met is an important part of a Cox regression analysis[87]. 
 
The proportional hazards assumption can be checked by plotting the Kaplan–
Meier survival curves together. If they cross, then the proportional hazards 
assumption may be violated. However, for small data sets, the survival curves 
may cross even under the proportional hazards assumption, and a log-log plot 
may be conducted. This plot will display parallel curves if hazards are proportional 
across the groups[88]. 
 
If the proportional hazards assumption is not met in a model, several techniques 
can be used. These include stratification by the categories of the variable for 
which the assumption fails; the use of separate Cox models for different time 
intervals; or the use of time-dependent covariates[89].  
 2.7.2 Statistical methods used in this thesis 
This thesis uses survival analyses to investigate the time to stroke recurrence and 
time to death after first-ever stroke. The analyses conducted in this thesis have 
been performed using a combination of ‘SPSS’, ‘STATA’ and ‘SAS’ statistical 
packages. Specific analyses have been undertaken to address the research 
objectives outlined in Section 1.9 of this thesis: 
 
x Can we estimate the risk of stroke recurrence at different time-points up to 
12 years after first-ever stroke? 
The survival probability will be estimated non-parametrically from observed 





product-limit) method. Patients will be censored at time of death, lost to follow-up, 
or if alive at the end of the follow-up period.  
 
Kaplan-Meier estimates will be calculated to model the risk of stroke recurrence 
(1-survival free of recurrent stroke) and therefore to measure the cumulative risk 
of stroke recurrence and 95% confidence intervals up to 12 years after initial 
stroke. Finally, a meta-regression model will be used to derive parameter 
estimates of cumulative risk as a function of time since first stroke, allowing 
comparisons to be made at time-points not analysed during the study.  
 
x Is it possible to identify factors which predict the risk of stroke recurrence, 
from variables including socio-demographic factors, risk factors diagnosed 
at the time of initial stroke, patterns in stroke subtype classifications, and 
stroke severity markers, at different time-points up to 12 years after first-
ever stroke? 
Hazard ratios (HR) and the corresponding 95% confidence intervals (CI) will be 
estimated using Cox regression analyses and the assumption of proportional 
hazards will be assessed using log minus log survival plots.  
 
Again, patients will be censored at time of death (if not due to stroke recurrence), 
if lost to follow-up, or if alive at the end of the follow-up period. In the multivariable 
analyses, the influence of socio-demographic factors, stroke severity, 
cardiovascular risk factors and stroke subtypes shall be investigated as potential 
predictors of stroke recurrence and results shall also be stratified by pathological 
and aetiological stroke subtype.  
 
Can effective management of stroke, and the appropriate use of secondary 
prevention medication at the appropriate time-point after initial stroke reduce the 





In order to estimate the effect of secondary prevention medication on the risk of 
stroke recurrence at any time point after first stroke time-dependent (or updated) 
covariate methods shall be used to fit a multi-level time-dependent predictive 
model. This will allow variables which may not have been part of the baseline 
assessment at time of first stroke to be included in the survival model. Therefore, 
the effect of secondary prevention medication, for example, anti-hypertensive 
therapy or anticoagulation with warfarin can be estimated within the analyses, 
regardless of at which time-point the medication is started. For example, for the 
Cox Regression model previously described, the formula relating a covariate x1 to 
the hazard h(t) is 
h(t) = h0(t) exp[b1 x1] 
where h0(t) is the baseline hazard. If repeated measurements of a covariate x1 
are available, this formula will change to  
h(t) = h0(t) exp[b1 x1(t)] 
where x1(t) is the value of x1 at time t. The coefficient b1 represents the additional 
relative hazard for each unit increase in x1 at any given time.  
 
x Does stroke recurrence have an effect on the risk of death after first 
stroke? 
Kaplan-Meier estimates will be calculated to model the risk of death (1-survival) 
and therefore to measure the cumulative risk of death using Hazard Ratios (HR) 
and corresponding 95% confidence intervals up to 15 years after first stroke.  
 
In the multivariable analyses, stratified Cox Proportional Hazards Models will be 
used to estimate the effect of stroke recurrence on the risk of death after first 
stroke adjusted for socio-demographic factors, stroke severity, cardiovascular risk 
factors, stroke subtypes, process of care variables, and time- dependent factors. 
Stroke recurrence will be treated as a time-varying covariate in the analyses, 





eventuality that an individual may die from a non-related cause before stroke 
recurrence, therefore not allowing a stroke recurrence to occur. 
 
The specifics of the methods used to fulfil these objectives shall be discussed in 
further detail in the relevant chapters of this thesis.  
 2.8 Summary 
This chapter presented the rationale for the use of the SLSR as a sampling frame 
for this thesis, as well as the general methods used in both the literature searches 
and statistical analyses presented in the rest of the thesis.  
 
As a starting point for the exploration of this thesis, the next chapter outlines the 
preliminary studies conducted to identify whether modifiable risk factors are 
important in predicting stroke recurrence within the SLSR population. These 
preliminary analyses also provide an opportunity to assess the SLSR dataset and 






Chapter 3. Frequency and predictors of stroke recurrence 
The description of the risk and predictors of, stroke recurrence up to 10 years 
after first stroke was presented as an oral presentation at the World Stroke 
Congress in 2008 and has been published as an original research paper in the 
Journal of Neurology, Neurosurgery and Psychiatry in 2009. (See Appendix 1). 
 Abstract 
Background- Data estimating the risk of, and predictors for long-term stroke 
recurrence are lacking.  
 
Methods- Data were collected from the population-based South London Stroke 
Register. Patients were followed up until March 2008 or for a maximum of 10 
years after first stroke. Kaplan-Meier estimates and Cox Proportional Hazards 
models were used to assess cumulative risk of and predictors for first stroke 
recurrence. Variables analysed included socio-demographic factors, stroke 
subtype (defined as cerebral infarction, intracerebral haemorrhage and 
subarachnoid haemorrhage), stroke severity markers and prior-to-stroke risk 
factors.  
 
Results- Between 1995 and 2004, 2874 patients with first-ever stroke were 
included. Mean follow-up period was 2.9 years.  During 8311 person-years of 
follow up, 303 recurrent events occurred. The cumulative risk of stroke recurrence 
at 1 year, 5 years and 10 years was 7.1%, 16.2% and 24.5% respectively. No 
differences in stroke recurrence were noted between the stroke subtypes. Factors 
increasing the risk of recurrence at 1 year, were previous myocardial infarction 
(HR 1.73; 95% CI 1.08-2.78) and atrial fibrillation (HR 1.61; 95% CI 1.04-4.27); at 
5 years, hypertension (HR 1.47; 95% CI 1.08-1.99) and atrial fibrillation (HR 1.79; 
95% CI 1.29-2.49); and at 10 years, older age (p=0.04), and  hypertension (HR 
1.38, 95% CI 1.04-1.82), myocardial infarction (HR 1.50, 95% CI 1.06-2.11), and 
atrial fibrillation (HR 1.51, 95% CI 1.09-2.09). 
 
Conclusions-Very long-term risk of stroke recurrence is substantial. Some 





cardiovascular risk factors were found to have a significant role in predicting 
stroke recurrence at all time-points up to 10 years.  
 3.1 Introduction 
Predictors of stroke recurrence remain largely unknown with socio-demographic 
factors, co-morbidities and stroke subtype outlined as important in different 
studies[17, 90, 91]. The aim of this study was to estimate the risk and predictors 
of first stroke recurrence up to 10 years after initial stroke within a population-
based setting. 
 
This is important as it was hypothesised that the treatment of modifiable 
predictors of stroke recurrence, at the appropriate time point after stroke 
recurrence reduces the risk of stroke recurrence. In order for this to be clinically 
as well as statistically relevant, modifiable risk factors need to convey increased 
risk of stroke recurrence within the population.  
 
The analyses presented in this chapter were conducted using data related to first-
ever strokes recorded prospectively for the South London Stroke Register from 
1995 to 2004. Whilst the use of a long-term sampling frame will undoubtedly be a 
strength of this study, these preliminary studies also provide an opportunity to 
assess the dataset and methods to be used, identify any gaps in the data 
collected, and investigate possible methods to reduce missing data later in this 
thesis.   3.2 Methods 
The use of the South London Stroke Register as the study population, the case 
ascertainment and data collection methods used in this chapter have previously 
been discussed in Chapter 2 of this thesis. 3.2.1 Variable definition 
Stroke was defined according to the World Health Organisation (WHO) 





infarction (CI), primary intracerebral haemorrhage (PICH), subarachnoid 
haemorrhage (SAH) or undefined (UND). Classification was based on results 
from at least one of the following: brain imaging performed within 30 days of 
stroke (computerised tomography or magnetic resonance imaging), analysis of 
cerebrospinal fluid (in all living patients with subarachnoid haemorrhage in whom 
brain imaging was not diagnostic) or necropsy examination.  3.2.1.1 Definition of stroke recurrence 
The definition of stroke recurrence was the same as for the index stroke. 
Additionally, clinical diagnosis of a new neurological deficit, or deterioration of a 
previous deficit not due to oedema, haemorrhagic transformation, or inter-current 
illness was required. Only recurrences 21 days after the initial event, or if earlier, 
clearly in a different vascular territory were included. The same referral sources 
were used for notification of stroke recurrences as for initial stroke ascertainment. 
All patients were eligible for follow-up if alive and having reached the specified 
point of follow-up by March 2008. 
 
As potential predictors of stroke recurrence, the following variables were selected. 
Demographic factors included age (categorised as <65, 65-74, ≥75), gender, 
ethnicity (categorised as white, black and other) and socio-economic status. 
Socioeconomic status categories were grouped into non-manual (I, II, and III non-
manual) or manual (III manual, IV, and V) according to the patient’s current (or for 
the retired and others not currently working, the most recent) employment. Co-
morbidities included history of transient ischaemic attack (TIA), ischaemic heart 
disease, atrial fibrillation (AF), hypertension, diabetes mellitus and smoking. 
Smoking status was recorded as current smoker or non- or ex-smoker. 
 
Stroke severity was defined as the maximum neurological deficit recorded during 
the acute phase, or first 14 days, after the initial stroke. Case severity variables 
included motor deficit, urinary incontinence, and Glasgow coma scale 





3.2.2 Statistical analyses 
Descriptive and univariate analyses using Kaplan-Meier estimates were used to 
model the risk of recurrent stroke (1- survival free of recurrent stroke) and 
therefore to measure the cumulative risk of stroke recurrence and 95% 
confidence intervals (CI) at 1, 5 and 10 years post initial stroke. For each variable 
individually, hazard ratios (HR) and the corresponding 95% confidence intervals 
(CI) were estimated using Cox regression analyses. The assumption of 
proportional hazards was assessed using log minus log survival plots. Patients 
were censored at time of death, or if alive at 10 years after stroke. 
 
In the multivariable analyses, the influence of demographics, pathological subtype 
of the initial event, stroke severity, and co-morbidities as predictors of stroke 
recurrence were investigated. When analysing age, the broad ≥75 category was 
used due to the small numbers of patients surviving to long term follow up who 
were in higher age groups. Variables included in the multivariable analyses were 
eliminated using the backward elimination procedure. In the backward elimination 
procedure all covariates were entered into the Cox model in the first step. With 
each proceeding step, the covariate showing the smallest contribution to the 
model is removed until just covariates which have a significant effect on the Cox 
model remain. As covariates were removed from the model at different steps, the 
multivariable analyses presented in Table 8 report hazard ratios and the 
significance level immediately prior to each covariate leaving the model.  
 
 
Possible interactions between age, stroke subtype and co-morbidities were 
controlled by adding terms of interaction to the regression model. Multivariable 
analyses were restricted to patients without missing values which totalled 2268 
patients. The number of patients with missing values ranged from 0 for the age, 
gender and stroke subtype variables, to 254 (8.8%) for incontinence at time of 






A sensitivity analysis was performed with patients censored at time of follow-up 
rather than at date of death, if death occurred more than 1 year after last follow-
up. 
 
Further sensitivity analyses were performed as requested as part of amendments 
to this thesis. Multiple imputation was performed to impute all missing baseline 
covariates. All baseline variables were included as well as the log of survival time 
and the recurrence indicator. Fully conditional specification method was used 
meaning that each variable with missing data were imputed one at a time using 
all the other variables. 20 imputations were carried out[93]. Cox models were 
fitted within imputed dataset and parameter estimates were combined using 
Rubin’s rules[94]. All variables were entered into the Cox Models in a single step.  
 
As the multivariable analyses presented estimate the cumulative risk of 
recurrence sensitivity analyses were also carried out to assess the associations 
between recurrence and baseline characteristics between defined specific time 
periods of 1 to 5 years and 5 to 10 years after initial stroke. Due to the small 
numbers of recurrences occurring in the 5 to 10 year period, variables included in 
these analyses were eliminated using the forward elimination procedure. 
All tests were two-tailed and p values <0.05 were regarded as statistically 
significant. Statistical analyses were performed using SPSS version 16.1 and 
STATA software version 10(SE). 
 3.3 Results 
This study included a total of 2874 first-ever stroke patients registered between 
January 1995 and December 2004. The mean follow-up time was 2.9 years, with 





included. During this period, 303 recurrent strokes were documented. Patient 
characteristics at time of initial stroke are presented in Table 5. 
 
The number of patients in the study at the different key time-points during the 10 
year study period are summarised in Table 6. The number participants remaining 
in the study throughout the study period by covariate, can be found in Appendix 6. 
 Total, N(%) 
Total 2874 
 
Age group  
   <65 863(30) 
  65-74 764(27) 
  75-84 1247(43) 
 
Gender  
  Female 1447(50) 
 
Ethnicity  
  White 2126(76) 
  Black 525(19) 
  Other 153(5.5) 
Socio economic status  
  Non-manual 730(25) 
  Manual 1604(56) 
  Unknown 540(19) 
 
Stroke Subtype  
  Infarct 2089(73) 
  PICH 395(14) 
  SAH 171(6.0) 
  Undefined 219(7.6) 
 
Risk factors  
  Previous TIA 358(13) 
  Hypertension 1714(64) 
  Diabetes Mellitus 483(18) 
  Previous MI 315(12) 
  Previous AF 463(17) 
  Smoker or ex-smoker 943 (36) 
 
Stroke severity Indices  
 GCS  ≤8 497(18) 
             9-12 422(15) 
            13-15 1835(67) 
  Motor deficit 2282(84) 
  Incontinence 1238(47) 
Table 5.Descriptive baseline statistics  










first stroke  
Number at 













study at end 
of time-period 
0-1 years 2874 142 1042 65 1625 
1- 5 years 1625 122 440 345 718 
5-10 years 718 39 203 391 85 
Table 6. The number of participants in the study throughout the study period. 
 3.3.1 Survival Analyses 
The cumulative risk of first stroke recurrence at 1 year, 5 years and 10 years was 
7.1% (95% CI 6.0 to 8.3%), 16.2% (95% CI 14.4 to 18.1%) and 24.5% (95% CI 
21.3 to 27.9%) respectively. Table 7 shows the univariate analyses of cumulative 





























 Cumulative risk of recurrence, % (95% CI) 
 At 1 year At 5 years At 10 years 
Total 7.1 (6.0-8.3) 16.2 (14.4-18.1) 24.5 (21.3 – 27.9) 
Age group    
  <65 6.2 (4.6-8.3) 12.6 (10.1-15.6) 17.2 (13.8-21.4) 
  65-74 6.6 (4.8-9.0) 16.2 (13.1-20.0) 29.6 (23.4-36.8) 
  ≥75 8.4 (6.6-10.6) 20.4 (17.0-24.5) 30.1 (21.3-41.4) 
Gender    
  Male 6.0 (4.7-7.6) 15.5 (13.1-18.2) 22.9 (19.1-27.4) 
  Female 8.4 (6.8-10.4) 17.1 (14.4-20.1) 26.4 (21.5-32.2) 
Ethnicity    
  White 7.4 (6.2-8.9) 16.1 (14.0-18.5) 25.1 (21.2-29.5) 
  Black 6.1 (4.1-8.8) 16.7 (13.0-21.3) 23.7 (18.4-30.2) 
  Other 7.7 (4.1-14.2) 15.7 (9.7-24.6) 20.8 (12.9-32.6) 
Socio economic 
status 
   
  Non-manual 6.5 (4.7-8.8) 14.7 (11.7-18.3) 26.3 (20.6-33.3) 
  Manual 7.7 (6.3-9.3) 17.5 (15.1-20.2) 24.9 (21.0-29.3) 
  Unknown 5.9 (3.2-11.0) 14.5 (9.3-22.3) 17.0 (10.6-26.5) 
Stroke Subtype    
  Infarct 6.9 (5.8-8.3) 16.6 (14.6-18.9) 25.7 (21.9-29.9) 
  PICH 7.7 (4.8-12.2) 16.5 (11.6-23.1) 19.5 (13.6-27.6) 
  SAH 4.7 (2.0-11.0) 4.7 (2.0-11.0) 7.5 (3.0-17.9) 
  Undefined 11.9 (6.5-21.2) 21.6 (13.6-33.3) 43.4 (25.5-66.8) 
Risk factors    
  No TIA 7.0 (5.9-8.4) 15.4 (13.4-17.6) 24.9 (21.4-28.8) 
  Previous TIA 9.5 (6.5-13.7) 22.0 (16.9-28.5) 26.5 (19.0-36.1) 
  No Hypertension 6.6 (4.9-8.8) 12.6 (10.0-15.8) 18.7 (14.7-23.7) 
  Hypertension 7,8 (6.4-9.5) 18.4 (16.0-21.1) 27.8 (23.6-32.5) 
  No Diabetes Mellitus 7.2 (6.0-8.6) 15.6 (13.6-18.0) 23.8 (22.2-41.3) 
  Diabetes Mellitus 8.4 (5.9-11.9) 20.0 (15.6-25.3) 30.6 (22.2-41.3) 
  No MI 6.9 (5.8-8.3) 15.7 (13.7-17.8) 23.4 (20.1-27.1) 
  Previous MI 11/3 (7.7-16.6) 22.6 (16.6-30.3) 41.1 (29.1-55.8) 
  No AF 6.9 (5.8-8.3) 15.4 (13.5-17.5) 24.6 (21.2-28.5) 
  Previous AF 9.9 (6.8-14.3) 24.7 (18.6-32.4) 27.5 (20.0-37.1) 
  Non-Smoker 8.1 (6.7-9.8) 17.5 (15.1-20.1) 26.4 (21.8-31.6) 
  Smoker or ex-       
smoker 
5.4 (4.0-7.4) 13.9 (11.2-17.1) 21.0 (17.1-25.6) 
Stroke severity 
Indices 
   
  GCS  ≤8 3.2 (1.1-9.2) 10.1 (4.7-20.9) 10.1 (4.7-20.9) 
            9-12 7.7 (4.9-11.9) 13.8 (9.5-19.9) 18.1 (11.6-27.4) 
           13-15 7.2 (6.1-8.6) 16.4 (14.4-18.6) 25.4 (21.8-29.4) 
  No motor deficit 6.1 (4.1-9.1) 16.0 (12.3-20.6) 22.5 (15.6-31.8) 
  Motor deficit 7.4 (6.2-8.8) 16.3 (14.3-18.6) 25.1 (21.7-29.0) 
  No incontinence 6.4 (5.2-7.9) 15.6 (13.4-18.0) 24.9 (20.9-29.3) 
  Incontinence 8.1 (6.2-10.6) 15.6 (12.4-19.5) 21.0 (16.3-26.8) 





Figure 2 shows a Kaplan-Meier plot graphically representing the risk of stroke 
recurrence (1-survival free of recurrent stroke) over 10 years stratified for stroke 
subtype.  
 
Figure 2. Cumulative risk of stroke recurrence stratified according to stroke subtype. 
 
The multivariable analyses for predictors of cumulative risk of stroke recurrence 
up to 1 year, 5 years and 10 year after first stroke, are shown in Table 8. Log-log 
plots were conducted to show that the proportional hazards assumption was 
fulfilled across all variables included in the model and can be found in Appendix 
4.  
 
Up to 1 year post-stroke, a past history of myocardial infarction and atrial 
fibrillation were found to be predictors of early stroke recurrence, whilst gender 





and atrial fibrillation were found to be predictors, with previous myocardial 
infarction demonstrating borderline significance; and up to 10 years, older age 
and a history of hypertension, myocardial infarction and atrial fibrillation 
diagnosed prior to first stroke, were found to be predictors of long-term stroke 
recurrence. However it is notable that for each covariate, the confidence intervals 
estimated throughout the 10 year time-period overlap, indicating that, for 
example, the cardiovascular risk factors identified as predictors in specific 
analyses are likely to predict the increased risk of stroke recurrence throughout 
the 10 year time-period. 
 
In the sensitivity analyses, no significant differences in cumulative risk of 
recurrence were observed if patients were censored at time of follow-up rather 
than at date of death, if death occurred more than 1 year after last follow-up. 
Furthermore, in the multivariable analyses the predictors of recurrence remained 
the same while hazard ratios and corresponding confidence intervals were stable. 
None of the interactions tested were found to be significant except between 
stroke subtype at 10 years and a history of previous TIA at 10 years. There was a 
higher risk of recurrent stroke experienced by SAH patients who had had a 
previous TIA. However, this interaction was based on a very small number of 
patients who had a SAH and therefore the results were not reported stratified. 
 
Sensitivity analyses were also conducted using multiple imputation to impute all 
missing baseline covariates into the multivariable analyses. The hazard ratios 
estimated using the imputed dataset are presented in Table 9. Due to the multiple 
imputation method used, p values have not been reported across the categorical 
variables.  
 
It is notable that the hazard ratios and confidence intervals estimated using the 
imputed dataset are similar to those estimated in the original analyses, with 
cardiovascular risk factors remaining important across the time period. Certain 





significant after multiple imputation. In the period up to 5 years after first stroke, 
the 95% Confidence Intervals estimated became wider when multiple imputation 
methods were used increasing from HR 1.47 (1.08-1.99) to HR 1.20 (95% CI 
0.90-1.59). 
 
As outlined in earlier in this chapter, these sensitivity analyses were performed 
with all variables entered into the Cox models in the same step, rather than by the 
backwards elimination method used in the main analyses which is likely to lead to 
slight variation in results. Furthermore, it has been previously commented that the 
fully conditional specification method of multiple imputation can lead to Type 2 
errors, leading to an under-estimation of hazard ratios obtained by this 
method[95]. For these reasons, and as the hazard ratios and confidence intervals 
estimated using these multiple imputation methods, are similar to those presented 
in the main analyses of this chapter (Table 8), sensitivity analyses using multiple 
imputation methods have not been performed in the remaining analyses in this 
thesis.  
 
Further sensitivity analyses were carried out to assess differences between the 
method of estimating cumulative risk of stroke recurrence (i.e. up to 5 years, and 
up to 10 years after first stroke) taken in the analyses of this thesis, compared to 
using defined specific time periods of 1 to 5 years and 5 to 10 years. In the 1 to 5 
year period, hypertension (HR 2.07 (95%CI 1.22-3.50); p<0.01) and atrial 
fibrillation (HR1.84 (95%CI 1.09-3.12) were found to be predictors of stroke 
recurrence. In the 5 to 10 year period, older age (age 65-74 (HR 4.13 95% CI 
1.64-10.4) and age 75< (HR 2.98 95% CI 1.03-8.61) when compared to age <65 
(overall p value 0.01)) and past history of a myocardial infarction (HR 2.49 95% 
CI 1.08-5.77) were identified to increase the risk of stroke recurrence. It should be 
noted that forwards elimination methods were used to estimate the predictors of 
stroke recurrence in the 5 to 10 year period due to the small numbers involved. 
The merits of estimating the cumulative risk of stroke recurrence compared to 
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This study estimated the risk of and predictors for stroke recurrence up to 10 years after 
initial stroke. The results show that the cumulative risk of first stroke recurrence is 
substantial (i.e.) up to 25% by 10 years post-initial stroke, and also identifies predictors 
of stroke recurrence up to 1, 5 and 10 years after first stroke. No independent influence 
of stroke subtype or stroke severity on stroke recurrence up to 10 years was identified 
and no differences between ethnic or socio-economic groups were revealed. Prior-to-
stroke risk factors were found to have a significant role in predicting stroke recurrence 
up to 10 years. 
 
The mean follow-up period for this study was 2.9 years. This may initially appear low 
however as demonstrated in Table 6, 1042 out of 2874 study participants (36.3%) died 
within the first year of this study. The risk of death after first stroke is known to vary 
widely between published estimates, and the impact of stroke recurrence on death after 
first stroke will be considered further in Chapter 7 of this thesis. 
 
The results estimated no significant differences between ischaemic and haemorrhagic 
stroke subtypes up to 1, 5 and 10 years post-stroke. This contrasts with research from 
Japan that found the risk of stroke recurrence to be significantly greater within 1 year of 
an initial ischaemic stroke compared with haemorrhagic stroke. However, these 
differences were not maintained beyond 1 year, and there were no significant 
differences noted during the rest of their follow-up period of 3 years[96]. Conversely, 
The Perth Community Stroke Study reported prognostic factors for recurrent stroke at 5 
years including advanced age and an initial stroke subtype of either PICH or SAH, 
which achieved borderline significance in their analyses[97].  
 
This study found no differences between markers of stroke severity as predictors of 
stroke recurrence at any time point. Baseline results from the African-American 
Antiplatelet Stroke Prevention Study (AAAPS) found that stroke severity and disability at 





in black patients during 2 years of follow-up[98]. The association between severity of 
first stroke and stroke recurrence is undoubtedly complex, as increased first stroke 
severity may mask the identification of stroke recurrence. The impact of stroke 
recurrence on disability after first stroke is not considered as part of this thesis, but 
clearly this is an area for further research, beyond this thesis, to be targeted.  
 
Work previously described by the SLSR has shown that black patients maintain a higher 
initial stroke risk than white patients[14], yet the results presented in this chapter 
indicate that this increased risk does not confer an increased susceptibility to stroke 
recurrence amongst our black population. It has previously been found by both the 
SLSR and the Northern Manhattan Stroke Study that different risk factors and co-
morbidities may be important in black and white patients[99, 100] and the SLSR has 
previously demonstrated increased survival after first stroke in black patients compared 
to white patients over 65 years[101]. This study importantly shows that these survival 
differences are not caused by differences in stroke recurrences between these ethnic 
groups. 
 
The results presented in this chapter demonstrate the importance of management of co-
morbidities and traditional vascular risk factors as predictors of recurrence At 1 year, 
atrial fibrillation and myocardial infarction were identified as predictors of stroke 
recurrence. This is also demonstrated in the FINMONICA Stroke Register, which 
identified myocardial infarction and atrial fibrillation to be independent predictors of 
recurrence at 1 year in patients ages 75 years and over[102]. Results from the Nanjing 
Stroke Registry showed hypertension, atrial fibrillation and smoking to be predictors at 1 
year, however these results found hypertension only became a significant predictor of 
recurrence during later follow-up, and smoking not to be a predictor at any time-point 
investigated[103]. 
 
Cardiovascular risk factors such as, hypertension and atrial fibrillation were identified as 
predictors for stroke recurrence up to 5 years post-stroke.  There is much variation in 





has been shown to be a predictor for recurrence beyond 1 year[97, 104], and up to 10 
years in patients with a first cerebral infarction[17]. The Lehigh Valley Recurrent Stroke 
Study found a past history of hypertension, and a transient ischaemic attack (TIA) after 
initial stroke to be independent predictors for stroke recurrence up to 5 years. However, 
similar to our results, they also found that a history of TIA prior to initial stroke was not a 
predictor of stroke recurrence[105, 106].  
 
The results demonstrate the importance of cardiovascular risk factors throughout the 
follow-up period, and supplement previous work identifying the impact of cardiovascular 
disease on long-term outcomes after first stroke[107] .  In this chapter, atrial fibrillation 
and myocardial infarction were identified as predictors for stroke recurrence throughout 
the follow-up period up to 10 years.. Atrial fibrillation and myocardial infarction are 
known to be associated with cardio-embolic strokes which have been found to have the 
highest recurrence rates amongst the aetiological subtypes[108]. Hypertension, which 
gained importance as a predictor for stroke recurrence in the middle and long term 
periods, is associated with small vessel disease which has been shown to be the 
aetiological cause related to lacunar infarcts[20]. Therefore, patients with small vessel 
disease may have a lower risk of stroke recurrence in the first years after initial stroke, 
and may experience stroke recurrence later than other subtypes.  
 
The plethora of prior-to-stroke risk factors identified as predictors of recurrence supports 
the hypothesis made in the previous chapter. The closely overlapping confidence 
intervals demonstrated in the analyses throughout the 10 year time period suggest that 
cardiovascular risk factors, in particular hypertension, atrial fibrillation and a previous 
history of myocardial infarction, are predictors of stroke recurrence throughout the study 
period. The failure to reach statistical significance might be due to Type 2 error. It 
seems probable that treatment of these cardiovascular risk factors, by targeted use of 
secondary prevention may well help to reduce stroke recurrence, or at least that it is 






This study had strengths and limitations. The main strengths lie in study design as by 
conducting a population-based study we have an unbiased sampling frame. Very long-
term estimates for stroke recurrence up to 10 years after initial stroke have been 
provided, using standardised methods for comparability to other studies. However, 
discrepancies in completeness of case detection of both initial and recurrent stroke, 
may affect the study as patients with very mild strokes which may not present to primary 
or secondary care services may be missed.  
 
Whilst the use of longitudinal data is undoubtedly a strength of this study, one of the 
main areas for consideration is that of missing data. It is important to ensure that the 
data collected is representative of the population it sets out to represent, and therefore 
to ensure that the maximum number of cases are included in analyses. In particular, the 
main multivariable analyses performed in this study, only used cases with complete 
data for the variables being analysed, so incomplete variables would be excluded in 
these analyses. Sensitivity analyses using multiple imputation methods to replace 
missing values were conducted as part of the amendments to this thesis. The hazard 
ratios and confidence intervals estimated using the imputed dataset were very similar to 
those presented in the main multivariate analyses of this chapter (Table 8) with similar 
cardiovascular predictors identified during the study period, therefore sensitivity 
analyses using multiple imputation methods have not been performed in the remaining 
analyses in this thesis 
 
The analyses conducted in this chapter estimate the cumulative risk of stroke 
recurrence from initial stroke up to defined time-points (1, 5 and 10 years). An 
alternative way of analysing the risk of stroke recurrence would be to report risk at 
defined time periods i.e. 0-1, 1-5 and 5-10 years after first stroke, however this is not 
conventionally used in published population-based studies. Further sensitivity analyses 
were carried out to assess differences between the method of estimating cumulative 
risk of stroke recurrence (i.e. up to 5 years, and up to 10 years after first stroke) taken in 
the analyses of this thesis, compared to the defined specific time periods of 1 to 5 years 
and 5 to 10 years. It is notable that similar predictors of stroke recurrence were 






Despite similar predictors of stroke recurrence being identified by both these methods, 
cumulative risk will be used in the remaining analyses in this thesis for three main 
reasons. Firstly, whilst it was possible to estimate risk of stroke recurrence up to 10 
years using defined time-periods, different methods needed to be used in the 5 to 10 
year period due to the small numbers involved. The use of different methods at different 
time-points makes longitudinal comparability difficult across the study period.  
 
Secondly, it is important for estimates to be compared with other published population-
based and hospital-based studies. A review of literature recorded on the Medline 
database was undertaken to identify methods used to estimate the risk of recurrence 
after first stroke in population-based and hospital-based studies in the two year period 
from 1 August 2013 to 29 August 2015. The following search terms: (stroke OR 
cerebrovascular disease OR cerebrovascular accident) AND stroke recurrence 
(recurren*) were used. Whilst these terms were the same as the terms used in the 
systematic review and meta-analyses in Chapter 4 of this thesis, many of the studies 
identified relate to a subset of stroke patients e.g. those with a diagnosis of atrial 
fibrillation only and therefore were not suitable for inclusion in the meta-analyses. 
 
1976 studies were identified by the search terms and reviewed by hand, 15 studies 
estimated risk of recurrence after first stroke, of which 14 studies estimated the 
cumulative risk of recurrence (Table 10) compared to one study estimating the risk of 
recurrence over defined time periods (0 to 1 day; 1 to 7 days; >7days) (Table 11). The 
use of cumulative estimates of stroke recurrence risk in the analyses in this thesis 
allows comparisons to be made with other published literature, whereas use of defined 
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Study authors/group Statistical methods used 
Mono et al [123] 
 
 
Recurrence-free survival time assessed using  
life- table analysis 
Estimates were given at time-points: (i) within 72 
hours of admission, (ii) in the period from 72 hours 
to 7 days, and  (iii)after 7 days, in patients 
presenting with non-disabling stroke, transient 
ischemic attack (TIA), or amaurosis fugax and 
with an ipsilateral symptomatic CA stenosis of 
50% or more. 
Table 11 Study identified using defined time periods to assess the risk of stroke recurrence over 2 
year period  
 
Finally, the use of defined time periods assumes the risk of stroke recurrence in that 
time period is independent to the risk estimated in the preceeding time-period, e.g. that 
the risk of stroke recurrence from 1 to 5 years is independent of the risk estimated from 
0 to 1 year. There are many reasons why this may not be the case, including late 
identification of risk factors during follow-up, or non-adherence to prescribed 
medication, Time-dependent covariates may provide a better option allowing post-
stroke risk factors to be included in analyses. The use of time-dependent covariates in 
the estimation of predictors of stroke recurrence shall be discussed further in Chapter 6.  
 
Since the start of the SLSR in 1995, the pathological Oxford Community Stroke Project 
(OCSP) classification of stroke subtype has been introduced, as well as an aetiological 
classification system based on the Trial of Org 10172 in Acute Stroke Treatment 
(TOAST) criteria[20], modified in South London to improve the rate of determined 
aetiology and to account for expected differences in stroke subtype for the local black 
population[82]. As both these classifications have previously been validated to be 
applied retrospectively as well as for prospective use, this provides an opportunity for 
patient records to be reviewed, in order to determine the OCSP and modified TOAST 






Furthermore, it is important to ensure complete case ascertainment, in particular by 
identifying patients who may have had a stroke recurrence prior to death. The SLSR 
uses 16 overlapping notification sources with high levels of capture-recapture 
consistently observed in analyses[14, 124]. However, whilst death data related to 
register participants are obtained regularly from the Office for National Statistics (ONS), 
there has previously been no further review of this data to see if a stroke recurrence 
occurred prior to death. Due to the high quantity of data received since 1995, it is 
impossible and impractical to review every single set of hospital and community notes to 
ascertain if a stroke recurrence, not previously recorded by the SLSR, occurred. The 
use of an algorithm based on the International Classification of Disease (ICD-9 or ICD-
10) codes related to stroke, may help to identify patients, who, by the code given to their 
cause of death and other pre-morbid conditions, may have had a further stroke before 
their death. 
 
In this study, a Cox Proportional Hazards model was used to identify predictors of 
stroke recurrence. Cox Proportional Hazards models make no assumption about the 
form the underlying hazard of stroke recurrence takes[125]. Previous population-based 
studies have used Cox models to undertake these analyses[97, 126], however no 
studies have been found that identify the form of the hazard distribution. By using a non-
specific statistical model such as the Cox model, the risk of stroke recurrence, and by 
default the effect of predictors of the risk of stroke recurrence may be under-estimated 
or over-estimated.. It would therefore be useful to clarify the distribution of the risk of 
stroke recurrence by fitting different statistical models to results, using a sufficiently 
large data sample, in order to ascertain the best fit model. This shall be explored further 
in Chapters 4 and 5 of this thesis. 
 3.5 Summary 
This preliminary study has shown that cardiovascular risk factors do have an important 
role in predicting the risk of stroke recurrence. However it also identified several factors 
to be addressed both methodologically and regarding the dataset used, prior to further 






Ensuring completeness of both case ascertainment and variables with missing data, 
where retrospective data collection is possible and has been validated e.g. the TOAST 
classification, is important for results to be as accurate as possible, and so that the right 
conclusions are made.  
 
Identification of the distribution of the risk of stroke recurrence is also important in order 
for the most accurate statistical model to be used in the analyses. In order for the 
correct model to be fit to the distribution, a large sample of data is needed. This shall be 






Chapter 4 Risk and cumulative risk of stroke recurrence: a systematic review of the literature and meta-analysis 
This systematic review and meta-analysis was presented as oral presentations at the 
UK Stroke Forum in 2009 and the European Stroke Conference in 2010 and was  
published in ‘Stroke’ journal in 2011. (See Appendix 1). 
 Abstract 
 
Background- Estimates of risk of stroke recurrence are widely variable and focused on 
the short-term. A systematic review and meta-analysis was conducted to estimate the 
pooled cumulative risk of stroke recurrence at different time-points after first-ever stroke 
and to determine the influence of the socio-demographic and clinical risk factor profile of 
the study populations, as well as study design and methodological factors on reported 
risk of stroke recurrence. 
 
Methods- Studies reporting cumulative risk of recurrence after first-ever stroke were 
identified using electronic databases and by manually searching relevant journals and 
conference abstracts. Overall cumulative risks of stroke recurrence at 30 days and 1, 5, 
and 10 years after first stroke were calculated using inverse-variance methods, and 
analyses for heterogeneity were conducted. Non-linear least squares analyses were 
used to fit statistical models to the pooled results to estimate the cumulative risk of 
stroke recurrence over time. 
 
Results- Sixteen studies were identified, of which 13 studies reported cumulative risk of 
stroke recurrence in 9115 survivors. The pooled cumulative risk was 3.1% (95% CI, 1.7-
4.4) at 30 days, 11.1% (95% CI, 9.0-13.3) at 1 year, 26.4% (95% CI, 20.1-32.8) at 5 
years, and 39.2% (95% CI, 27.2-51.2) at 10 years after initial stroke. Substantial 
heterogeneity was found at all time points with I2 values ranging from 88-96%. The 
results also demonstrate a temporal reduction in 5-year risk of stroke recurrence from 






Conclusions- The cumulative risk of recurrence varies greatly up to 10 years. This may 
be explained by differences in case mix and changes in secondary prevention over time 
However, methodological differences are likely to play an important role and consensus 
on definitions would improve future comparability of estimates and characterisation of 
groups of stroke survivors at increased risk of recurrence.
4.1 Background 
Patients surviving an initial stroke are known to be at a significantly increased risk of 
further strokes, compared to the rest of the population however quantification of how 
great the risk of recurrence is at different time-points after first stroke is limited[36]. 
Identification of patients at high risk of stroke recurrence at specific time points after first 
stroke is important in order for modifiable risk factors to be targeted and to prevent 
reduce the risk of these strokes occurring[37]. There is considerable variation in the risk 
of stroke recurrence in the reported literature, however reasons for these differences 
are unclear. For example, the 5 year risk of stroke recurrence has been reported to 
range from 12-42%[127, 128] with other population-based studies reporting cumulative 
5 year risk of 19% in Manhattan and 29% in Rochester, both in the USA; 30% in 
Oxfordshire, United Kingdom; and 32% in Perth, Australia [17, 91, 129] .Furthermore it 
is unclear if, despite variations in reported results across different study groups, it is 
possible to fit a statistical model to combined results to predict the cumulative risk of 
stroke recurrence over time.  
 
The aim of this systematic review is to examine the literature related to risk of stroke 
recurrence at different time-points after first-ever stroke and to determine the influence 
of the socio-demographic and clinical risk factor profile of the study populations, as well 
as study design and methodological factors on reported risk of stroke recurrence. 
 4.2 Methods  
 4.2.1 Identification of papers 
This review aims to identify all studies from hospital-based or community-based stroke 
registers reporting the risk of stroke recurrence at any time point after first-ever stroke 
irrespective of study design and setting, or language. Ovid Medline (1950-December 
2009), EMBASE (1950-December 2009) and the Web of Science were searched by use 





stroke (stroke OR cerebrovascular disease OR cerebrovascular accident) AND stroke 
recurrence (recurren*). 
 
In addition, the reference lists of all identified studies and the contents pages of relevant 
peer-reviewed journals (Stroke, Lancet Neurology, New England Journal of Medicine, 
Cerebrovascular Diseases, the Journal of Neurology, Neurosurgery and Psychiatry, and 
the British Medical Journal), as well as abstracts from national and international 
conferences related to stroke were hand-searched in order to identify studies not 
previously identified by the electronic searches.  
 4.2.2 Inclusion Criteria  
This review included studies reporting the risk of stroke recurrence at any time-point 
after a first-ever stroke. Studies reporting recurrence after ischaemic strokes, primary 
intra-cerebral haemorrhages, sub-arachnoid haemorrhages and undefined strokes were 
included. A stroke ‘recurrence’ was defined as a focal neurological deficit lasting more 
than 24 hours and occurring after an initial stroke. This definition was utilised in order to 
include all studies reporting stroke recurrence at any time point after a first stroke. 
Studies reporting data from both hospital-based and population-based stroke registers 
were included, however, studies reporting on only a particular subset of patients (e.g. 
diabetic patients or men only) were excluded. Multiple publications from the same study 
group, were reviewed to avoid the use of the same data from over-lapping cohorts.  
 
The meta-analyses included studies reporting the cumulative risk of stroke recurrence, 
estimated using survival analysis (time to stroke recurrence) methods, only. Data were 
extracted from studies to undertake estimates of pooled cumulative risk of stroke 






4.2.3 Data extraction  
A matrix was used to extract information from the included studies. This is summarised 




Length of follow-up period 
Clinical setting 
Inclusion criteria for study 
Definition of stroke 
Definition of stroke recurrence 
Exclusion period before stroke recurrence defined 
Population characteristics 
Socio-demographic factors 
Prior-to-stroke risk factors 
Stroke severity markers 
Subtype of initial and recurrent stroke 
Outcome measures 
Risk of stroke recurrence at any reported time-points 
Cumulative risk of stroke recurrence at any reported time-points 
Figure 3. Data extracted from included studies 4.2.4 Data collection 
In instances where incomplete data were obtained from included publications, the 
authors were contacted in writing, for permission to obtain data for further analyses. 
This was repeated if no response was received within 2 weeks, and further 





 4.2.5 Data analyses 
The risk of stroke recurrence, i.e. the probability of a stroke recurrence having occurred 
by a given time-point, was obtained directly from the studies included in the systematic 
review. Additionally, the cumulative risk of stroke recurrence, defined as the probability 
that an individual will have a stroke recurrence at a given time-point assuming that they 
do not die from some other cause[130], and related 95% Confidence Intervals (CI) were 
calculated 30 days, 1, 5 and 10 years after first stroke for individual studies and pooled 
estimates were derived.  
 
Inverse-variance methods were used to calculate the pooled estimates and associated 
95% CIs[131]. Due to presumed differences in study design across the 13 studies, the 
Der Simonian and Laird method of random effects meta-analyses was used[132]. In a 
random-effects meta-analysis, the standard error of the study estimates are adjusted to 
account for heterogeneity among the estimates observed in different studies 
 
Forest plots were constructed for each time point (30 days, 1, 5 and 10 years after first 
stroke).  Analyses for heterogeneity were conducted using the Chi-squared test.  A 
sensitivity analysis was conducted to compare the pooled cumulative risk at 1 year after 
first stroke, for hospital and community-based stroke populations.  
 
Non-linear least squares analyses were used to construct Exponential and Weibull 
random effects meta-regression models. These models were fit to the risk of stroke 
recurrence, estimated in the individual studies, to establish the model of best-fit and to 
model cumulative risk as a function of time since first stroke. The Weibull (a 
generalisation of the exponential distribution) was the simplest model providing an 
adequate fit to the meta-analytic estimates of stroke recurrence [125]. The use of these 
models allowed for the prediction of the cumulative risk at time-points not directly 





Weibull distribution with a bivariate random effects model for the study specific 
parameters.  
 
Analyses were conducted using SPSS Version 17, Review Manager Version 5 and  
PROC NL MIXED of SAS version 9.1.  SPSS was used to estimate the cumulative risk  
and corresponding 95% Confidence Intervals for studies where raw data was obtained 
from the study authors. Review Manager was used to obtain the pooled estimates and 
construct Forest plots for each time point. Finally SAS was used to fit statistical models 
to the pooled results to allow estimation of the cumulative risk of stroke recurrence at 
time-points not directly analysed in the meta-analyses.  4.3 Results 
2497 studies were identified by the electronic database searches, of which 24 studies 
met our inclusion criteria.  A further 4 studies were added by hand-searching journals 
and conference abstracts related to stroke. Therefore, a total of 28 studies reporting the 
risk of stroke recurrence were included in this review.  
 4.3.1 Risk of stroke recurrence 
The risk of stroke recurrence, i.e. the probability of a stroke recurrence having occurred 
by a given time-point, was reported to range from 1.1% in South London[133] to 15% in 
Oxfordshire, UK[134] by 1 month; from 7.0% in Lisbon, Portugal[135] to 20.6% in 
Nanjing, China[103] by 1 year; from 16.2% in South London[133] to 35.3% in Hisayama, 
Japan by 5 years[136]; and from 14% in Rome, Italy[137] to 51.3% in Hisayama, 
Japan[136] by 10 years post-initial stroke. Figure 4 shows the estimates of risk of stroke 
recurrence up to 10 years after initial stroke, across all the included studies. It is notable 







Figure 4. Risk of stroke recurrence after first stroke across all 16 included studies. 
 4.3.2 Cumulative risk of stroke recurrence 
16 studies reporting the cumulative risk of stroke recurrence were identified of which, 
from 13 studies sufficient data was obtained to be included in the meta-analysis. The 
cumulative risk of stroke recurrence, was defined as the probability that an individual will 
have a stroke recurrence at a given time-point assuming that they do not die from some 
other cause and is estimated using survival or time-to-event analyses [130]. The 







Figure 5. Systematic review flowchart 
For the three studies not included in the study, repeated attempts were made to obtain 
data at the time-points needed to be included in the study, however, this data was not 
available. A summary table with details of these three studies is shown in Table 12. 
Authors Population studied Reason for exclusion 
Lai et al[138] Lehigh Valley Recurrent 
Stroke Study 
Kaplan-Meier estimates at 3 months presented 
without standard error. Unable to contact study 
investigators to obtain more data to conduct 
analyses despite multiple attempts 
Elneihoum et 
al[104] 
Malmo Stroke Registry 
(STROMA) 
Kaplan-Meier estimates at 3 years estimated as 6% 
but presented without standard error. Despite 
multiple correspondences, the data was unable to be 
located by the Malmo Stroke Registry team.  
Acciarresi et 
al[139] 
Perugia Stroke Unit, 
Italy. Hospital based 
study. 
Kaplan-Meier estimate at 3 months presented 
without standard error. Unable to contact study 
investigators to obtain more data to conduct 
analyses despite multiple attempts 
   





Key details of the 13 studies included in the meta-analysis are displayed in Table 13 
(table over 3 pages). Table 14 displays the estimates of cumulative risk of stroke 
recurrence up to 30 days, 1 year, 5 years and 10 years after first stroke in the studies 
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   Authors 
How
 recurrence defined 
Hardie 
As for stroke 
Petty 





As for stroke. In addition the presence of a new
 neurological deficit, evidence of different vascular territory, or acute 
focal neurology after “stabilisation of initial stroke required. 
Burn 
Stroke only (not TIA). Clinically apparent events only.  
Hata 
As for initial stroke. In addition, new
 focal neurological deficit or a new
 deterioration of a previous deficit that w
as 













As for stroke. In addition the presence of a new









As for stroke. Clinically apparent events only  
Salgado 
A
cute focal neurology after “stabilisation of initial stroke” 
Appelros 
As for stroke.  
Coull 
Stroke only (not TIA). Clinically apparent events only.  
M
ohan 
As for stroke. In addition the presence of a new




ation, or intercurrent illness w
as required.  
Rundek 
As for stroke. In addition the presence of a new
 neurological deficit, evidence of different vascular territory, or acute 
focal neurology after “stabilisation of initial stroke required. 
 Table 13. Characteristics of studies included in the m
eta-analyses.






Cumulative risk of stroke 
recurrence (%) 








Hardie et al[140]  Perth,    
Australia 
 
1989-1990 328 2.1 16.0 32.0 43.0 
Petty et al[17] Rochester,   
USA 
 














1983-1988 655 1.5 7.7 18.3 - 
Burn et al[129] Oxfordshire, 
UK 
 
1981-1986 675 - 13.2 29.5 - 
Coull et al[134] Oxfordshire, 
UK 
 
2002-2003 87 15.0 - - - 
Kolominsky-




1994-1998 583 - 11.0 - - 
Mohan et al[133] South London, 
UK 
 
1995-2004 2874 1.1 7.1 16.2 24.5 
Hata et al[136] Hisayama, 
Japan 
 












1999-2000 377 - 9.0 - - 
Xu et al[103] Nanjing, 
China 
 





1990-1993 145 - 7.0 - - 







The pooled cumulative risk of stroke recurrence was 3.1% (95% CI 1.7-4.4) at 30 days 
(Figure 6); 11.1% (95% CI 9.0-13.3) at 1 year (Figure 7);26.4% (95% CI 20.1-32.8) at 5 
years (Figure 8); and 39.2% (95% CI 27.2-51.2) at 10 years after initial stroke (Figure 
9). Substantial heterogeneity was found between the studies at all time points with I2 
values ranging from 88-96%. (No differences were observed when the cumulative risk 
of recurrence between hospital-based and community-based stroke populations were 
compared 1 year after first-ever stroke. Significant heterogeneity remained between 
study estimates within the 2 groups, and therefore results were not stratified according 
to study population). 
 
Figure 6. Cumulative risk of stroke recurrence at 30 days post-initial stroke  
 






Figure 8. Cumulative risk of stroke recurrence at 5 years post-initial stroke 
 
Figure 9. Cumulative risk of stroke recurrence at 10 years post-initial stroke 
An Exponential meta-regression model was fitted to the cumulative risk of stroke 
recurrence of the individual studies and pooled estimates of the cumulative risk of 






Figure 10. Exponential distribution modelling the cumulative risk of stroke recurrence after first-
ever stroke. 
 
As shown in Figure 10, the Exponential model under-estimated the risk of stroke 
recurrence up to approximately 6 years after first stroke, after which time the model 
over-estimated the predicted risk. 
 
In order to improve the fit of the pooled estimates to the meta-regression model, a 
Weibull model was then fit to the cumulative risk of stroke recurrence of the individual 
studies and pooled estimates of the cumulative risk of stroke recurrence were 
calculated with 95% Confidence Intervals (Figure 11). It is notable that at each time-
point analysed up to 10 year after first-ever stroke, the pooled estimates closely follow 






Figure 11. Weibull distribution modelling the cumulative risk of stroke recurrence after first-ever 
stroke. 
 4.3.3 Updated literature search results 
The literature searches undertaken for this systematic review were completed in 
November 2009 at which time I was working at the SLSR. For completeness these 
literature searches were updated in January 2014 to identify any studies published from 
November 2009 to 11 January 2014 suitable for inclusion in the meta-analyses. A 
flowchart summary of the studies identified is shown in Figure 12.  
 
A summary table with details of the four studies for full-article review but not meeting the 
criteria for inclusion in this meta-analysis, is shown in Table 15. 
 







 Figure 12 Flowchart of updated literature searches (November 2009- January 2014) 
 
Authors Population studied Reason for exclusion 




The study investigates the risk of, and predictors for 
primary intra-cerebral haemorrhage however, 
includes previous ischaemic stroke as a risk factor.  
 
Feng et al (2010) 
[147] 
South Carolina, USA. This study provides the cumulative risk of stroke 
recurrence in a cohort of patients admitted with first 
stroke. The end-point used was a composite 
measure recording which occurred first of recurrent 
stroke, MI and vascular death. 
   
Melkas et al(2012) 
[148] 
 
Helsinki, Finland The study only included patients aged 55-85 years. 
  
An et al (2011) 
[149] 
Tangshan, China It is unclear whether is study reported first-ever 
strokes only. The full text of the study article was 
unavailable as it was published in the ‘Zhonghua Liu 
Xing Bing Xue Za Zhi’ journal in Chinese only. 





 4.4 Discussion 
The results from this systematic review and meta-analysis demonstrate wide variation in 
the reported cumulative risk of stroke recurrence up to 10 years after first stroke and 
significant heterogeneity was observed between studies at all time points. This degree 
of heterogeneity, and its consistency throughout all time-points analysed suggest that 
the observed differences are unlikely to be due to chance. 
 
Differences in study design and population demographics exist between the included 
studies, however they share important characteristics as described in Table 13. In 
particular, the definition of ‘stroke’ and ‘recurrence’ and how participants are followed up 
are similar across studies, whilst key differences lie in the dates of initial study period, 
study setting and the use of an exclusion period for recurrent stroke.  
 
Whilst case-mix and differences in prior-to-stroke risk factors between the populations 
may be responsible in part for these observed variations, differences in case inclusion 
criteria are also likely to be contributory factors. One possible reason for this is that 
studies using both hospital and population-based stroke registers were included in the 
analyses. Not all patients with a stroke present to hospital, either in the acute period or 
at all, therefore hospital based stroke registers cannot fully ascertain the incidence of 
initial, or recurrent stroke fully within a population[150] . Furthermore it is impossible to 
predict which patients are more or less likely to present to hospital after a stroke, as 
both patients with very mild and very severe strokes may not present to hospital for a 
variety of reasons[151]. In this meta-analysis, no significant differences were noted 
between hospital and community-based estimates at 1 year after first-ever stroke, and 
stratification of results did not remove the observed heterogeneity. This indicates that 
other factors, are likely to also be important in differences in cumulative risk of stroke 






Variations in eligibility criteria for study inclusion may also have importance in observed 
differences between the study groups. Both data from the Northern Manhattan Stroke 
Study (NOMAS) and the Hisayama study only included stroke patients aged over 40 
years of age in their analyses [136, 141, 142] Furthermore NOMAS patients were only 
included in analyses conducted by Dhamoon et al if they had a telephone in order for a 
telephone follow-up interview to be conducted six months after their initial stroke[142]. 
This may result in those from a lower socio-economic background or older patients who 
may not have access a telephone to be included in the study. Increasing age, and lower 
socio-economic status have both been previously associated with increased incidence 
of stroke and stroke recurrence[133, 152], therefore by excluding younger people and 
those without telephones, these studies may be under–estimating the true incidence of 
both stroke and stroke recurrence within the source population. 
 
Significantly, studies included in this review differed in the way they defined both a 
stroke and a recurrence. Modrego et al demonstrated recurrence rates of 9.5% at 1 
year and 26% at 5 years post-initial stroke, however, this study, is an example of one of 
many studies which excluded patients with a subarachnoid haemorrhage (SAH) or 
included ischaemic stroke patients only[144]. Studies from the South London Stroke 
Register have found that sub-arachnoid haemorrhage confers an increased risk of 
recurrence in the first six months after initial stroke, after which there is no increase in 
risk of stroke recurrence reported up to 10 years of follow-up[133]. By excluding this 
subgroup, artificially higher rates of recurrence may have been achieved in these 
studies.  
 
The Oxfordshire Community Stroke Project (OCSP) followed up patients for 6.5 years 
and found a cumulative risk of recurrence of 30% at 5 years[129]. The methodology 
used by the OCSP investigators included transient ischaemic attacks (TIAs) as an initial 
stroke event. TIAs can also be considered as a risk factor for strokes, particularly those 
of an atherosclerotic aetiology[153]  and including these events as initial strokes may 







The reported differences in risk of recurrence may also be explained by different 
definitions of what constitutes a ‘stroke recurrence’ used between studies.  There was 
wide variation in the definition of stroke recurrence used, ranging from any focal 
neurological deficit lasting for more than 24 hours occurring after the initial stroke[17, 
136, 141, 142] to an exclusion period of 28 days, only after which further strokes would 
be considered as a ‘recurrence’[104, 154]. Investigators of the Vascular Events In Non 
cardiac Surgery Patients Cohort Evaluation Study (VISION) demonstrated that a high 
proportion of patients with minor stroke have both clinical and radiological recurrences 
in the same vascular territory as their initial event in the first days after their stroke, 
whilst recurrent events outside of the initial vascular territory or perfusion defect were 
rare[155].  
 
Furthermore, Coull and Rothwell have previously demonstrated the effect of different 
definitions of stroke recurrence on estimates of risk 90 days reported after initial stroke 
in the Oxford Vascular Study (OXVASC) and Oxford Community Stroke Project (OCSP) 
cohorts[156]. They found that the risk of stroke recurrence in OXVASC and OCSP 
respectively, ranged from 18.3% and 14.5% when including all stroke recurrences 
occurring 24 hours after the initial stroke, to 5.9% and 4.8% using the definition of only 
stroke recurrences occurring after 28 days employed in the Monitoring Trends and 
Determinants in Cardiovascular Disease (MONICA) study and other population-based 
studies[141, 156]. 
 
This is particularly important when considering the reported risk of stroke recurrence at 
30 days, where an exclusion period of 21 or 28 days imposed in some included 
studies[133, 140], may substantially impact the observed risk of stroke recurrence 
reported 30 days after initial stroke. In this review, studies excluding recurrences 
occurring in the first 21 days after initial stroke were at the lower end of estimates of risk 
of stroke recurrence reported at 30 days[133, 140]. However, the effect of excluding 
recurrent strokes in the first weeks after initial stroke may be seen in reported risks of 





an atherosclerotic origin recur earlier than other stroke subtypes, and therefore by 
excluding recurrent strokes occurring in these critical first weeks after initial stroke, 
artificially lower risk of stroke recurrence may be reported[104].  
 
The studies included in this review have a combined study period encompassing fifty 
years (Table 14). Temporal trends in stroke management and, in particular, the advent 
and increasing importance given to secondary prevention after initial stroke, may be 
another important contributory factor of variation in the risk of stroke recurrence during 
this period. In particular, Figure 8 largely demonstrates a temporal reduction in the risk 
of stroke recurrence, across the different study populations, with smaller recurrence risk 
reported in later studies. The exception to this is the study performed by Hata et al[136]. 
This population reported very high rates of recurrence after haemorrhagic strokes, and 
in particular subarachnoid haemorrhage, with high rates of stroke recurrence 
maintained up to 10 years after initial stroke, making this study distinct when compared 
to the other included studies. Differences in the source population may play an 
important role in explaining these findings, however further investigation is needed in 
this area.  
 
These analyses provide long-term pooled estimates of cumulative stroke recurrence risk 
up to 10 years after first stroke. High levels of heterogeneity indicated by I2 values 
ranging from 88-96% were observed at across all time-points. Random-effects models 
were used in the meta-analysis to account for heterogeneity between studies as 
differences in study design were presumed across the 13 studies. However, the effect 
of variation in population demographics, and indeed temporal trends described briefly in 
this section, may be considered as reasons for pooling of estimates across study 
populations not to be undertaken.  
 
Advances in both secondary prevention and radiological imaging have changed the way 
stroke and recurrence are both identified and managed over the last decades. However 





demographics or temporal trends due to temporal trends, which may preclude from 
estimates being pooled, are lacking.  
 
In particular, meta-analyses investigating the differences in stroke incidence and stroke 
subtypes in Chinese compared to white populations have described a higher proportion 
of intracerebral hemorrhage in Chinese populations, but found no evidence for different 
distributions of ischemic stroke subtypes and associated risk factors[157, 158]. The 
study by Xu et al from the Nanjing Stroke Registry included in the meta-analysis, 
estimates the cumulative risk of recurrence in patients with first ischaemic stroke 
only[103].  
 
Comparison of stroke recurrence risk across study populations is widely described in 
the literature and the purpose of this chapter has been to highlight differences between 
study populations and potential reasons for differences in estimates. Clearly, the use of 
comparable, population-based case ascertainment and similar classification methods 
across different study populations would allow more in-depth comparisons regarding the 
cumulative risk of stroke recurrence to be drawn between study populations.  
 4.5 Summary 
In conclusion, this review and meta-analysis has found substantial variation and 
heterogeneity in the reported risk of stroke recurrence at time points ranging from 30 
days to 10 years after initial stroke and a temporal reduction in the risk of stroke 
recurrence across the different study populations, with smaller recurrence risk reported 
in later studies. Whilst many methodological factors may play a part, this review has 
demonstrated that genuine differences between populations and temporal changes in 
stroke management and secondary prevention may also be important in explaining 
these results. This indicates that further research is therefore needed to investigate the 
effect of secondary prevention measures on the risk of stroke recurrence at different 
time-points ranging from the first weeks to beyond 10 years after first stroke. These 





Chapter 5  The cumulative risk of stroke recurrence 
The analyses described in this chapter were displayed as a poster presentation at the 
European Stroke Conference in 2011 (Appendix 1).  Abstract  
Background - Data reporting long-term patterns of cumulative risk of stroke recurrence 
between different aetiological and pathological stroke subtypes are lacking. 
Furthermore, information regarding transition in subtype of first and recurrent stroke is 
not widely available.  
 
Methods - Patients registered with the SLSR were followed up for a maximum of 12 
years. Kaplan-Meier estimates were used to assess cumulative risk of stroke recurrence 
and this was stratified to investigate time trends and by using the Trial of Org 10172 in 
Acute Stroke Treatment (TOAST) and Oxford Community Project Classification (OCSP) 
classifications. Initial and recurrent stroke subtypes were cross-tabulated to calculate 
transition probabilities. 
 
Results- Between 1995 and 2009, 4023 patients with first-ever stroke were included in 
the SLSR. Mean follow-up period was 3.0 years. In 11981.7 person-years of follow up, 
394 recurrent strokes were documented. The overall cumulative risk of stroke 
recurrence was to estimated to be 6.7% by 1 year, 15.1% by 5 years, 21.5% by 10 
years and 23.5% by 12 years after first stroke. Time trends indicated a significant 
reduction in risk of stroke recurrence up to 1 year after first stroke between 1995-1999, 
2000-2004, and 2005-2009 (p=0.03). 
 
Between 1999 and 2009, the cumulative risk of stroke recurrence 1 year post stroke 
ranged from 4.0% in the small vessel occlusion (SVO) group to 6.5% in the large artery 





intracerebral (PICH) and sub-arachnoid (SAH) haemorrhages which were 8.6% and 
8.8%. Transition in aetiological subtype between initial and recurrent stroke was seen in 
51.0% at 1 year, increasing to 61.9% 10 years after first stroke.  
 
Conclusions- The cumulative risk of stroke recurrence is wide-ranging between 
aetiological and pathological subtypes.  Further research is needed to identify predictors 
for increased risk of recurrence amongst different stroke subtypes and to investigate 
whether implementation of intensified secondary prevention medication can reduce the 
long-term risk of stroke recurrence.  
 5.1 Background 
Accurate identification of the time after first stroke when a recurrence is most likely to 
occur is important for both targeted secondary prevention therapy regimes to be 
developed, as well as to predict outcome after stroke[159]. This time of increased risk 
may be different depending on the subtype of initial stroke. However most studies have 
stratified strokes using pathological classifications only, i.e. differentiating between 
ischaemic and haemorrhagic strokes, and focussing on the first years after first stroke.  
 
As reported in Chapter 3, previous studies from the SLSR have found no differences in 
the risk of recurrence between ischaemic and haemorrhagic strokes up to 10 years after 
first stroke[133]. However, this contrasts with both research from Japan that found the 
risk of stroke recurrence to be significantly greater within 1 year of the first-ever stroke 
in patients with an initial ischaemic stroke compared with haemorrhagic stroke, and 
results from the Perth Community Stroke Study (PCSS) who reported prognostic factors 
for recurrent stroke up to 5 years after first stroke to be an initial stroke subtype of either 
PICH or SAH[91, 136].  
There have been limited population-based studies investigating differences in 
recurrence rates between the aetiological ischaemic stroke subtypes, and in particular, 





recurrences are likely to be of the same aetiological subtype as the first stroke. This is 
important as it is known that some aetiological subtypes are more closely linked to 
specific risk factors. Therefore knowledge of which subtypes are more likely to recur, 
should both help critical time-periods to be identified, as well as allowing modifiable risk 
factors to be targeted in order to prevent stroke recurrence[20].  
 
The aim of this study was to estimate the risk of stroke recurrence up to 12 years after 
first-ever stroke, and to estimate the percentage transition of aetiological subtype 
between first and recurrent (second) strokes recorded at the South London Stroke 
Register. 
 5.2 Methods 
The use of the South London Stroke Register as the study population, the case 
ascertainment and data collection methods used in this chapter have previously been 
described in Chapter 2 of this thesis. 
 5.2.1 Variable definition 
Stroke was defined according to the World Health Organisation (WHO) criteria[81]. 
Pathological stroke subtypes were classified using neuroradiology or necropsy results 
into ischaemic stroke, primary intracerebral haemorrhage or subarachnoid 
haemorrhage.  
 
Ischaemic strokes occurring from January 1999 were further investigated according to 
an investigation algorithm and categorised by a study clinician into aetiological subtypes 
according to the TOAST classification[20] with local modifications to improve 
investigation rates in different ethnic groups[82]. Ischaemic stroke subtypes included in 





large artery atherosclerosis and intracranial large artery atherosclerosis), cardio-
embolism (CE), small vessel occlusion (SVO), other aetiology (OTH) (including other 
vascular aetiology, other haemoglobinopathy aetiology, other hypercoaguable aetiology, 
migrainous stroke, and other aetiology not previously mentioned) and no aetiology 
identified (UND). 
 
The definition of stroke recurrence was the same as for the index stroke. Additionally, 
clinical diagnosis of a new neurological deficit, or deterioration of a previous deficit not 
due to oedema, haemorrhagic transformation, or inter-current illness was required. Only 
recurrences 21 days after the initial event, or if earlier, clearly in a different vascular 
territory were included. The same referral sources were used for notification of stroke 
recurrences as for initial stroke ascertainment. All patients were eligible for follow-up if 
alive and having reached the specified point of follow-up by August 2010. 
 5.2.2 Statistical analyses 
Univariate analyses using Kaplan-Meier estimates were used to model the risk of 
recurrent stroke (1- survival free of recurrent stroke) and therefore to measure the 
cumulative risk of stroke recurrence and 95% confidence intervals (CI) 1, 5, 10 and 12 
years after initial stroke. The risk of recurrent stroke was also estimated 1, 5 and 10 
years after initial stroke stratified for year of first stroke (categorised as 1995-1999, 
2000-2004, 2005-2009).Log rank tests were conducted to estimate differences between 
the time-periods analysed. 
 
The cumulative risk of stroke recurrence, was defined as outlined in Chapter 2, i.e. the 
probability that an individual will have a stroke recurrence at a given time-point 
assuming they do not die from some other cause[130]. Patients were censored at time 
of death, if lost to follow-up, or if alive at 10 years after stroke. In patients with an initial 
stroke between 1999 and 2009, the estimated cumulative risk of recurrence was 





(TOAST) classification[82]. Initial and recurrent stroke subtypes were cross-tabulated to 
calculate the percentage transition between subtypes up to 10 years after first stroke. 
 
As with the pooled estimates used in Chapter 5, non-linear least squares analyses were 
used to construct Exponential and Weibull models which were fit to the estimates of 
cumulative risk of stroke recurrence to establish the model of best-fit and to model 
cumulative risk as a function of time since first stroke. The Weibull is a generalisation of 
the exponential distribution, however whilst the exponential assumes that the hazard is 
constant, the Weibull model allows it to vary. The Weibull was the simplest model 
providing an adequate fit to the study results therefore more complex modelling was not 
undertaken[125].  
 
 Analyses were conducted using SPSS Version 17 to undertake the cross-tabulation 
calculations; and SAS version 9.1 to calculate the Kaplan-Meier estimates and to fit the 
Exponential and Weibull models to the estimates using non-linear least squares 
analyses. 
 5.3 Results 5.3.1 Demographic data 
This study included a total of 4023 first-ever stroke patients registered between January 
1995 and December 2009. The mean follow-up time was 3.0 years, and a total of 
11981.7 person years of follow-up were included. During this period, 394 recurrent 
strokes were documented. Patient characteristics at time of initial stroke are presented 
in Table 16. The number of patients remaining in the study at key time points during the 








 Total, N(%) 
Total 4023 
Age group  
   <65 1248 (31) 
  65-74 1041 (26) 
  75-84 1734 (43) 
Gender  
  Male 2024 (50) 
Ethnicity  
  White 2890 (72) 
  Black 805 (20) 
  Other 225 (5.6) 
Socio economic status  
  Non-manual 1082 (26) 
  Manual 2148 (53) 
  Economically inactive 562 (14) 
  Unknown 221 (5.5) 
Risk factors  
  Previous TIA 472 (12) 
  Hypertension 2436 (61) 
  Diabetes Mellitus 712 (18) 
  Previous MI 415 (10) 
  Previous AF 629 (16) 
  Smoker or ex-smoker 2404 (60) 
Table 16. Baseline demographic data 
 
Time after first 
stroke  
Number at start 





censored - died  
Number 
censored – at 
last follow-up 
Number in 
study at end of 
time-period 
0-1 years 4023 191 (4.7%) 688 (16.9%) 891 (22.2%) 2253 (56.0%) 
1- 5 years 2253 149 (6.6%) 290 (12.9%) 824 (36.6%) 990 (43.9%) 
5-12 years 990  53  (5.4%) 165 (16.7%) 660 (66.7%) 112 (11.3%) 
Table 17. The number of participants in the study throughout the study-period 5.3.2 Survival Analyses 
The cumulative risk of first stroke recurrence was estimated to be 6.7% (95% CI 5.8 to 
7.6%) up to 1 year, 15.1% up to 5 years (95% CI 13.5 to 16.7%), 21.5% up to 10 years 
(95% CI 19.2 to 23.9%) and 23.5% (95% CI 20.6 to 26.4%) up to 12 years after first-






5.3.2.1 Trends in risk of stroke recurrence 
The risk of stroke recurrence stratified for year of initial stroke is shown in Table 18. A 
log rank tested showed significant differences between the risk of stroke recurrence 
during the three time intervals, up to 1 year (p=0.03), 5 years (p<0.01) and 10 years 
(p<0.01) after first stroke. 
 1 year 5 years 10 years 
1995-1999 8.2 (6.6-9.8) 18.6 (16.1-21.1) 26.4 (23.1-30.0) 
2000-2004 6.4 (4.8-8.0) 12.5 (10.1-14.9) 18.7 (10.1-27.3) 
2005-2009 5.0 (3.5-6.5) 15.8  (8.5-23.1) - 
Table 18 Trends in risk of stroke recurrence up to 10 years after initial stroke from 1995-1999, 
2000-2004 and 2005-2009 
 5.3.2.2 Fitting a model of risk of recurrence  
Exponential (Figure 13) and Weibull models (Figure 14) were fit to the estimates to 
ascertain the best-fit model to predict cumulative risk up to 12 years after first stroke. As 
can be seen in Figure 13, the exponential model does not closely follow the Kaplan-
Meier curve. It under-estimates the risk of stroke recurrence up to approximately five 
years after initial stroke, after which time it over-estimates the risk. In comparison, the 







Figure 13 Exponential distribution modelling the cumulative risk of stroke 
recurrence 
  Figure 14 Weibull distribution modelling cumulative risk of stroke recurrence 
 5.3.2.3 Cumulative risk of stroke recurrence stratified by aetiological subtype 
Between 1999 and 2009, 201 stroke recurrences were recorded. The cumulative risk of 





stratified according to the modified TOAST classification. These univariate analyses are 
displayed, compared to the risk of stroke recurrence after an initial PICH or SAH, in 
Table 19. 
 
Stroke subtype Cumulative risk of recurrence, % (95% CI) 
 Up to 1 year Up to 5 years Up to 10 years 
All Ischaemic    
      LAA 6.5(2.8-10.2) 14.4(7.3-21.5) 14.4(7.3-21.5) 
      CE 6.3(3.6-9.0) 15.3(10.4-20.2) 27.1(7.3-46.9) 
      SVO 4.0(1.3-6.7) 13.5(9.6-17.4) 17.9(12.2-23.6) 
      OTH 5.4(0.0 -11.3) 10.1(1.5-18.7) 20.1(0.2-40.1) 
      UND 6.2(4.2-8.2) 12.4(9.6-15.2) 17.0(11.5-22.5) 
PICH 8.6(4.5-12.7) 15.0(9.1-20.9) 21.5(8.0-35.0) 
SAH 8.8(3.0-14.7) 8.8(3.0-14.7) 8.8(3.0-14.7) 
Table 19 Cumulative risk of stroke recurrence stratified by aetiological stroke subtype 
 
Abbreviations: CI: Confidence Interval; LAA: Large Artery Atherosclerosis; CE: Cardio-embolic; SVO: Small 
Vessel Occlusion; OTH: other; UND: undefined; PICH: Primary Intra-cerebral Haemorrhage; SAH: 
Subarachnoid Haemorrhage.  
 5.3.3 Transition between stroke subtypes 
Transition in aetiological subtype after 1 and 10 years initial stroke are seen in Table 20 
and Table 21 respectively. Table 22 shows transition in stroke subtype between all 
ischaemic strokes, compared to haemorrhagic strokes. A change in aetiological subtype 
after initial ischaemic stroke was seen in 47.1% at 1 year, increasing to 53.8% at 5 
years and 54.4% 10 years after first-ever stroke. This compared to a 58.3% transition in 
subtype estimated 10 years after an initial PICH. The transition probability estimated 
after an initial SAH remained constant at 75% from 1 to 10 years after first stroke, as all 










Table 20.  The 1 year transition in aetiological subtype between first and recurrent stroke 
Abbreviations:LAA: Large Artery Atherosclerosis; CE: Cardio-embolic; SVO: Small Vessel Occlusion; OTH: other; 
UND: undefined; PICH: Primary Intra-cerebral Haemorrhage; SAH: Subarachnoid Haemorrhage.  
 
Table 21 The 10 year transition in aetiological subtype between first and recurrent stroke. 
Abbreviations: LAA: Large Artery Atherosclerosis; CE: Cardio-embolic; SVO: Small Vessel Occlusion; OTH: other; 






  Recurrent stroke subtype n,(%) 
  LAA CE SVO OTH UND PICH SAH 
Initial LAA 8 (72.7) 0  (0) 0  (0) 0 (0) 3 (27.3) 0 (0) 0 (0) 
Stroke CE 0  (0) 15 (71.4) 0  (0) 0 (0) 5 (23.8) 1 (4.8) 0 (0) 
subtype SVO 1  (5.9) 3   (17.6) 5 (29.4) 0 (0) 7 (41.2) 1 (5.9) 0 (0) 
 OTH 0  (0) 0   (0) 0 (0) 1(33.3) 1 (33.3) 0 (0) 1(33.3) 
 UND 2   (5.7) 2   (5.7) 9 (25.7) 1 (2.9) 17(48.6) 3 (8.6) 1 (2.9) 
 PICH 1   (6.7) 4    (26.7) 3  (20.0) 0 (0)  1  (6.7) 6 (40.0) 0 (0) 
 SAH 0   (0) 0   (0) 0  (0) 5(62.5) 1 (12.5) 0 (0) 2 (25.0) 
  Recurrent stroke subtype n,(%)    
  LAA CE SVO OTH UND PICH SAH 
Initial LAA 10 (55.6) 3  (16.7) 0  (0) 0 (0) 5 (27.8) 0 (0) 0 (0) 
Stroke CE  1  (2.6) 24 (61.5) 1  (2.6) 0 (0) 8 (20.5) 4 (10.3) 1 (2.6) 
subtype SVO  4  (8.3) 4   (8.3) 16(33.3) 0 (0) 22(45.8) 2 (4.2) 0 (0) 
 OTH  1  (16.7) 0   (0) 1  (16.7) 1(16.7) 2(33.3) 0 (0) 1(16.7) 
 UND 2   (3.4) 5   (8.6) 15(25.9) 2 (3.4) 26(44.8) 7 (12.1) 1 (1.7) 
 PICH 1   (4.2) 4  (16.7) 3  (12.5) 0 (0) 6 (25.0) 10(41.7) 0 (0) 






 Recurrent stroke subtype 
 All ischaemic PICH SAH 
Initial stroke subtype n,(%)    
All ischaemic 153 (90.5) 13 (7.7) 3 (1.8) 
PICH 14  (58.3) 10 (41.7) 0 (0) 
SAH 6    (75.0)  0   (0) 2 (25.0) 
Table 22. The 10 year transition in pathological subtype between first and recurrent stroke.  5.4 Discussion 
This study provides long-term estimates of the cumulative risk of stroke recurrence up 
to 12 years after initial stroke. The results indicate that the cumulative risk of first stroke 
recurrence is substantial (i.e.) up to 23.5% at 12 years post-initial stroke and wide-
ranging between aetiological and pathological subtypes over time, with lower 1 year 
recurrence rates reported in the ischaemic stroke subtypes, compared to the 
haemorrhagic stroke subtypes. By 10 years, the risk of stroke recurrence amongst the 
ischaemic subtypes ranged from 14.4% (95%CI 7.3 to 21.5%) to 27.1% (95%CI 7.3 to 
46.9), comparable with the 10 year risk of recurrence after PICH of 21.5% (95%CI 8.0 to 
35.0) but contrasting with the SAH group, in which the cumulative risk of recurrence 
remained constant at 8.8% (95% CI 3.0 to 14.7%) from 1 year to 10 years. 
 
The results also demonstrate a temporal decrease in the risk of stroke recurrence after 
first stroke between 1995 and 2009. In particular the 1 year recurrence rate was 
estimated to be 8.2% (95%CI 6.6-9.8%) between 1995 and 1999; 6.4% (95% CI 4.8-
8.0%) between 2000 and 2004; and 5.0% (95%CI 3.5-6.5%) between 2005 and 2009 
(p=0.003). Whilst a reduction in stroke incidence during this time-period has been 
documented in previous literature, this is the first study to compare temporal trends in 
risk of stroke recurrence in a population-based setting[14, 15, 160]. The observed risk of 
stroke recurrence may be due to the increasing use of primary and secondary 
prevention throughout this time-period. However further studies investigating the effects 
of secondary prevention on risk of stroke recurrence are needed to test this hypothesis 






This study has shown differences in the pattern of stroke recurrence between the 
different aetiological stroke subtypes. The LAA subtype had the highest risk of stroke 
recurrence (6.5% (95 CI 2.8-10.2%)) amongst the ischaemic stroke subtypes up to 1 
year after first stroke. This was maintained up to 5 years after first stroke, after which 
time the risk of stroke recurrence in this subtype plateaued. Previous population-based 
studies have found the risk of recurrence amongst the LAA group to vary widely from 
1% at 2 years after initial stroke in Erlangen, Germany[143], to 18.5% at 1 month in 
Rochester, USA[17].. Furthermore, a meta-analysis performed by Lovett et al, studying 
the risk of recurrent stroke by aetiological TOAST subtype, found patients with the LAA 
subtype were consistently at 3 times higher risk of stroke recurrence up to 3 months 
after first stroke, compared to other aetiological subtypes[161]. One reason for observed 
variation between studies may be that the in order for the LAA subtype to be classified, 
investigation of the carotid intra and extra-cerebral arteries is essential, without which a 
diagnosis is unlikely to be made. Adams et al, when defining the original TOAST 
classification, suggested that a large proportion of the UND subgroup had strokes 
secondary to atheroma[20], indicating that an under-estimation of this sub-group may 
be occurring within some study groups. 
 
The CE subgroup maintained consistently high levels of stroke recurrence up to 10 
years after first stroke. This was also found by Yamamoto et al who used the TOAST 
classification to examine the aetiological stroke subtype of consecutive stroke 
recurrences in a hospital-based setting and compared them to the initial stroke subtype. 
They found a 77% concordance between first and recurrent strokes for the CE subtype, 
the highest of all the groups studied[162]. 
 
Patients with an initial SVO stroke had the lowest risk of stroke recurrence at 1 year, 
increasing substantially at 5 and 10 years after first stroke. Studies have found the SVO 
subtype to have both increased odds of an excellent outcome, defined as a combination 
of a Glasgow Outcome Scale score of 1 and a Barthels Index score of 19 or 20 (on a 





defined by Rankin scale scores of 1-2, at 6 months[164]; and to have an increased 
likelihood of survival at 1 and 2 years after first stroke compared to other TOAST 
subtypes[165]. Studies from the SLSR have indicated that hypertension may be an 
important predictor of stroke recurrence up to 5 and 10 years after first stroke. 
Hypertension is associated with small vessel disease which has been shown to be the 
aetiological cause related to lacunar infarcts[124] Therefore, patients with small vessel 
disease have a lower risk of stroke recurrence at 1 year, and may experience stroke 
recurrence later than other stroke subtypes[133]. 
 
The observed difference in risk of recurrence between stroke subtypes highlights the 
importance of thorough investigation to identify the aetiology of the initial stroke. It is 
evident that for some stroke subtypes, LAA for example, the critical time period for risk 
factor management is in the very early period after first stroke, however for the CE 
subtype this increased risk is sustained into the long-term period and secondary 
prevention measures should be continued.  
 
The results presented in this chapter are the first results from a population-based stroke 
register comparing the cumulative risk of recurrence between aetiological stroke 
subtypes up to 10 years after first-ever stroke. Previous population-based and hospital-
based studies have used pathological classifications to compare the risk of stroke 
recurrence. Results have shown that at 10 years after first ischaemic stroke, 85 to 91% 
of recurrences were also of an ischaemic pathology[136, 140, 143]. More recently, 
Hillen et al using data from the SLSR, demonstrated change in Oxford Community 
Stroke Project (OSCP) subtype in 45.5% of patients with a recurrence after first-ever 
stroke[90].  
 
Hillen also noted that both PICH and lacunar strokes were more likely to change 
subtype between first stroke and recurrence, compared to initial SAH and non-lacunar 
strokes[90]. In the analyses from this chapter, strokes of the LAA and CE subtypes were 





after first-ever stroke compared to the SVO groups. These descriptive analyses are 
consistent with findings from hospital-based studies, using the TOAST classification to 
stratify first and recurrent stroke, which have found the PICH and lacunar subtypes to 
be the most divergent stroke subtypes[136, 162]. Both the PICH and SVO changes are 
known to occur due to the effect of hypertensive disease on small blood vessels. Lower 
levels of concordance between first and recurrent stroke in these subtypes may be as a 
result of the tight control of blood pressure after first stroke. However before 
associations can be made, further research is needed, to investigate the effect of 
treated risk factors, such as hypertension, on the short and long-term risk of stroke 
recurrence.  
 
This study had strengths and limitations. The main strengths lie in study design as by 
using a population based stroke register as a sampling frame, we have an unbiased 
sampling frame. Long-term estimates for stroke recurrence up to 12 years after initial 
stroke have been provided, using standardised methods for comparability to other 
studies. These analyses also provide aetiological data on ischaemic stroke subtypes, 
and percentage transition between the different stroke subtypes up to 10 years after first 
stroke. However, despite the follow-up period being extensive, the number of stroke 
recurrences obtained and used in particular for the TOAST subtype cross-tabulations 
are small. Therefore it is was not possible to conduct further analyses identifying 
predictors for the different aetiological subtypes due to the small numbers of each 
subtype over the 10 year period.  
 5.5 Summary 
In conclusion, this chapter provides long-term estimates of the cumulative risk of stroke 
recurrence, and compares the risk of recurrence up to 12 years after first stroke. It has 
identified aetiological subtypes at increased risk of stroke recurrence at different time-
points, and mapped the transition between aetiological stroke subtypes up to 10 years 
after first-ever stroke.  Further research is needed to identify predictors for increased 





whether implementation of intensified secondary prevention medication in high-risk 





Chapter 6  The effect of secondary prevention on risk of stroke recurrence Abstract 
Background - Inequalities between patient groups in the use of appropriate secondary 
prevention medications are known to exist. However, despite these differences, the 
relationship between the use of these medications and risk of stroke recurrence remains 
unclear. This chapter examines the association between the use of commonly used 
secondary prevention medications (anti-hypertensive medication, anticoagulants, lipid-
lowering and antiplatelet agents) on risk of stroke recurrence, up to 12 years after first 
stroke.  
 
Methods – Using data from the SLSR, time-dependent variables were constructed to 
represent change in use of anti-hypertensive, anticoagulant, lipid-lowering and 
antiplatelet agents. Time-dependent Cox proportional hazard models were used to 
estimate the effect of risk factor modification on the risk of stroke recurrence up to 12 
years after first stroke in the SLSR population. Subset analyses were conducted to 
estimate the effect on patients with a first ischaemic stroke only.  
 
Results – A total of 4023 patients with first strokes were followed up for a total of 12 
years. Up to 5 years after initial stroke, 322 recurrent strokes were recorded. A non 
significant decrease in hazard ratios estimating risk of stroke recurrence were observed 
when patients were prescribed anti-hypertensive, lipid-lowering and anticoagulant 
medications at any time point during follow-up, compared to patients diagnosed with  
the relevant conditions but not prescribed medication. The hazard ratios for 
hypercholesteriolaemia were shown to decrease from 1.46 (95%CI 0.82-2.60) for those 
not on treatment, to 0.57 (0.34-0.95) for those known to be on lipid-lowering treatment. 
 
By 12 years after initial stroke, 376 stroke recurrences had occurred. Again, a decrease 
in hazard ratios were reported but only the use of statins and other agents to reduce 





decrease the risk of stroke recurrence for all stroke subtypes (HR 0.56 95%CI 0.35-
0.91; p=0.05), as well as for ischaemic strokes only (HR 0.60 95%CI 0.37-0.99; p=0.04). 
 
Conclusions -The results demonstrate reduction in stroke recurrence risk at both 5 and 
12 years when lipid-lowering medications were used in the treatment of 
hypercholesterolaemia. Non-significant decreasing trends in risk of stroke recurrence 
were also noted in patients using anti-hypertensive and anticoagulant medication to 
treat diagnoses of hypertension and atrial fibrillation up to five and 12 years after first 
stroke, therefore type 2 error cannot be excluded.   6.1 Background 
Knowing when a recurrent stroke is most like to occur, and what its subtype is likely to 
be, provides clinicians with useful information when planning treatment, particularly 
secondary prevention plans for patients after a first or subsequent recurrent stroke.  
 
Risk factors which develop after a first stroke, also require management in a similar 
fashion. For example, an individual may have repeated normal blood pressure readings 
at the time of their first stroke, and therefore not be diagnosed with high blood pressure 
and not require anti-hypertensive medication. During routine follow-up with their GP 
three years later, they may be found to be hypertensive and started on appropriate 
medication.  
 
As described in Chapter 1 of this thesis, there are many effective secondary prevention 
interventions available for stroke patients with the aim of reducing the risk of stroke 
recurrence, however population-based data on the effectiveness of this on reducing 
stroke recurrence risk is lacking. This is particularly important as both UK and European 
time-trends indicate that more patients have been prescribed medications to control 
cardiovascular risk factors over the last decade than previously, and stroke patients 






Most studies estimating risk reduction estimate cardiovascular risk and are not powered 
for a primary stroke-specific endpoint, and certainly not an endpoint for stroke 
recurrence, due to factors included small numbers of participants, choice of population 
studied, and the choice of study design used[167].  
In the Heart Protection Study, 3280 patients with a previous stroke and 17256 with 
previous vascular disease or diabetes were randomly allocated 40 mg simvastatin daily 
or a matched placebo. Whilst the investigators found that patients with a previous stroke 
had no reduction in stroke recurrence rate, a significant 20% (8–29%) reduction in the 
rate of any major vascular event (defined as non-fatal myocardial infarction, coronary 
death, stroke of any type, and coronary or non-coronary revascularisation) was noted 
during the 5 year study period[168].  
 
As described in Chapter 1, The Stroke Prevention by Aggressive Reduction of 
Cholesterol Levels (SPARCL) study investigated the effect of aggressive atorvastatin 
therapy (80mg/day) on patients who had a previous TIA or stroke, had a low-density 
lipoprotein (LDL) level between 100 mg/dl and 190 mg/dl (2.58-4.91mmol/l) and had no 
evidence of coronary artery disease. Patients were followed up for 6 years and a 16% 
risk reduction in time to stroke was demonstrated in the atorvastatin group, compared to 
the control group as well as a 35% reduction in coronary events. However as mentioned 
earlier in this thesis, a 66% increased risk of intra-cerebral haemorrhage was found in 
the atorvastatin group[64].  
 
A recent article by Hankey in 2014, reviewed the evidence for selected secondary 
prevention medications and interventions to reduce the risk of stroke recurrence both in 
the short and long-term period[169]. The review highlights the importance of timing 
when initiating antiplatelet and anticoagulant medications after first stroke. Sandercock 
et al in 2008 conducted a systematic review and meta-analysis of over 40000 patients 
given aspirin 160-300mg daily 48 hours after first stroke and continuing for a period of 





recurrent ischaemic stroke reduced by 23% (OR 0.77, 95%CI 0.69-0.87); and the odds 
of any recurrent stroke reduced by 12% (OR 0.88, 95%CI 0.79-0.97). However the odds 
of symptomatic intracranial haemorrhage increased by 22% during the study period (OR 
1.22 95%CI 1.00-1.50)[170].  
 
Similarly, another systematic review by Sandercock investigating patients with acute 
ischaemic stroke of cardiac or arterial origin found that anticoagulation started within 48 
hours of stroke had no effect on the risk of early ischaemic stroke (OR 0.85, 95%CI 
0.66-1.09) but substantially increased the risk of intracranial haemorrhage (OR 2.55 
95%CI 1.19-5.45). These results were independent of the type of anticoagulant used, 
and patient’s susceptibility to both thrombotic and haemorrhagic events[171]. 
 
In the longer term, the benefits of anticoagulant and antiplatelet medications in reducing 
the risk of stroke recurrence is more evident in the randomised control trial setting. As 
described in Chapter 1, large studies such as the second European Stroke Prevention 
Study (ESPS-2), and the CAPRIE and MATCH trial have demonstrated a decrease in 
risk of stroke recurrence conveyed by the use of antiplatelet medications[52, 53, 55]. 
Similarly the European Atrial Fibrillation Trial demonstrated the benefits of warfarin on 
risk of stroke recurrence in patients with atrial fibrillation, provided patients did not have 
a known contraindication to the use of warfarin[57]. 
 
The effect of anti-hypertensive medication on the risk of stroke recurrence is less clear, 
even when comparing the results of randomised control trials. As demonstrated in the 
PROGRESS study, comparing a perindopril-based blood pressure lowering regimen in 
individuals with a previous stroke or TIA, both hypertensive and non-hypertensive 
patients noted a 25% reduction in risk in stroke recurrence over the 4 year follow-up 
period[49]. Hypertension is widely considered one of the most important stroke risk 
factors, and was cited as being responsible for up to 35% of the population attributable 
risk of stroke in the INTERSTROKE multi-centre case-control study.  Further research is 





factor and risk of stroke recurrence, and to reduce the hypertension-associated burden 
of stroke and stroke recurrence [172].  
 
Inequalities in the use of appropriate primary and secondary prevention medications 
between different patient groups still exist[173]. However, despite these differences, it 
remains unclear how the association between secondary prevention medications and 
risk of stroke recurrence translates to population-based cohorts. Therefore, this chapter 
estimates the association between use of secondary prevention medication (anti-
hypertensive medication, anticoagulants, lipid-lowering, and antiplatelet agents) and risk 
of stroke recurrence up to 12 years after initial stroke in the population-based South 
London Stroke Register. 
 6.2 Methods 
The use of the SLSR as the study population, the case ascertainment and data 
collection methods used in this chapter have previously been detailed in Chapter 2. 
 6.2.1 Variable definition 
With the exception of the variables related to the use of secondary prevention, the main 
explanatory and outcome variables used in this study have been defined previously in 
this thesis.  
 
The four additional variables used in this study map the use of anti-hypertensive, 
anticoagulant, lipid-lowering, and antiplatelet medications during the study period.  
These variables were created by categorising the different classes of anti-hypertensive, 
lipid-lowering, anticoagulant and antiplatelet medications prescribed to SLSR patients 





each variable can be found in Appendix 5. The categories of these variables used are 
described in Table 23. 
Variable Categories 
 
Hypertension No hypertension 
Hypertension diagnosed – no treatment 
Hypertension diagnosed - on treatment 
Hypertension diagnosed - unknown treatment 
Hypertension status unknown 
 
Statin No hypercholesterolaemia 
Hypercholesterolaemia - no treatment 
Hypercholesterolaemia diagnosed - on treatment 
Hypercholesterolaemia diagnosed - unknown treatment 
Hypercholesterolaemia status unknown 
 
Anticoagulation No atrial fibrillation 
Atrial fibrillation diagnosed - no treatment 
Atrial fibrillation – on treatment 
Atrial fibrillation – unknown treatment 
Atrial fibrillation status unknown 
 
Antiplatelet No antiplatelet medication 
On antiplatelet medication 
Antiplatelet medication status unknown 
Table 23. Time-dependent variables 
 
These variables were derived using data collected as part of the initial and annual 
follow-up interviews at the SLSR as well as at the time of stroke recurrence. At each 
time point, questions enquiring about a past medical history or recent diagnosis of 
hypertension, high cholesterol and atrial fibrillation were asked to the SLSR participant 
or their relative by the fieldworker conducting the interview. Additionally, a full list of all 
medication taken was obtained from the own patient’s pharmacy medication list or from 
the GP if the list was not available. The full list of questions asked at both initial and 
annual follow-up can be found in Appendix 2. It is important to note that the questions 
regarding a diagnosis of hypercholesterolaemia, or the use of medication to treat the 
condition, was only routinely collected at the South London Stroke Register from 1999.  
 






6.2.2 Statistical methods 
Time-dependent covariates were constructed to represent change in use of anti-
hypertensive, anticoagulant, lipid-lowering and antiplatelet medications using the 
programming statement method in SAS.  
 
The SAS statistical package was used in order to undertake these analyses at the 
advice of my PhD supervisor Professor Andy Grieve. The SAS programming statement 
method was used as the dataset only included one record for each individual and 
therefore the time‐varying covariates were defined within the programming 
statements[174]. Whilst this allowed the time-dependent covariates to be created as 
outlined below, multivariable time-dependent Weibull proportional hazard models were 
unable to be constructed, therefore Cox proportional hazards models were used to 
undertake the analyses in this chapter. As mentioned earlier in this thesis, Cox 
Proportional Hazards models make no assumption about the form the underlying 
hazard of stroke recurrence takes and therefore are suitable to be used as a proxy in 
these analyses[125]. 
 
Indicator variables were created to represent the covariate changes, as the time-
dependent covariates in this study have potential to move between categories more 
than once. For example, someone known at a certain time-point to be on medication for 
hypertension may have the medication discontinued at a later time-point for a variety of 
reasons. Output records were then created for each time-period at which a covariate 
remains constant using DO statement loops from the first time-period (at 3 months) until 
the end of the study period (12 years after first stroke).  
 
Multivariable time-dependent Cox proportional hazard models were constructed using 
the PROC PH Reg application of SAS version 9.2. ARRAY statements were used to 
introduce the different covariate categories and assignment statements were used to 





therefore used to estimate the effect of time-dependent risk factor modification on the 
risk of stroke recurrence up to 12 years after first stroke in the SLSR population. Subset 
analyses were conducted to estimate the effect on patients with a first ischaemic stroke 
only.  
 
Studies by Peduzzi et al, have previously investigated the effect of differing events per 
independent variable (EPV) on proportional hazards regression analysis using Monte 
Carlo simulation techniques on data from randomised control trials[176]. Their studies 
found that whilst a single figure cut-off figure was difficult to set, an EPV of 10 or greater 
was not associated with significant bias or precision issues in the results reported. [176-
178]. The studies reported in this chapter were designed to maintain an EPV of 
approximately 10.  
 6.3 Results 6.3.1 Demographic data 
The prior-to-stroke characteristics of the study population were described in Section 
5.3.1 and are summarised in Table 16 (taken from Section 5.3.1). The number of 
patients included the both the full study analyses as well as the ischaemic stroke only 
subset analyses, during the 12 year study period are summarised in Table 24. The 
number of participants remaining in the study throughout the study period by covariate, 










 Total, N(%) 
Total 4023 
Age group  
   <65 1248 (31) 
  65-74 1041 (26) 
  75-84 1734 (43) 
Gender  
  Male 2024 (50) 
Ethnicity  
  White 2890 (72) 
  Black 805 (20) 
  Other 225 (5.6) 
Socio economic status  
  Non-manual 1082 (26) 
  Manual 2148 (53) 
  Economically inactive 562 (14) 
  Unknown 221 (5.5) 
Prior to stroke risk factors  
  Previous TIA 472 (12) 
  Hypertension 2436 (61) 
  Diabetes Mellitus 712 (18) 
  Previous MI 415 (10) 
  Atrial Fibrillation 629 (16) 
  Smoker or ex-smoker 2404 (60) 
       Table 16. Demographic data 
 
 
Time after first stroke  Number at start 





censored - died  
Number 
censored – at 
last follow-up 
Number in 
study at end of 
time-period 
All strokes      
0-1 years 4023 191 (4.7%) 688 (16.9%) 891 (22.2%) 2253 (56.0%) 
1- 5 years 2253 149 (6.6%) 290 (12.9%) 824 (36.6%) 990 (43.9%) 
5-12 years 990 53 (5.4%) 165 (16.7%) 660 (66.7%) 112 (11.3%) 
      
Ischaemic strokes only      
0-1 years 3293 162 (4.9%) 503 (15.3%) 709 (21.5%) 1919 (58.3%) 
1- 5 years 1919 130 (6.8%) 263 (13.7%) 724 (37.7%) 802 (41.8%) 
5-12 years 802 47 (5.7%) 146 (18.2%) 526 (65.6%) 83 (10.3%) 
Table 24. The number of participants in the study during the study period   6.3.2 The effect of time-dependent risk factor modification on the risk of stroke recurrence after first stroke 
The effect of the time-dependent variables on the risk of stroke recurrence up to 5 years 





shown in Table 25. The results are displayed for all stroke patients as well as for 
patients with an ischaemic first stroke only.  
 
At 5 years after initial stroke, 322 recurrent strokes were recorded, with the number 
decreasing to 276 recurrences when only ischaemic first strokes were considered. 
When all stroke subtypes were included, it was notable that there was a general 
decrease in the hazard ratios estimating risk of stroke recurrence when patients were 
on anti-hypertensive, lipid-lowering and anticoagulant medications compared to having 
a diagnosis of the relevant conditions but not on medication. The hazard ratios for 
hypercholesteriolaemia were shown to decrease from 1.46 (95%CI 0.82-2.60) for those 
not on treatment, to 0.57 (0.34-0.95) for those known to be on lipid-lowering treatment. 
However, these results did not show statistical significance and the related 95% 
Confidence Intervals were found to be wide. Similar results were noted when only 
participants with an ischaemic first stroke subtype were analysed.   
 
12 years after an initial stroke, 376 stroke recurrences were recorded (322 recurrences 
when only ischaemic first strokes were analysed). When both patients with all stroke 
subtypes as well as those with ischaemic strokes only were analysed, a general non-
significant decrease in hazard ratios was found for patients on anti-hypertensive, lipid-
lowering, and anticoagulant medications compared to those with a diagnosis of 
hypertension, hypercholesterolaemia and AF who were not on medication. Again the 
hazard ratio was shown to be considerable, i.e. the hazard ratio for patients with atrial 
fibrillation not on treatment was estimated to be 1.55 (95%CI 1.00-2.43) reducing to 
1.29 (95%CI 0.56-2.96) when patients were on treatment.  
 
The use of statins and other agents to reduce hypercholesterolaemia showed statistical 
significance for both all stroke subtypes (p=0.05) and for ischaemic strokes categories 
only (p=0.04). The effect of the four time-dependent variables on risk of recurrence up 






As requested in the revisions to this thesis, the time–dependent variables were re-
parameterised using the untreated condition as the baseline comparator value. For 
example, for the hypertension variable, ‘Hypertension- no treatment’ was used as the 
baseline variable. Estimates relating to the use of antiplatelet medication were not re-
parameterised as they were not linked to a specific cardiovascular risk factor in the 
original analyses. All other covariates were entered into the multivariable model 
unchanged. 
 
The re-parameterised time-dependent covariates estimated up to 5 years after first 
stroke are presented in Table 27, estimates up to 12 years are presented in Table 28. A 
substantial reduction stroke recurrence risk can be observed in individuals with 
hypercholesterolaemia on treatment compared to those who not on treatment.  This risk 
reduction was estimated at time-points up to both 5 years (HR 0.39 95%CI 0.19-0.80; 
HR 0.35 95% CI 0.18-0.74) and 12 years after first stroke (HR 0.37 95%CI 0.17-0.73; 
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Table 25 The effect of risk factor m
anagem
ent on the risk of stroke recurrence in a) all stroke patients b) patients with an ischaem
ic stroke only, up to 5 
years after first stroke. 
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Table 26 The effect of risk factor m
anagem
ent on the risk of stroke recurrence in a) all stroke patients b) patients with an ischaem
ic stroke only, up to 12 years 
after first stroke. 
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This chapter investigated the association between the use of four widely used 
secondary prevention measures (anti-hypertensive medication, lipid-lowering 
medication; antiplatelet agents and anticoagulants) and risk of stroke recurrence at five 
and 12 years after first stroke. The results demonstrate a decreasing hazard of risk of 
stroke recurrence in patients using anti-hypertensive, lipid-lowering and anticoagulant 
medication, compared to those with diagnoses of hypertension, hypercholesterolaemia 
and AF not taking medication during both the five and 12 year time-periods. The use of 
statins and other anti-cholesterol medication had the largest effect on reducing the risk 
of stroke recurrence. with statistical significance noted across the 
hypercholesterolaemia categories throughout the time-period analysed  for both all 
stroke subtypes and ischaemic strokes only. 
 
Analyses described in Chapter 3 of this thesis highlight the importance of cardiovascular 
risk factors as predictors of stroke recurrence up to 10 years after first stroke within the 
South London population. Atrial fibrillation and myocardial infarction were estimated to 
increase the risk of stroke recurrence throughout the time period analysed, and a 
previous diagnosis of hypertension was identified as a predictor of stroke recurrence up 
to 5 and 10 years after first stroke. The overlapping confidence intervals in the analyses 
in Chapter 3, demonstrated throughout the 10 year time period, indicate that 
cardiovascular risk factors, in particular hypertension, atrial fibrillation and a previous 
history of myocardial infarction, may be predictors of stroke recurrence throughout the 
study period and have failed to gain significance due to Type 2 error. 
 
As described previously, there is no consensus in previous literature regarding 
predictors for stroke recurrence beyond 1 year with a past history of hypertension  
reported as a predictor of recurrence up to 5 years, and a history of diabetes reported 
up to 10 years after first stroke [17, 97, 104, 105]. In Chapter 1 of this thesis, it was 
hypothesised that ‘the treatment of modifiable predictors of stroke recurrence, at the 





On the basis of the results described in Chapter 3 as well as the predictors outlined in 
the previous literature, it is therefore surprising that, in these analyses, only the 
hypercholesterolaemia covariate supports this hypothesis.  
 
One reason could be due to the small sample size. As demonstrated in Table 24, the 
number of participants with a stroke recurrence at each time-point, decreased 
throughout the study period and by the end of the time-period very small numbers of 
participants had a stroke recurrence. The small sample size reduces power and could 
lead to a type 2 error whereby a real difference was missed.  
 
As with any longitudinal study, the loss of participants during the follow-up period is 
common. As the sensitivity analyses undertaken in Chapter 3 found similar results when 
and imputed dataset was used compared to the main analyses further multiple 
imputation was not undertaken as part of this thesis. As yet unpublished analyses 
undertaken at the SLSR found baseline stroke severity indicators to be important 
predictors of being lost-to-follow-up. Associations between stroke severity markers and 
the development and subsequent treatment of cardiovascular risk factors has not been 
extensively covered in the published literature so this may be an area for further work to 
be focused outside of this thesis.  
 
Tables indicating the number of participants remaining in the study, by covariate, are 
displayed in Appendix 6. As mentioned earlier in this chapter, the variables related to 
hypercholesterolaemia, used to derive the time-dependent covariate, were only 
collected by the SLSR from 1999 onwards so this variable was missing in participants 
from the earlier years of the SLSR. As analyses still indicated that medication to treat 
hypercholesterolaemia reduced the risk of stroke recurrence up to 5 and 12 years after 
first stroke it may be the case that due to the small sample size a smaller effect size has 
been noted in these analyses, due to type 2 error. This may also be the case for the 
treatment of atrial fibrillation variable as when the estimates were re-parameterised, the 
hazard ratios both up to 5 years and 12 years indicated a potential risk reduction in 





(95%CI 0.27-1.94) up to 5 years for all strokes; HR 0.43 (95%CI 0.29-2.11) up to 5 
years for ischaemic strokes only; HR 0.80 (95% 0.32-1.99) up to 12 years for all 
strokes; HR 0.52 (95% 0.18-1.55) up to 12 years for ischaemic strokes only.  
 
As described above, the hazard ratios estimated for hypertension, 
hypercholesterolaemia and AF show decreasing hazard ratios when secondary 
prevention is used at both five and 12 years after first stroke and the 95% confidence 
intervals were wide-ranging. Whilst the analyses in this chapter maintain an events per 
variable ratio (EPV) equal to or greater than 10 with the exception of the risk of 
recurrence up to 5 years for ischaemic stroke only analyses which have an EPV of 8.5, 
the EPV range was at the lower end of the acceptable range of values. It has been 
described by Peduzzi et al that low EPV can lead to conservative tests being carried 
out, with the null hypothesis being rejected less often than the stated significance level, 
leading to a type 2 error[178].  
 
For this reason, analyses were not carried out to estimate the effect of secondary 
prevention on the risk of recurrence up to one year after first stroke. 190 stroke 
recurrences were reported during this time period leading to the number of events per 
variable falling below 6. One way of mitigating against a low number of events per 
variable could be by reducing the number of categories for each secondary prevention 
variable. In these analyses, two ‘unknown’ variables were used distinguishing between 
those known to have the condition, for example hypertension, but not known if they 
were on medication, from those for whom no information was available regarding their 
hypertension status. The wide confidence intervals for these missing data categories 
indicate small numbers in these groups which could be masking the true effect of these 
secondary prevention variables and risk of stroke recurrence. Therefore combining 
these groups for future analyses should be considered 
 
The use of time-dependent variables enables the development and treatment of 
cardiovascular risk factors throughout the follow-up period for to be taken into account 





SLSR. Verification of medication by the GP of the participant gives a record of what an 
individual should be taking. As discussed in Chapter 1, compliance can be a serious 
issue.  
 
A study looking at factors associated with medication non-persistence six and 12 
months after stroke by Lummis et al in Canada, found that in particular for anticoagulant 
medications, younger patients were less likely to discontinue medication than those 
aged 80 years or more (OR 0.23, 95% CI 0.06-0.81), and people who were considered 
disabled before admission were more likely to be discontinue medications than those 
not disabled (OR 7.01, 95% CI 1.66-29.58)[175]. Another Canadian study by Tsai et al 
found that the provision of a prescription to stroke patients strengthens adherence one 
week after discharge for both prior and new users of both anti-hypertensive and lipid-
lowering drugs. This was particularly important as the authors found medication 
adherence one week after discharge for acute ischaemic stroke predicted adherence for 
secondary preventive therapies at 1 and 2 years highlighting the importance of early 
compliance amongst these patients [179].  
 
The capture-recapture system used at the SLSR, coupled with the algorithm described 
in the Chapter 2 of this thesis used to identify any previously unrecorded stroke 
recurrences from ONS data, reduce the risk of ‘missed’ stroke recurrences. However 
the data collected by the SLSR does not account for those who died from causes not 
related to their initial or a subsequent stroke, who may have gone on to have a second 
stroke if they had not died. The results presented in this chapter may therefore under-
estimate the true effect of secondary protection on risk of stroke recurrence if this group 
of SLSR participants were taken into account. The effect of stroke recurrence on the 
risk of death after initial stroke, and in particular the association between stroke 
recurrence and death, will be explored in more detail in Chapter 7.  
 
Whilst it appears likely that the methodological factors described above have a key role 
in the hazard ratios demonstrating a decreasing trend, but not reaching statistical 





the true result. One explanation could be that whilst the cardiovascular risk factors 
tested in this chapter were demonstrated in Chapter 3 to be important predictors of 
increased recurrence risk, the management of other risk factors may more important for 
certain aetiological stroke subtypes. Large artery atherosclerosis has been shown to be 
an important cause of transient ischaemic attacks, and if the stenosis is severe, carotid 
revascularisation may be performed to reduce the stenosis[134]. Future research 
conducted should include the association of carotid revascularisation on risk of stroke 
recurrence.  
 
The SLSR dataset used for these analyses covers a wide time-period, since 1995, 
during which time the primary and secondary prevention used in stroke care has 
changed considerably. Univariate analyses described in Chapter 5 estimate the 
cumulative risk of stroke recurrence one year after initial stroke to have decreased from 
8.2% in 1995-1999, to 6.4% in 2000-2004,and to 5.0% from 2005-2009 (Table 18). 
Better management of all stroke patients due to measures such as the prompt use of 
thrombolytic agents, stroke unit admissions and the aggressive risk factor management 
of patients with secondary prevention medication such as anti-hypertensive and 
anticoagulant medications may have reduced the risk of stroke recurrence for all 
patients in this study. Further analyses stratified by year of stroke for different time 
period (i.e.) 1995-1999; 2000-2004; 2005-2009, or by including year of stroke as a 
covariate in the time-dependent model could help to understand the effect of temporal 
differences in stroke care.  
 6.5 Summary 
 
In conclusion, this chapter uses time-dependent survival analyses to provide long-term 
estimates of the effect of commonly used secondary prevention medication on the risk 
of stroke recurrence up to 12 years after first stroke. The results demonstrate reduction 
in stroke recurrence risk at both 5 and 12 years when lipid-lowering medications were 
used in the treatment of hypercholesterolaemia, and  non significant decreasing trends 





medication to treat diagnoses of hypertension and atrial fibrillation during both the five 
and 12 year time-periods.  
 
Lack of statistical significance demonstrated may be due to Type 2 error caused by 
methodological issues e.g. small number of events at annual time points measured, 
rather than due to a lack of clinical significance. Temporal differences in the 
management of stroke patients since the SLSR began should also be considered in 
further analyses.  
 
The effect of stroke recurrence on the risk of death after initial stroke, and in particular 
associations between stroke recurrence and death in the time-period after an initial 











Chapter 7 The effect of stroke recurrence on risk of death after first-ever stroke Abstract 
Background – Data estimating the association between stroke recurrence and risk of 
death after first stroke, and in particular taking into account the association between 
stroke recurrence and death are lacking. Furthermore it is unclear whether a critical 
time-period during which a stroke recurrence has a greater effect on risk of death can 
be identified.  
 
Methods – Kaplan-Meier estimates and stratified Cox proportional hazards models were 
used to assess the effect of stroke recurrence on risk of death 1, 5, 10 and 15 years 
after first stroke in SLSR patients. Adjustment in multivariable analyses included socio-
demographic factors, stroke subtype, case-mix, prior-to-stroke risk factors, process of 
care and time-dependent variables. Stroke recurrence was constructed as a time-
dependent covariate in the multivariable analyses, using STATA to split the dataset at 
time of stroke recurrence. 
 
Results - Between January 1995 and December 2011, 4478 patients with first-ever 
stroke were registered at the SLSR. The mean follow-up time was 4.03 years, with 
18025.81 person years of follow-up included. During this period, 395 recurrent strokes 
were documented. The risk of death 1, 5, 10 and 15 years after initial stroke was 31.7% 
(95% CI 30.3 to 33.1%), 52.9% (95% CI 51.4 to 54.5%), 70.2% (95% CI 68.5 to 71.8%) 
and 81.6% (95%CI 79.6 to 83.5%) respectively. Stroke recurrence was found to be 
significantly associated with an increase the risk of death at all time points analysed and 
was therefore considered to be a predictor. When stroke recurrence was categorised 
according to the time-point the recurrence took place, increased risk was found at all 
time-points analysed, up to 15 years after first stroke. Stroke recurrence within the first 
year after the initial stroke was particularly associated with increased risk of death at all 
time points. The 1 year risk of death was estimated to be over five times higher in those 





higher in those with a stroke recurrence by 1 year (HR 8.08(95%CI 5.27-12.4%) 
compared to those without a stroke recurrence. 
 
Conclusions -This study demonstrates that increased risk of death associated with 
stroke recurrence during the first year after first stroke, is maintained up to 15 years. 
This identifies the first year after stroke as a critical time-period for targeted risk factor 
management. Further work is needed to improve methods of identification of those at 
greatest risk of early stroke recurrence.  
 7.1 Background 
Knowledge of a patient’s long-term prognosis for survival after a stroke is important to 
both patients and their clinicians. Prognostic information can help aid the selection of 
appropriate treatments for the patient and facilitate the provision of accurate information 
to the patient and their family [27].  
 
Despite indications that survival post-stroke is improving, stroke survivors remain at an 
increased risk of death after first stroke. Both Aarnio et al, who studied 30 day survivors 
of first-ever ischaemic stroke aged 15-49 years in Finland, and Rutten-Jacobs et al, who 
investigated mortality and cause of death after acute stroke in adults aged 18-50 years 
in the Netherlands, found the observed risk of mortality to be significantly higher than 
expected for these groups,[180, 181]. In particular, Aarnio et al reported mortality 
amongst stroke patients to be seven times higher than that for the general population 
matched for age, sex, calendar year and geographical area (standardised mortality ratio 
6.94; 95% CI 5.84-8.04)[180].  
 
As observed in Chapter 1 of this thesis, there is a wide variation in stroke mortality 
trends worldwide in particular between countries with low and declining stroke mortality 
rates and those with high and increasing mortality[8]. However there have been few 





after initial stroke over time. In 2005, Hardie et al reported the cumulative risk of death 
up to 5 years after first stroke to be 59% (95%CI 53-65%) in 1989-90 and 58% (52-
65%) in 1995-96 with no statistical significant improvement in survival seen between the 
cohorts[91]. However in a more recent hospital-based study in Taiwan, Chen et al 
reported a 1 year mortality risk reduction of 15-20% amongst patients with an ischaemic 
stroke and 20-25% for those with an intracranial haemorrhage when comparing the 
time-periods of 1997-2002 and 2003-2008 to 1991-1996[182],  
 
As with stroke recurrence the estimates of risk of death after first stroke reported in the 
published literature are wide-ranging. One of the major methodological factors for the 
variations observed is whether studies report the risk of death at all time-points after first 
stroke, or whether the risk of death is reported in 30 day survivors only. The cumulative 
risk of death after first stroke was found to range from: 2.7% in Helsinki, Finland [183]to 
28% in Copenhagen in Denmark [184]up to 1 month; from 2.4% in a multi-centre study 
in Japan[185] to 41% in Copenhagen up to 1 year[184]; and from 7.8% in Japan[185], to 
60% in both Copenhagen, Denmark and Connecticut  in the USA[184, 186] up to 5 
years after first stroke.  
 
Several stroke studies reported the risk of death for a certain group of stroke patients, 
for example, those with a specific stroke subtype only, or patients of a defined age-
range. As described for stroke recurrence in Chapter 5 of this thesis, there has also 
been variation noted in risk of death estimated between different stroke subtypes. With 
higher death rates reported after a haemorrhagic stroke compared to an ischaemic 
stroke at both 30 days and 1 year after first stroke[37, 127, 182, 187], Studies have also 
reported differences between the aetiological stroke subtypes[139, 183, 188]. Petty et al 
reported the risk of death  by five years after first stroke to be 32.2% (95% CI 21.1-
43.2%) after large-artery atherosclerosis; 80.4% (95% 73.1-87.6%) after a cardio-
embolic stroke; 35.1% (95% 23.6-46.0%) after a lacunar stroke, and 48.6% (95% 40.5-






Predictors of increasing risk of death after first stroke can be identified from the 
published literature. At all time points ranging from 30 days to 10 years after first stroke, 
older age was the most commonly reported predictor for death[27, 144, 145, 185, 190]. 
Cardiovascular risk-factors, such as, ischaemic heart disease, diabetes mellitus and AF 
recorded at the time of first stroke [127, 145, 191, 192] were also found to be consistent 
predictors of death, as were stroke severity markers, in particular a low GCS or urinary 
incontinence recorded at the time of initial stroke or during the acute phase[27, 145, 
193]. 
  
Stroke recurrence has also been reported in some studies as a predictor of death after 
first stroke[190, 193]. It is surprising that stroke recurrence has not been implicated 
more often in previous literature as a key predictor of death after first stroke, as those 
with a stroke recurrence are known to be at higher risk of complications, and recurrent 
stroke has been described as a predictor of disability up to 5 years after first stroke[27].  
 
This chapter seeks to explore the relationship between stroke recurrence and risk of 
death at time-points from 1 to 15 years after first stroke to ascertain the effect of stroke 
recurrence on death, and whether increased risk of death is dependent on the time-
point after first stroke at which the stroke recurrence occurs.  
 7.2 Methods  
 7.2.1 The main variables used in multivariable analyses 
Potential predictors of death after first stroke were identified through review of the 
literature and the following variables were selected: 
Demographic factors included age (categorised as <65, 65-74, ≥75), gender, ethnicity 
(categorised as white, black and other) and socio-economic status. Socioeconomic 





manual, IV, and V) or economically inactive, according to the patient’s current (or for the 
retired and others not currently working, the most recent) employment[83].  
 
Stroke severity was defined as the presence of neurological deficit during the acute 
phase of the initial stroke. The level of consciousness was assessed using the Glasgow 
Coma Scale (GCS) dichotomized into GCS <13 (impaired consciousness) and GCS13-
15 [84]. 
 
Classification of pathological stroke subtype was categorised into ischaemic stroke, 
PICH or SAH based on results from at least one of the following: brain imaging (CT or 
MRI scan) and post-mortem studies. 
 
A range of indicators of the processes of care after an acute stroke, suggested to be 
useful proxy measures for the overall quality of stroke care, were examined The UK 
National Clinical Guidelines for Stroke published in 2012 emphasise the strong 
evidence in favour of specialised stroke unit care [16]. Patients were therefore classified 
as (1) not admitted to hospital; (2) admitted to stroke unit; (3) admitted to general 
medical ward/intensive care; and (4) unknown, in order for differences in risk of death 
related to the presence or absence of stroke unit care to be adjusted for in the analyses.  
 
Data were also collected regarding a diagnosis of hypertension prior to first stroke, and 
the use of anti-hypertensive medication during the first 3 months of stroke. 
 7.2.2 Handling missing data 
The main methods used to handle missing data in this thesis have been described in 
Chapter 2. Within the SLSR, reasons for missing data during follow-up include 
occasional retrospective registrations; patients lost to follow up either for a specific time 





the patient or main carer not agreeing to being followed-up at a particular time-point. 
Due to the nature of the primary outcome variable and the six-monthly review of ONS 
records for SLSR participants who may have died, the quality of the death notifications 
used in this study have been considered to be accurate and up-to-date for the duration 
of the study period. 
 7.2.3 Statistical methods  
Data were available from January 1 1995 and complete records were obtained up to 
June 30 2013. All index cases (first-ever stroke) registered up to December 31 2011 
and follow-up data collected until June 30 2013 were included in analyses. Survival time 
was calculated from date of stroke to date of death, confirmed using ONS records. 
Patients with no record of death were censored 15 years after stroke. 
 
Kaplan-Meier estimates were calculated to model the risk of death (1-survival) and 
therefore to measure the cumulative risk of death using Hazard Ratios (HR) and 
corresponding 95% confidence intervals up to 15 years after first stroke. Survival curves 
were constructed stratified for presence or absence of stroke recurrence, using the 
Kaplan-Meier method (unadjusted) and log rank tests.  
 
Hazard ratios (HR) and the corresponding 95% confidence intervals (CI) were estimated 
using Cox regression analyses and the assumption of proportional hazards were 






Patients were censored if lost to follow-up, or if alive at the end of the follow-up period. 
In the multivariable analyses, stratified Cox Proportional Hazards Models were used to 
estimate the effect of stroke recurrence on the risk of death after first stroke adjusted for 
socio-demographic factors, stroke severity markers, cardiovascular risk factors, initial 
stroke subtype, process of care variables, and time-dependent factors. All analyses 
were conducted using STATA12 statistical package. 
 
Stroke recurrence was constructed as a time-dependent covariate in these analyses. 
STATA was used to split the dataset at time of stroke recurrence, to adjust for the 
eventuality that an individual may die from a non-related cause before stroke 
recurrence, therefore not allowing a stroke recurrence to occur.   
Possible interactions between ethnicity and the other explanatory variables including 
age, cardiovascular factors, case-mix variables, and stroke unit care, were tested by 
constructing interaction terms in the stratified Cox models.  
 7.3 Results 7.3.1 Descriptive analyses 
This study included a total of 4478 first-ever stroke patients registered at the SLSR 
between January 1995 and December 2011. The mean follow-up time was 4.03 years, 
with a total of 18025.81 person years of follow-up included. During this period, 395 
recurrent strokes were documented. The mean age of those included in the study was 
69.9 years. Patient characteristics at time of initial stroke are presented in Table 29. The 
number of patients in the study at the different key time-points during the 15 year study 
period are summarised in Table 30. The number participants remaining in the study 








   
 Total, N(%) 
Total 4478 
Age group  
   <65 1440 (32) 
  65-74 1126 (25) 
Gender  
  Female 2210 (49) 
Ethnicity  
  White 3153 (72) 
  Black 956   (22) 
  Other 257   (5.9) 
Socio economic status  
  Non-manual 1206 (27) 
  Manual 2302 (51) 
  Unknown 
  Economically inactive 
274   (6.1)   
696   (16)    
Stroke Subtype  
 Infarct 3350 (81)                
 PICH 577  (14)      
 SAH 





224   (5.4) 
 
1305  (29)        
1074  (24)        
 997    (22)           
1102   (25) 
Risk factors  
 Hypertension 
 Use of anti-hypertensives by 3 months  
 2724   (64) 
 1194   (32) 
Stroke severity Indices  
 GCS  <13 1201    (28)       
            13-15 3086     (72) 
Process of care variables  
Not admitted to hospital 
Admitted to general medical ward/ITU 
Admitted to Stroke Unit 
Unknown 
 521     (12)     
1715     (38)        
 2,154   (48)        
  88       (2.0) 
  Table 29 Descriptive baseline statistics 
Abbreviations: PICH Primary Intracerebral Haemorrhage, SAH Subarachnoid  






















































1- 5 years 
2982 














356    (21.1%
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103    (15.0%
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148    (21.6%
) 
 29   (4.2%
) 
 Table 30.  The num
ber of participants rem
aining in the study at each during the 15 year study period 
 7.3.2 Survival Analyses 7.3.2.1 Univariate analyses 
The cumulative risk of death up to 1 year, 5 years, 10 years and 15 years after the initial 
stroke were estimated to be 31.7% (95% CI 30.3 to 33.1%), 52.9% (95% CI 51.4 to 
54.5%), 70.2% (95% CI 68.5 to 71.8%) and 81.6% (95%CI 79.6 to 83.5%) respectively. 
Table 31 displays the univariate analyses of cumulative risk of death up to 15 years for 
all participants, and stratified according to stroke recurrence. 
 
Cumulative risk of recurrence, % (95% CI) 












Stroke recurrence     
       No recurrence  33.2 (31.7-34.7) 53.7 (52.0-55.4) 69.8 (68.0-71.6) 80.4 (78.2-82.5) 
       Recurrence 16.2 (12.9-20.3) 45.1 (40.2-50.2) 70.8 (65.9-75.5) 85.8 (80.9-89.9) 
     
Table 31. Univariate analyses: cumulative risk of death after initial stroke 
Figure 15 shows Kaplan-Meier plots graphically representing the survival (1-risk of 
death) up to 15 years after initial stroke, and survival stratified by stroke recurrence. 
Interestingly, Figure 15 indicates that those without a stroke recurrence are at an 
increased risk of death up to roughly 7 years after first stroke, after which time the lines 
on the Kaplan-Meier plot meet and cross-over. This is likely to be due the association 
between stroke recurrence and death, as an individual has to remain alive in order to be 
able to have a stroke recurrence. This association will be adjusted for in the 






Figure 15. i) Survival probability (1- risk of death) up to 15 years after first stroke; ii) Survival up to 
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7.3.2.2 Multivariable analyses 
The multivariable analyses estimating the effect of stroke recurrence on the risk of 
death when adjusted for the socio-demographic, case-mix, prior to stroke risk factors, 
process of care and time-dependent variables, up to 1, 5, 10 and 15 years after first 
stroke are shown in Table 32. It is notable that in these analyses stroke recurrence is 
estimated as a binary (no recurrence/recurrence) variable. Stratified Cox proportional 
hazards models were fit for each time-point analysed, and the proportional hazards 
assumption was found to be fulfilled across all variables included in the model.  
 
After adjustment for the risk factors mentioned above, stroke recurrence was found to 
significantly increase the risk of death at all time points analysed and was therefore a 
predictor. In particular, stroke recurrence conferred over six times the risk of death up to 
1 year after first stroke, compared to those without a stroke recurrence HR 6.30(95% 
4.60-8.62). However, even up to 15 years after first stroke, second stroke was 
associated with twice the risk of death compared to those without a recurrence HR 
2.18(95% 1.88-2.52). 
 
Further multivariable analyses estimating the effect of stroke recurrence on risk of death 
were carried out. Analyses were once more adjusted for the variables described above, 
but stroke recurrence was categorised according to when the recurrence took place i.e. 
up to 3 months, 1 year, 5 years, and 10 years after first stroke to identify if this is an 
important factor. The results of these analyses are displayed in Table 33, Table 34, 
Table 35 and Table 36. 
 
These multivariable results demonstrate that a stroke recurrence occurring at all time-
points up to 10 years after first stroke, was associated with an increased risk of death. 
This increased risk was found to be evident at all time-points analysed, up to 15 years 
after first stroke. Stroke recurrence within the first year after initial stroke was 
particularly associated with increased risk of death at all time points. Of note, the risk of 





recurrence by 3 months (HR 5.45(95%CI 3.46-8.59%), and eight time higher in those 
with a stroke recurrence by 1 year (HR 8.08(95%CI 5.27-12.4%) compared to those 
without a stroke recurrence. 
 
The results displayed in Tables 33 to 36 demonstrate that regardless of how early or 
late the stroke recurrence occurs, individuals remain at approximately double the risk of 
death even up to 15 years after the first stroke. Whilst remaining a significant predictor 
for increased risk of death throughout the study period, the results reported up to 10 and 
15 years after first stroke, show a slightly decreased hazard ratio if a stroke recurrence 
occurred before 5 years after first stroke compared to the other time-points analysed. 
For both time-points, hazard ratios of approximately 1.8, with 95% Confidence Intervals 
of approximately 1.4-2.3 were obtained, compared to hazards of 2.4 (95%CI 
approximately 1.8-3.4%) estimated if the stroke recurrence occurred up to 3 months, 1 
year, and 10 years after first stroke. 
 
None of the interactions tested were found to be significant and therefore the results 
have not been presented  stratified. 
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 1 Year 5 Years 10 Years 15 Years 
 HR (95%CI) P value HR (95%CI) P value HR (95% CI) P value HR (95% CI) P value 
Stroke recurrence         
No 1 <0.001 1 <0.001 1 <0.001 1 <0.001 
Yes 6.30(4.60-8.62)  2.63(2.18-3.18)  2.25(1.93-2.62)  2.18(1.88-2.52)  
Age group         
  >65 1 <0.001 1 <0.001 1 <0.001 1 <0.001 
  65-74 2.49(1.89-3.29)  2.49(2.05-3.02)  2.48(2.11-2.92)  2.50(2.14-2.91)  
  >75 3.54(2.71-4.63)  4.42(3.68-5.32)  4.52(3.86-5.29)  4.46(3.84-5.17)  
Gender         
  Male 1 0.508 1 0.392 1 0.482 1 0.274 
  Female 0.95(0.82-1.10)  0.95(0.86-1.06)  0.97(0.88-1.06)  0.95(0.87-1.04)  
Ethnicity         
  White 1 <0.001 1 <0.001 1 <0.001 1 <0.001 
  Black 0.67(0.54-0.82)  0.70(0.60-0.82)  0.68(0.59-0.77)  0.68(0.60-0.77)  
  Other 0.63(0.43-0.92)  0.68(0.51-0.88)  0.64(0.50-0.80)  0.66(0.53-0.82)  
Socio economic status         
  Non-manual 1 <0.001 1 <0.001 1 <0.001 1 <0.001 
  Manual 1.20(1.00-1.44)  1.19(1.05-1.36)  1.11(1.00-1.24)  1.11(1.00-1.24)    
  Unknown 3.10(2.10-4.58)  2.46(1.78-3.40)  1.88(1.40-2.55)  1.79(1.34-2.40)  
  Economically inactive 1.89(1.52-2.34)  1.76(1.48-2.09)  1.68(1.44-1.96)  1.69(1.45-1.97)  
Stroke Subtype         
   Infarct 1 0.079 1 0.629 1 0.206 1 0.251 
   PICH 1.21(1.00-1.47)  0.93(0.79-1.09)  0.95(0.82-1.09)  0.94(0.82-1.09)  
   SAH 1.32(0.93-1.87)  0.94(0.69-1.30)  0.78(0.58-1.05)  0.81(0.61-1.07)  
Year of initial stroke          
  1995-1998 1 <0.001 1 <0.001 1 <0.001 1 <0.001 
  1999-2002 0.69(0.58-0.82)  0.71(0.62-0.82)  0.73(0.64-0.82)  0.74(0.66-0.84)  
  2003-2006 0.42(0.32-0.55)  0.57(0.48-0.68)  0.60(0.51-0.70)  0.60(0.51-0.70)  
  2007-2011 0.66(0.52-0.83)  0.76(0.63-0.91)  0.74(0.62-0.88)  0.73(0.62-0.87)  
Risk factors          
No hypertension 1 0.195 1 0.301 1 0.406 1  0.804 
 Hypertension 0.91(0.78-1.05)  0.94(0.84-1.06)  0.96(0.86-1.06)  0.99(0.891.09)  
 No anti-hypertensives  1 <0.001 1 <0.001 1 <0.001 1 <0.001 
 Anti-hypertensives at 3m 0.91(0.67-1.24)  0.97(0.82-1.13)  1.06(0.93-1.21)  1.05(0.92-1.19)  
 Unknown  8.44(6.67-10.68)  3.22(2.79-3.72)  2.59(2.28-2.95)  2.52(2.23-2.85)  
Stroke severity          
 GCS  <13 1 <0.001 1 <0.001 1 <0.001 1 <0.001 
           13-15 0.30(0.26-0.35)  0.38(0.34-0.43)  0.42(0.39-0.47)  0.43(0.38-0.47)  
Process of care          
  Not admitted to hospital 1 <0.001 1 <0.001 1 <0.001 1 <0.001 
Admitted to general 
medical ward 
3.68(2.47-5.49)  2.44(1.97-3.07)  2.12(1.78-2.53)  1.92(1.63-2.26)  
Admitted to Stroke Unit 2.71(1.81-4.07)  1.90(1.52-2.39)  1.82(1.52-2.19)  1.71(1.44-2.04)  
Unknown 3.42(1.71-6.84)  1.91(1.08-3.39)  1.79(1.04-3.07)  1.67(0.98-2.86)  
Table 32 Multivariable analyses using stratified Cox Proportional Hazards models 1: the cumulative risk of death up to 
1, 5, 10 and 15 years post-first stroke*                          





 HR (95%CI) P value 
Stroke recurrence   
    No 1 <0.001 
   <3m  5.45(3.46-8.59)  
    1 year 8.08(5.27-12.4)  
Age group   
     <65 1 <0.001 
     65-74 2.48(1.88-3.26)  
     >75 3.55(2.71-4.64)  
Gender   
     Male 1 0.511 
     Female 0.95(0.82-1.10)  
Ethnicity   
     White 1 <0.001 
     Black 0.67(0.55-0.83)  
     Other 0.63(0.43-0.92)  
Socio economic status   
     Non-manual 1 <0.001 
     Manual 1.19(0.99-1.43)  
     Unknown 3.02(2.05-4.47)  
     Economically inactive 1.87(1.51-2.32)  
Stroke Subtype   
     Infarct 1 0.079 
     PICH 1.21(0.99-1.47)  
     SAH 1.33(0.94-1.89)  
Year of initial stroke    
     1995-1998 1 <0.001 
     1999-2002 0.68(0.57-0.81)  
      2003-2006 0.42(0.32-0.55)  
      2007-2011 0.65(0.52-0.82)  
Risk factors   
      No hypertension 1 0.173 
      Hypertension 0.90(0.78-1.05)  
     No anti-hypertensive medication 1 <0.001 
     Anti-hypertensive medication at 3m 0.93(0.68-1.26)  
     Unknown anti-hypertensive medication 8.49(6.71-10.75)  
Stroke severity    
      GCS  <13 1 <0.001 
             13-15 0.30(0.26-0.35)  
Process of care    
     Not admitted to hospital 1 <0.001 
     Admitted to general medical ward 3.70(2.48-5.52)  
     Admitted to Stroke Unit 2.72(1.81-4.08)  
     Unknown 3.43(1.71-6.86)  
Table 33 Multivariable analyses 2: the cumulative risk of death up to 1 year post-initial stroke *                                                  








 HR (95%CI) P value 
Stroke recurrence   
    No 1 <0.001 
   <3m  2.79 (1.95-4.00)  
    1 year 2.82 (2.14-3.72)  
    5 years  2.31 (1.66-3.20)  
Age group   
     <65 1 <0.001 
     65-74 2.49(2.05-3.02)  
     >75 4.45(3.70-5.35)  
Gender   
     Male 1 0.361 
     Female 0.95(0.85-1.06)  
Ethnicity   
     White 1 <0.001 
     Black 0.70(0.61-0.82)  
     Other 0.66(0.50-0.87)  
Socio economic status   
     Non-manual 1 <0.001 
     Manual 1.19(1.05-1.35)  
     Unknown 2.44(1.76-3.37)  
     Economically inactive 1.76(1.48-2.08)  
Stroke Subtype   
     Infarct 1 0.627 
     PICH 0.93(0.79-1.09)  
     SAH 0.94(0.68-1.29)  
Year of initial stroke    
     1995-1998 1 <0.001 
     1999-2002 0.71(0.62-0.82)  
      2003-2006 0.57(0.48-0.68)  
      2007-2011 0.75(0.63-0.90)  
Risk factors   
      No hypertension 1 0.295 
      Hypertension 0.94(0.84-1.06)  
     No anti-hypertensive medication 1 <0.001 
     Anti-hypertensive medication at 3m 0.97(0.82-1.13)  
     Unknown anti-hypertensive medication 3.22(2.79-3.72)  
Stroke severity    
      GCS  <13 1 <0.001 
             13-15 0.38(0.34-0.43)  
Process of care    
     Not admitted to hospital 1 <0.001 
     Admitted to general medical ward 2.42(1.95-3.01)  
     Admitted to Stroke Unit 1.88(1.50-2.36)  
     Unknown 1.89(1.07-3.36)  
Table 34 Multivariable analyses 3: the cumulative risk of death up to 5 years post-initial stroke *                                                  








 HR (95%CI) P value 
Stroke recurrence   
    No 1 <0.001 
   <3m  2.46(1.77-3.40)  
    1 year 2.44(1.92-3.11)  
    5 years  1.85(1.44-2.38)  
   10 years 3.08(2.00-4.73)  
Age group   
     <65 1 <0.001 
     65-74 2.49(2.12-2.93)  
     >75 4.54(3.88-5.32)  
Gender   
     Male 1 0.405 
     Female 0.96(0.87-1.06)  
Ethnicity   
     White 1 <0.001 
     Black 0.68(0.60-0.78)  
     Other 0.63(0.50-0.80)  
Socio economic status   
     Non-manual 1 <0.001 
     Manual 1.11(0.99-1.24)  
     Unknown 1.87(1.38-2.53)  
     Economically inactive 1.69(1.44-1.98)  
Stroke Subtype   
     Infarct 1 0.202 
     PICH 0.95(0.82-1.10)  
     SAH 0.78(0.58-1.05)  
Year of initial stroke    
     1995-1998 1 <0.001 
     1999-2002 0.73(0.64-0.82)  
      2003-2006 0.60(0.51-0.70)  
      2007-2011 0.74(0.62-0.88)  
Risk factors   
      No hypertension 1 0.418 
      Hypertension 0.96(0.86-1.06)  
     No anti-hypertensive medication 1 <0.001 
     Anti-hypertensive medication at 3m 1.06(0.92-1.21)  
     Unknown anti-hypertensive medication 2.58(2.27-3.03)  
Stroke severity    
      GCS  <13 1 <0.001 
             13-15 0.42(0.38-0.47)  
Process of care    
     Not admitted to hospital 1 <0.001 
     Admitted to general medical ward 2.08(1.75-2.49)  
     Admitted to Stroke Unit 1.80(1.49-2.16)  
     Unknown 1.76(1.03-3.03)  
Table 35 Multivariable analyses 4: the cumulative risk of death up to 10 years post-initial stroke *                                                  







 HR (95%CI)  P value 
Stroke recurrence   
    No 1 <0.001 
   <3m  2.46(1.79-3.38)  
    1 year 2.41(1.91-3.04)  
    5 years  1.81(1.43-2.29)  
   10 years 2.41 (1.68-3.47)  
Age group   
     <65 1 <0.001 
     65-74 2.51(2.16-2.93)  
     >75 4.49(3.87-5.21)  
Gender   
     Male 1 0.224 
     Female 0.94(0.86-1.04)  
Ethnicity   
     White 1 <0.001 
     Black 0.68(0.60-0.77)  
     Other 0.65(0.52-0.82)  
Socio economic status   
     Non-manual 1 <0.001 
     Manual 1.10(0.99-1.23)  
     Unknown 1.77(1.32-2.37)  
     Economically inactive 1.70(1.45-1.98)  
Stroke Subtype   
     Infarct 1 0.247 
     PICH 0.95(0.82-1.09)  
     SAH 0.80(0.61-1.06)  
Year of initial stroke    
     1995-1998 1 <0.001 
     1999-2002 0.74(0.66-0.83)  
      2003-2006 0.59(0.51-0.69)  
      2007-2011 0.73(0.61-0.87)  
Risk factors   
      No hypertension 1 0.799 
      Hypertension 0.99(0.90-1.09)  
     No anti-hypertensive medication 1 <0.001 
     Anti-hypertensive medication at 3m 1.06(0.93-1.20)  
     Unknown anti-hypertensive medication 2.61(2.31-2.97)  
Stroke severity    
      GCS  <13 1 <0.001 
             13-15 0.4530.38-0.47)  
Process of care    
     Not admitted to hospital 1 <0.001 
     Admitted to general medical ward 1.89(1.60-2.22)  
     Admitted to Stroke Unit 1.69(1.42-2.00)  
     Unknown 1.65(0.96-2.82)  
Table 36 Multivariable analyses 5: the cumulative risk of death up to 15 years post-initial stroke *                                                  






This chapter investigates the association between stroke recurrence and the risk of 
death up to 15 years after first stroke. The results demonstrate that stroke 
recurrence increases the risk of death after initial stroke, and this increased risk is 
maintained up to 15 years after the first stroke. Stroke recurrence at any time during 
the follow-up period is associated with a significantly higher risk of death, however 
within the first year recurrence was shown to be particularly important with the very 
high risk of death conferred persisting up until the end of the 15 year study period.   
Of note, the risk of death 1 year after first stroke was over five times higher in those 
with a stroke recurrence by 3 months (HR 5.45(95%CI 3.46-8.59%), and eight time 
higher in those with a recurrence by 1 year (HR 8.08(95%CI 5.27-12.4%) compared 
to those without a stroke recurrence. The results demonstrate poor prognosis in 
those with early stroke recurrence, emphasising the need for effective and timely 




The UK National Clinical Guidelines for Stroke, published by the Royal College of 
Physicians in 2012, recommends that appropriate secondary prevention be 
instigated as soon as possible after first stroke, usually in the acute phase if safe to 
do so. However, the number of trials supporting this hypothesis are fewer than those 
for primary prevention and many of the studies cited as evidence, report outcomes 
after TIA rather than stroke only[43, 44]. As mentioned in Chapter 6, secondary 
prevention medications have been shown not just to reduce the risk of recurrence, 
but to have a role in reducing the overall cardiovascular disease burden by lowering 
mortality and morbidity rates[46]. Kong et al conducted a hospital based study in 
China looking at the predictors of 1 year death and disability in women after 
ischaemic stroke. They found suboptimal use of antiplatelet agents and anti-
hypertensive therapies to be independent predictors of increased risk of death 1 year 







Antiplatelet agents were also identified by Ding et al as independent protective 
predictors of all-cause death (hazard ratio (HR) 0.42; 95% confidence interval (CI) 
0.21-0.86; P=0.017) and recurrent cerebrovascular events (HR 0.58; 95%CI 0.36-
0.92; P=0.021). Their study, a multi-centre hospital-based study of patients after 
ischaemic stroke, was again undertaken in China and further studies are needed to 
ascertain if these results are generalisable to other non-Chinese populations.  
 
 
There may also be differences in risk of stroke recurrence between stroke subtypes. 
Previous studies from the SLSR found no differences in the risk of recurrence 
between ischaemic and haemorrhagic strokes up to 10 years after first stroke[133]. 
Even among ischaemic stroke subtypes, differences in risk of stroke recurrence at 
different time points have been found. As mentioned in Chapter 5, Lovett et al, 
studying the risk of recurrent stroke by aetiological TOAST subtype, found patients 
with the LAA subtype were consistently three times more likely to have a stroke 
recurrence up to 3 months after first stroke, compared to other aetiological 
subtypes[161]. However studies have also demonstrated an increased risk of death 
amongst patients with an initial LAA subtype stroke compared to other ischaemic 
stroke subtypes without a stroke recurrence, up to 5 years after first stroke[183] 
indicating that this group may be increasingly disadvantaged and be at considerable 
risk of poorer outcomes if risk factors are not identified and managed adequately at 
the time of initial stroke.  
 
The analyses in this chapter also suggest an increased risk of death in those with a 
stroke recurrence up to both 5 and 10 years after first stroke when compared to 
those with no recurrence. It is notable that whilst the risk of death has been 
estimated to increase at all time-points, the effect of a stroke recurrence up to 5 
years after first stroke is decreased compared to the hazard estimated for a stroke 
recurrence up to 10 years.  
 
These results may be again be indicative of the subtype of the initial stroke. Studies 





predictor for stroke recurrence 5 and 10 years after first stroke[133]. Hypertension is 
associated with small vessel disease which is pathognomonic of the small vessel 
occlusion (SVO) subtype, and has been shown to be the aetiological cause of 
lacunar infarcts, generally considered to be related to less severe strokes. Therefore, 
patients with small vessel disease may experience a less severe stroke recurrence 
later than other stroke subtypes and may have better than expected survival after 
recurrence as a result of tight blood pressure control[124]. As described in Chapter 
5, studies have shown the SVO stroke subtype to have increased odds of an 
excellent outcome, defined as a combination of a Glasgow Outcome Scale score of 
1 and a Barthels Index score of 19 or 20 (on a scale of 0 to 20), at 3 months[20]; to 
have the highest rates of independent patients, as defined by Rankin scale scores of 
1-2, at 6 months[164]; and to have an increased risk of survival 1 and 2 years after 
first stroke compared to other TOAST subtypes[1, 108, 165].  
 
Finally, it is important to note that death is not the only outcome of relevance post-
stroke. It would be useful to repeat these analyses to include the effect of stroke 
recurrence on risk of disability measured by the Barthels Index, or using a composite 
measure to combine the risk of disability and death after a recurrent stroke. Again 
these analyses could be conducted as future analyses related to this thesis.   
Multivariable analyses were used to reduce the risk of confounding in this study as 
analyses were adjusted for variables thought to be impact the risk of death after first 
stroke. In particular, the adjustment of the statistical model to take into account the 
association between risk of death and stroke recurrence is a strength of these 
analyses and has not been demonstrated previously in similar analyses published in 
the literature.  
 
However, even with the substantial adjustments undertaken it is probable that a 
degree of residual confounding remained in the analyses. In particular, other 
cardiovascular risk factors may be important predictors of increased risk of death. 





myocardial infarction have been shown in other studies to be important predictors of 
death, but only for ischaemic strokes[195, 196]. Due to the total number of stroke 
recurrences being only approximately 400, the study results were not stratified for 
stroke subtype, and therefore these cardiovascular risk factors were not adjusted for 
in the analyses. For similar reasons, the role of secondary prevention in reducing the 
risk of death after first stroke was not explored further as antiplatelet and anti-
cholesterol medications, both adjusted for in the analyses in Chapter 6, are 
commonly used as secondary prevention after ischaemic stroke[29]. 
 
Another advantage is the ability for these results to be generalised to other 
populations, again due to the robust methods used in the analyses. Despite the 
methodological differences between stroke studies discussed in Chapter 4 of this 
thesis, and the ethnic diversity, considered to be a key strength of the SLSR 
population with only 56% self-defining themselves as being of a White ethnicity 
compared to 86% of the UK population[79], it could be possible to estimate the effect 
of stroke recurrence on risk of death after first stroke across the whole UK using 
national stroke data and data from the General Practice Research Database 
(GPRD)[197]. This requires data related to stroke recurrence and the other 
explanatory variables adjusted for in these analyses to be consistently collected. 
However, at the current time, these data are not collected across the UK.  
 
The impact of missing data on the results may also be important. In this study the 
highest percentage of data missing from the baseline variables analysed was 7.3% 
of data missing from the GCS stroke severity variable. As this is generally 
considered to be a low level of missingness, sensitivity analyses were not performed 
due to time constraints. However, it is important for sensitivity analyses to be 
considered as a part of future analyses, in order to better understand the impact of 
the missing data on the risk of death estimated in this study.  
 
Since 1999 ethnic differences in survival after stroke have been described within the 





over the white population [13]. Therefore possible interactions between ethnicity and 
the other explanatory variables were tested. As none of the interactions tested were 
found to be significant the results were not stratified, but it is important to 
acknowledge that other variables, for example age or sex, could potentially also 
cause interactions. Further analyses could be conducted to identify other significant 
interactions within these analyses. 
 7.5 Summary 
This chapter demonstrates that increased risk of death in individuals with a 
recurrence at all time-points after initial stroke, is maintained up to 15 years after first 
stroke. The analyses highlight the first year after stroke as a particularly critical time-
period during which patients should be followed up regularly in order for risk factors 
to be aggressively managed.  
 
An important challenge remaining for both Stroke Physicians and policy researchers 
is how to accurately identify those at increased risk of early stroke recurrence.  
However this is achieved, this study highlights that early identification and risk factor 
modification is paramount, both to reduce the risk of stroke recurrence, but to also to 
reduce the risk and impact of premature death in both the early and long-term period 









Chapter 8 Conclusions 
 8.1 Summary of findings 
 
This thesis was designed to estimate the natural history of stroke recurrence after 
first-ever stroke, using the population-based South London Stroke Register as a 
sampling frame.  
 
The systematic review and meta-analysis presented in Chapter 4 of this thesis 
identified 16 studies published between 1994 and 2009 estimating the cumulative 
risk of stroke recurrence at time points from 30 days to 10 years after first stroke, of 
which, 13 studies contained sufficient data to be included in the meta-analysis. The 
pooled cumulative risk of stroke recurrence was 3.1% (95% CI 1.7-4.4) by 30 days; 
11.1% (95% CI 9.0-13.3) by 1 year; 26.4% (95% CI 20.1-32.8) by 5 years; and 
39.2% (95% CI 27.2-51.2) by 10 years after initial stroke. A temporal reduction in the 
risk of stroke recurrence was found across the different study populations, with 
smaller recurrence risk reported in later studies. Substantial heterogeneity was found 
between the studies at all time points with I2 values ranging from 88-96%.  
 
Whilst there were undoubtedly methodological differences between the study 
populations such as differences in case inclusion, and differences in definition of 
both a stroke an differences between populations and temporal changes in stroke 
management and secondary prevention may also be important in explaining these 
results.  
 
Meta-regression models were fit to the cumulative risk of stroke recurrence of the 
individual studies and pooled estimates of the cumulative risk of stroke recurrence 
were calculated with 95% Confidence Intervals. The Exponential model fit was 
shown to under-estimate the risk of stroke recurrence up to approximately 6 years 





Weibull model was then fit to the results, which closely followed the pooled estimates 
up to 10 years after first stroke.  
 
The South London Stroke Register, a prospective longitudinal population-based 
stroke register, established in a multi-ethnic, inner city population of 271,817, meets 
the criteria to be an ideal sampling frame to estimate the natural history of stroke 
recurrence up to 12 years after first-ever stroke. Predictors for stroke recurrence 
were identified from variables including socio-demographic factors, risk factors 
diagnosed at the time of initial stroke, patterns in stroke subtype, and stroke severity 
markers, taking into account the effect of temporal changes in stroke management, 
e.g. the use of secondary prevention medication.  
 
The results of the analyses of the SLSR data presented in this thesis showed the 
cumulative risk of first stroke recurrence up to 1 year, 5 years and 10 years to be  
7.1% (95% CI 6.0 to 8.3%), 16.2% (95% CI 14.4 to 18.1%) and 24.5% (95% CI 21.3 
to 27.9%) respectively. At all time-points from 1 year up to 10 years after first stroke, 
the presence of cardiovascular risk factors at time of first stroke were shown to 
increase the risk of stroke recurrence. However time trend analyses suggest a 
reduction in risk of stroke recurrence 1 year after first stroke between 1995-1999, 
2000-2004, and 2005-2009 (p=0.03). 
 
When differences between aetiological stroke subtypes were analysed for strokes 
registered with the SLSR between 1999 and 2009 only, the cumulative risk of stroke 
recurrence up to 1 year after first stroke ranged from 4.0% in the small vessel 
occlusion (SVO) group to 6.5% in the large artery occlusion (LAA) group. These 
results were lower than 1 year recurrence rates for both intracerebral (PICH) and 
sub-arachnoid (SAH) haemorrhages which were 8.6% and 8.8% respectively. 
Transition in aetiological subtype between initial and recurrent stroke was seen in 
51.0% at 1 year, increasing to 61.9% 10 years after first stroke.  
  
The use of time-dependent Cox proportional hazard models estimating the 





recurrence up to 5 years after first stroke demonstrated a general decrease in 
hazard ratios estimating risk of stroke recurrence when patients were on anti-
hypertensive and anticoagulant medications compared those untreated. However 
only the use of lipid-lowering medications in those with a diagnosis of 
hypercholesterolaemia demonstrated a reduction in stroke recurrence risk. By 12 
years a general decrease in hazard ratios were also reported however the use of 
statins and other agents to reduce hypercholesterolaemia showed statistical 
significance for both all strokes and for ischaemic strokes only. The analyses 
demonstrated no significant associations in this cohort between stroke recurrence 
and prescription of other effective secondary prevention, but the analyses cannot 
exclude a Type 2 error. 
 
The risk of death 1, 5, 10 and 15 years after initial stroke was 31.7% (95% CI 30.3 to 
33.1%), 52.9% (95% CI 51.4 to 54.5%), 70.2% (95% CI 68.5 to 71.8%) and 81.6% 
(95%CI 79.6 to 83.5%) respectively. The association of stroke recurrence on risk of 
death after first stroke was estimated and stroke recurrence was found to 
significantly increase the risk of death at all time points analysed. When stroke 
recurrence was categorised according to when the recurrence took place, increased 
risk was found at all time-points up to 15 years after first stroke. Stroke recurrence 
within the first year after initial stroke was particularly associated with increased risk 
of death at all time points.  
 8.2 Strengths and limitations of this thesis 
 
The main strengths of this thesis are related to the methods used. This thesis 
presents estimates of cumulative risk and predictors of stroke recurrence up to 12 
years after first stroke using a well-established population-based sampling frame 
which meets recognised criteria to allow comparability of stroke incidence[75]. The 
overlapping notification sources and capture-recapture techniques used at the SLSR 







The thesis uses meta-regression to develop predictive models to best estimate the 
risk of stroke recurrence at time-points not analysed directly. The analyses 
conducted using both pooled estimates from the meta-analyses and the SLSR 
dataset, demonstrate the risk of stroke recurrence follows a Weibull distribution, 
therefore challenging the assumptions made in previous literature, that the 
distribution was unknown.  
 
The use of time-dependent survival analyses to estimate the association between 
secondary prevention variables and risk of stroke recurrence, and to adjust for 
associations between death and stroke recurrence is another strength of this thesis. 
In particular, adjusting the results to account for an individual dying from a non-
stroke related cause and therefore not being alive for a recurrence to occur, reduces 
the risk of under-estimation of the association between stroke recurrence and risk of 
death. 
 
The main limitations of this thesis are also methodological. In order to obtain the 
longitudinal estimates recorded in the study, long-term data collection is needed. The 
limitations of this long-term dataset, such as missing data, were addressed by 
recollecting stroke recurrence data to reduce missingness; by the derivation and 
application of an algorithm to ONS death data to increase completeness of case 
ascertainment; and by statistical methods including sensitivity analyses. Whilst the 
degree of missingness in variables used in the analyses is generally low, certain risk 
factors or stroke subtype classifications e.g. the TOAST classification, have only 
been cited as important in recent years, and so have not been collected at the SLSR 
since 1995, leading to incomplete variables within the SLSR dataset. Missing data 
also plays a role during the follow-up of individuals at risk of stroke recurrence. 
Whilst multiple imputation methods used to create an imputed dataset for sensitivity 
analyses in Chapter 3 of this thesis, produced similar predictors of stroke recurrence 
compared to the dataset used in the main analyses, the impact of missing data 
during patient follow-up on risk of stroke recurrence remains unclear. Whilst this 





individual having a stroke recurrence, further work is needed to confirm this 
assumption. 
 
The other main limitation of this thesis relates to sample size. Just under 400 stroke 
recurrences were recorded at the SLSR during the study period. .As discussed in 
Chapter 6, whilst the stroke recurrence to predictor variable ratio  was greater than 
10 for most of the analyses undertaken in this thesis, studies by Peduzzi et al 
indicate that under-estimation of the event hazard are more likely to occur at lower 
recurrence to predictor ratios[176]. Pooling data from different stroke registers could 
provide a larger sampling frame for future pooled or individual level meta-analyses to 
be developed. 
 8.3 My personal development whilst undertaking this thesis 
This thesis was a steep learning curve for me. I began the research for this thesis, 
having been working as a hospital medical registrar, and with no previous statistics 
training or experience of using statistical software packages. I learned how to apply 
the necessary statistical and epidemiological methods to answer the questions 
posed in this thesis, however this did pose problems when analyses terminated 
unexpectedly, or did not run as expected, and often I had to learn more in order to 
work out what I had done wrong. This made undertaking the statistical analyses 
presented in this thesis a long process.  
 
However this also meant that I was presented with many opportunities to develop 
and learn new skills, in particular related to statistical methods, whilst undertaking 
this thesis. I learned to use three difference statistical packages (SPSS, STATA and 
SAS) in order to undertake the analyses presented.  
 
I feel that I made good use of the opportunities presented to me during this thesis, 





leaving the South London Stroke Register in 2011. Combining full-time Public Health 
speciality training with writing this thesis made it more difficult to maintain momentum 
and contributed to this thesis being submitted just prior to the six year submission 
deadline.   
 
There were many reasons why this thesis was not completed sooner. One reason 
was that the time allocated for the re-collection of the stroke recurrence data, which I 
undertook between 2009-2011 in order to improve data quality, proved to be 
insufficient. The data collection relied heavily on microfiche records being 
transported back to London from data storage facilities and then being reviewed 
page by page in order to obtain the necessary information. In total this data 
collection exercise took almost two years.  
 
During my four years working on the SLSR, I learned first-hand about the challenges 
of working on a longitudinal epidemiological study, whilst learning about the clinical 
and radiological features related to a diagnosis of stroke and stroke recurrence from 
expert stroke physicians. I also had the opportunity to present my research at 
international and national conferences, to write articles for publication in peer-
reviewed journals, and to contribute to book chapters.  8.4 Implications of results for public health and clinical practice 
 
This thesis has produced important results with implications for stroke service 
planning and resource allocation. The annual costs of stroke in the UK are estimated 
to be between £3.7 billion and £8 billion, including direct health care costs, 
productivity loses due to mortality and morbidity, and informal care costs[11, 198]. In 
2010, Round 7 of The Royal College of Physicians (RCP) National Sentinel Stroke 
Clinical Audit found that 81% of patients admitted to hospital with stroke had known 
vascular risk factors, 29% had a previous stroke or TIA and 57% had a previous 





‘The evidence from this audit is that there is still more that could be done at a critical 
time of a patient’s life to modify lifestyle stroke risk factors with only just over half of 
patients having documented evidence of such risk factors being discussed’[199]. 
 
The ‘Progress in improving stroke care’ survey conducted by the National Audit 
Office in 2010 similarly indicated that there is more work to be done regarding risk 
factor management after first stroke[200]. This online and postal survey, conducted 
between June to September 2009, gathered the views of 760 people with stroke or 
who cared for people with stroke. Only half of respondents said they received advice 
on further stroke prevention when leaving hospital, with a third of patients not 
receiving a follow-up appointment within six weeks of their first stroke.    
 
As mentioned earlier in this thesis, The UK National Clinical Guidelines for Stroke, 
published by the Royal College of Physicians in 2012, recommends that appropriate 
secondary prevention be instigated as soon as possible after first stroke, usually in 
the acute phase if safe to do so. However, the number of trials supporting this 
hypothesis are fewer than those for primary prevention and many of the studies cited 
as evidence, report outcomes after TIA rather than stroke only[43]. 
  
The analyses in this thesis provide long-term estimates about the cumulative risk of 
stroke recurrence. The results highlight the importance of stroke aetiology in 
predicting increase risk of both stroke recurrence and death after first stroke, and 
suggest that the critical period for stroke recurrence may vary according to the 
aetiological subtype of the first stroke. However the results identify the first year after 
a stroke as a critical time-period during which significantly increased risk of death 
conveyed on an individual having a stroke recurrence is maintained for at least the 
next 15 years. This provides evidence that intensive risk factor management and 
lifestyle modification during the first year after stroke is important both for individuals 





throughout the decade after first stroke was shown to significantly increase the risk 
of death compared to no recurrence.  
  
Individuals at high-risk of stroke recurrence should therefore be quickly identified by 
clinicians at the time of first stroke and secondary prevention medication initiated. 
They should receive regular primary care follow-up to ensure these risk factors are 
aggressively monitored to reduce the risk of stroke recurrence.  
 
Risk factor management after stroke features as part of the Quality and Outcomes 
Framework (QOF), the voluntary annual reward and incentive programme for all GP 
surgeries. Updated QOF Indicators are produced annually by the National Institute 
for Health and Care Excellence (NICE) and used by the four UK nations to set QOF 
indicators for the coming year[201]. The QOF contains five main components,: 
Clinical; Public Health; Public Health - Additional Services; Patient Experience; 
Quality and Productivity. Each domain consists of a set of achievement measures, 
known as indicators, against which each practice score points according to their level 
of achievement. 
 
The QOF 2015-16 includes 5 indicators specifically related to patients with stroke 
and TIA, with no changes recommended compared to last year[202]. These 
indicators are displayed in Table 37.  It is notable that the stroke-specific QOF 
indicators relate primarily to the identification and management of risk factors after 
first stroke or TIA and therefore support the conclusions drawn from this thesis that 
regular primary care follow-up is needed to ensure risk factors are aggressively 
monitored to reduce the risk of stroke recurrence. However it is important that the 
QOF indicators are not considered to be the extent of risk-factor management after 
stroke or TIA but that patients at high-risk of stroke recurrence have access to more 
regular review by primary care professionals, if necessary, in order to establish and 






QOF 2015-16 indicator Threshold required 
The contractor establishes and maintains a register of 
patients with stroke or TIA 
 
- 
The percentage of patients with a stroke or TIA 
(diagnosed on or after 1 April 2014) who have a record 
of a referral for further investigation between 3 months 
before or 1 month after the date of the latest recorded 
stroke or the first TIA  
 
45-80% 
The percentage of patients with a history of stroke or TIA 
in whom the last blood pressure reading (measured in 
the preceding 12 months) is 150/90 mmHg or less 
 
40-75% 
The percentage of patients with stroke or TIA who have 
had influenza immunisation in the preceding 1 August to 
31 March  
 
55-95% 
The percentage of patients with a stroke shown to be 
non- haemorrhagic, or a history of TIA, who have a 
record in the preceding 12 months that an anti-platelet 
agent, or an anti- coagulant is being taken  
57-97% 
Table 37. The QOF 2015-16 indicators related to stroke and TIA 
 
Accurate identification of individuals at high risk of a stroke recurrence can pose a 
significant challenge, and further work is needed to develop and trial stroke-specific 
prognostic indicators with a high sensitivity and specificity for identifying those at 
high-risk of early stroke recurrence. By preventing early stroke recurrences, 
significant and long-lasting reductions in risk of death after stroke can be made, 
regardless of initial stroke subtype, severity, or the age of the patient.  
 
Poor adherence to secondary prevention is undoubtedly an important factor in risk 
factor management and needs to be addressed. Younger age, incomplete 
understanding of perceived benefit of medication, poor cognitive function and a lack 
of routine have been identified as key reasons for non-compliance amongst stroke 
patients[169]. However, work needs to be undertaken to optimise secondary 
prevention plans for all stroke patients, with a particular emphasis on older patients 
and those without co-existing coronary heart disease, who been found to be 






8.5 Implications for future research 
 
This thesis explores the natural history of stroke recurrence using the population-
based South London Stroke Register as a sampling frame. The results present a 
broad basis for future research related to a variety of different themes presented in 
this thesis. A key area for future study involves further investigation of the 
association between the prescription of secondary prevention and the risk of stroke 
recurrence. There are many ways this work could be built on, for example, by re-
categorising the time-dependent variables to amalgamate the ‘unknown’ categories. 
It would also be important to minimise missing data, and an alternative could be for 
current risk factor levels to be ascertained, by incorporating recent blood pressure 
readings and blood test results, for example using a patient’s most recent low-
density-lipoprotein (LDL) cholesterol levels as a marker of current 
hypercholesterolaemia status at the time of follow-up interview.  
 
Further research should also be undertaken looking at the effect of time on stroke 
recurrence in particular by identifying time-trends in the use and association of 
secondary prevention and risk of stroke recurrence. This could be achieved by 
including a year of initial stroke covariate into multivariable analyses to allow 
adjustment.  
 
It was demonstrated in Chapter 4 of this thesis that despite methodological 
differences between different study populations, useful conclusions can be drawn by 
using a larger sampling frame, for example a meta-analysis of stroke registers to 
study the association between secondary prevention and risk of stroke recurrence. 
As mentioned in Chapter 4, it is important to differentiate studies using stroke only as 
the first ‘event’ from studies using stroke and transient ischaemic attack as a 
composite start point for analyses in order for results from different stroke registers 






As described in Chapter 7, death is not the only outcome of relevance in the post-
stroke period and the effect of stroke recurrence on other outcomes, such as 
disability, dementia or depression would provide a important information to build a 
more complete picture of the natural history of stroke recurrence. The results 
described in this thesis and could be used in the development of a predictive tool to 
help clinicians estimate the risk of stroke recurrence for an individual patient based 
on key predictors identified at the time of initial stroke, and in the post-stroke period. 
As outlined in Chapter 1 of this thesis, a simple, accurate, cost-effective predictive 
tool is not currently available. Future studies should observe the cost-effectiveness 
of this and other interventions aimed at reducing the risk of stroke recurrence after 
initial stroke. 
 8.6 Summary 
This thesis demonstrated that the risk of stroke recurrence after first stroke is 
considerable, up to 25% at 12 years after first stroke. Cardiovascular risk factors are 
important predictors of stroke recurrence however further research is needed to 
explore the association between secondary prevention and risk of stroke recurrence. 
Stroke recurrence was shown to be associated with increased risk of death at all 
time-points up to 15 years after first stroke. Recurrence in the first year after stroke 
was associated with the biggest increase in risk of death, identifying a potentially 
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Appendix 2. South London Stroke Register (SLSR) documentation 
 
 
(i) SLSR INITIAL FORM 
(ii) SLSR RECURRENCE FORM 
(iii) SLSR ANNUAL FOLLOW-UP FORM 

















































































(iii) SLSR FOLLOW UP FORM 
 
SOUTH LONDON STROKE REGISTER 
ANNUAL FOLLOW UP 
 
Thank you for taking time to complete this questionnaire. It will help us to 
know how you are getting on since your stroke. 
Please read the following guidelines before beginning. 
Answer all questions. We are well aware that some questions might not seem 
relevant to you personally, but please try to answer them all as best you 
can. 
You should complete the form yourself, however if you are unable to then a 
carer or relative may help you. 
Most questions require you to select your answer from choices given to you 




1. What is today's date?              Click here to enter a date. 
 
 
2. What is your date of birth?   Click here to enter a date. 
 
3. Where do you live? 
Private household alone                     Community hospital 
Private household with others       Private hospital 
Sheltered home                             Long term hospital care  
Residential home                       Other 
Nursing home     Specify: Click here to enter text.                                                  
 
4. What is your current employment status? 
Full time employed (more than 30hrs/wk) 





Unemployed and looking for work 
Retired  
Unable to work due to disability/ill-health 
Carer for home/family/dependents 
 
 
5a. Have you had another stroke in the last year? 
Yes                         No                           I don't know  
5b.Have you been readmitted to hospital since the last follow up? 
Yes                         No  ÆGo to question 6 
 
5c.What was the name of the hospital? 
Click here to enter text. 
 
5d. Were you in hospital because you had had another stroke? 
Yes                         No                           I don't know  
 
6. In the last year have you experienced any of the following symptoms? 
a. New visual problems              Yes No   I don't know 
c. New weakness of arms/legs  Yes No   I don't know 
b. New speech problems           Yes No    I don't know        
 
6d.If yes to any of the above, did you see your GP about the new symptoms? 
Yes                           No 
 
7a. In the last 2 weeks, have you required help from another person for 
everyday activities (such as making a cup of tea)? 
Yes                           No  ÆGo to question 
7b. If yes, who did you receive most help from? 











Other professional care (paid/unpaid) 
Other- Specify: Click here to enter text. 
8. Has a member of your family given up work since the stroke to care for you? 
Yes                           No 
 
9. Are you still in hospital, a nursing home, or a residential home? 
Yes  ÆGo to question 17                  No 
 
10. Do your friends and family help you (at least once a week) with any of the 
following?  
a. Cleaning the house             Yes                  No 
b. Preparing meals                  Yes                  No 
c. Shopping                           Yes                  No 
d. Having a bath or shower     Yes                  No 
 
11. In the last week have you had any meals on wheels? 
How many times? 
Yes                              No 
                     How many times?           . 
 
12. In the last week have you had any home help? 
Yes                              No 








13. In the last week have you attended a day centre? 
Yes                              No 
                            How many times?             . 
                        
14. In the last week have you attended a day hospital? 
Yes                              No 
                            How many times?             . 
                        
15. In the last week have you had a district nurse visit you? 
Yes                              No 
                            How many times?             . 
                        
16. In the last year, have you been admitted to a respite home for a short time 
to give yourself and your carer a rest? 
Yes                           No 
 
17a. Have you had any physiotherapy in the last year? 
Yes                           NoÆGo to question 18    
             
17b. Have you had this therapy in the last month? 
Yes                           NoÆGo to question 18    
 
17c.Where was the therapy received? 
Private      Acute stroke unit  Generic rehab unit 
Geriatric    Acute Medical      Community rehab centre 
ITU/HDU   Neurosurgery       Rehab at home team 
Surgery     Rehab stroke unit Other- 





                               
18a. Have you had any occupational therapy in the last year? 
Yes                           NoÆGo to question 19    
 
 
18b. Do you still have this therapy? 
Yes                           NoÆGo to question 19    
 
18c.Where was the therapy received? 
Private      Acute stroke unit  Generic rehab unit 
Geriatric    Acute Medical      Community rehab centre 
ITU/HDU   Neurosurgery       Rehab at home team 
Surgery     Rehab stroke unit Other- 
                                                  Specify: Click here to enter text. 
 
19a. Have you had any speech or language therapy in the last year? 
Yes                           NoÆGo to question 20  
19b. Do you still have this therapy? 
Yes                           NoÆGo to question 20 
 
19c. Where was the therapy received? 
Private      Acute stroke unit  Generic rehab unit 
Geriatric    Acute Medical      Community rehab centre 
ITU/HDU   Neurosurgery       Rehab at home team 
Surgery     Rehab stroke unit Other- 
                                                     Specify: Click here to enter text. 
                                                                               
20a. Have you seen a GP in the last year? 






20b. Have you seen them in the last month? 
Yes                              No 
                          How many times?              . 
                        
21a. Have you seen a specialist hospital doctor in the last year? 
Yes                           NoÆGo to question 22 
 
 
21b. Have you seen them in the last month? 
Yes                              No 
                         How many times?             . 
                       
22a. Have you seen a specialist nurse in the community in the last year? 
Yes                           NoÆGo to question 23 
 
22b. Have you seen them in the last month? 
Yes                              No 
                          How many times?             . 
                        
 23a. Has your blood pressure been checked in the last year? 
Yes                           NoÆGo to question 24 
 
23b. When was your blood pressure checked? 
Today                In the past week  1week-1month ago 
1-6months ago   6-12months ago 
 
23c. What was the most recent blood pressure? 
Systolic  4   .       Diastolic    .        I don't remember 






24. Do you currently have weakness or paralysis of a complete body side or an 
arm or a leg? 
Yes                         No                         I don't know 
 
25. Do you currently have slurred speech or problems talking to somebody 
because your mouth was unable to articulate words or sentences 
correctly? 
Yes                         No                          I don't know  
 
26. Do you currently have any trouble swallowing? 
Yes                         No                          I don't know  
 
27. Have you been diagnosed with any of the following in the last year? 
Depression          Yes       No         I don't know  
Hypertension       Yes       No         I don't know  
High Cholesterol Yes       No         I don't know  
Diabetes               Yes       No         I don't know  
Atrial fibrillation   Yes      No         I don't know  
(Irregular heartbeat) 
Angina               Yes      No          I don't know  
Peripheral  
vascular disease  Yes     No          I don't know  
(narrowing of arteries in legs)  
Epilepsy                Yes     No          I don't know 
Myocardial  
infarction              Yes      No         I don't know 
(heart attack)                              
                  Was it within the last month? Yes       No 
28. Have tried any of the following in the last year? 
Cutting down on salt              Yes  No    Don’t Need to 





Eating less to lose weight      Yes  No    Don’t Need to 
Exercising to lose weight       Yes  No    Don’t Need to 
Exercising to get fitter           Yes  No   Don’t Need to 
29a.Do you smoke? 
Yes                           NoÆGo to question 29d 
 
29b. If you are a smoker, how much do you smoke a day? 
Cigarettes (number)                              
Tobacco (grams)                                .  
Cigars (number)                                 .  
 
29c.If you are a smoker, have you tried to cut down in the last year? 
Yes                           No 
29d.If you are a non smoker now, are you an ex-smoker? 
Yes                           NoÆGo to question 30 
 
29e.If you are an ex-smoker, have you given up in the last year? 
Yes                           No 
 
30a. Do you drink any alcohol? 
Yes                           NoÆGo to question 31 
30b. How much do you drink a week? 
Beer (pints)                      .   
Wine (glasses)                     I don't drink every week 
Spirits                            .      
 
30c Have you cut down on the amount of alcohol you drink in the last year? 
Yes                  No                    Tried but didn’t 
31. Do you feel that you have made a complete recovery from the stroke? 






32. Have you had any written information about preventing further strokes? 
Yes                  No                    I don't know 
 
33. Have you had any advice from your GP about preventing strokes? 
Yes                  No                    I don't know 
 
34a. Are you currently on any medication, including aspirin? 




34b. Please list all the medications you are currently taking in the spaces 
provided below 
 Name of Drug Dose  How often do you take the 
drug? (Select from 
drop-down options) 
   
   
   
   
 
Please answer yes or no to the following questions about support you receive 
from those around you 
 
Is anyone helping you to complete the questions in this section? 
No, I am answering on my own                  





I am a carer/family/friend answering on his/her behalf 
 
1. If you needed help, do you have anyone (e.g. friends, neighbours, family) 
that you can turn to? 
Yes                           No 
 
2. Do you have somebody (e.g. friends, neighbours, family) who shows that 
they care about you? 
Yes                  No                    I don't have any 
 
3. Do you see as much of your neighbours as you would like? 
Yes                  No                    I don't have any 
 
4. Do you see as much of your relatives as you would like? 
Yes                  No                    I don't have any 
 
5. Do you see as much of your friends as you would like? 








On the following two pages are some questions about your ability to look after 
yourself. They may not all seem to apply to you but please answer them 
all by selecting one option which you feel best describes your situation. 
 
Is anyone helping you to complete the questions in this section? 





Yes, my carer/family/friend is helping me 
I am a carer/family/friend answering on his/her behalf 
 
1. In the bath or shower, do you: 
manage on your own? 
need help getting in and out? 
need other help? 
need to be washed in bed? 
never have a bath or shower? 
 
2. Can you climb stairs at home: 
without anyone's help? 
with someone encouraging you? 
with someone carrying your frame? 
with physical help? 
not at all? 
don't have stairs? 
 
3. Do you get dressed: 
without any help? 
just with help with buttons? 
with someone helping you most of the time? 
 
4. Do you walk indoors: 
without anyone’s help or with a frame? 
with one person watching over you? 
with one person helping you 
with more than one person helping you? 
not at all? 






5. Do you move from bed to chair: 
on your own? 
with a little help from one person? 
with a lot of help from one or more people? 
not at all? 
 
6. Do you eat food: 
without any help? 
with some help(such as cutting food or spreading butter)? 
with more help? 
 
7. Do you use the toilet or commode: 
without anyone's help? 
with some help but can do some things? 
with quite a lot of help? 
 




9. Do you lose control of your bladder? (are you incontinent of urine?): 
never 
less than once a week 
less than once a day 
more often 
or do you have a catheter managed for you? 
 












We are interested in finding out how often you carry out some activities. As 
you will see, the first page is about activities during the last 3 months 
and over the page asks about the last 6 months. 
Please remember to select one box only for each question. 
 
Is anyone helping you to complete the questions in this section? 
No, I am answering on my own                  
Yes, my carer/family/friend are helping me 
I am a carer/family/friend answering on his/her behalf 
 
In the last 3 months how often have you carried out these activities? 
 
1. Preparing main meals (not just a snack) 
Never     Less than once a week     1 or 2 times a week         Most days 
 
2. Washing up (Do all after one meal or share equally with another person) 
Never     Less than once a week     1 or 2 times a week         Most days 
 
Over the last 3 months how often have you carried out these activities? 
 
3. Washing clothes (e.g. loading and unloading washing machine) 
Never     Only once or twice           1 to 4 times a month      At least once a 
week 
 





Never     Only once or twice           1 to 4 times a month      At least once a 
week  
 
5. Heavy housework (e.g. hoovering, or making beds) 
Never     Only once or twice           1 to 4 times a month      At least once a 
week 
 
6. Local shopping 
Never     Only once or twice           1 to 4 times a month      At least once a 
week 
 
7. Social occasions (including going to church) 
Never     Only once or twice           1 to 4 times a month      At least once a 
week 
 
8. Walking outside for over 15 minutes 
Never     Only once or twice           1 to 4 times a month      At least once a 
week 
 
9. Taking part in a hobby activity 
Never     Only once or twice           1 to 4 times a month      At least once a 
week 
 
10. Going on a bus or driving a car 
Never     Only once or twice           1 to 4 times a month      At least once a 
week 
 
In the last 6 months how often have you carried out the following activities? 
 
11. Travel outings or car rides (travel for pleasure, not just for routine trips) 








Never    Light (e.g. occasional weeding) Moderate  
All necessary (Includes heavy digging)   
                                                                                                           
13. Household or car maintenance 
Never    Light (e.g. small repairs)   Moderate (painting)       All necessary  
 
14. Reading books (not just magazines) 
Never      One in 6 months       Less than 1 a fortnight     More than 1 a 
fortnight 
 
15. Paid work 
None       Up to 10hrs a week   10-30hrs a week            More than 30hrs a 
week 
 
The following questions ask for your views about your health, how you feel 
and how well you are able to do your usual activities. 
If you are unsure about how to answer any questions please give the best 
answer you can. Do not spend too much time in answering as your 
immediate response is likely to be the most accurate. 
 
Is anyone helping you to complete the questions in this section? 
No, I am answering on my own                  
Yes, my carer/family/friend are helping me 
I am a carer/family/friend answering on his/her behalf. 
1. In general, would you say your health is: 
Excellent            Very Good             Good         Fair          Poor 
 
2. Health and daily activities. The following questions are about activities you 
might do during a particular day. Does your health limit you in these 






A. Moderate activities (such as moving a table, pushing a vacuum, bowling or 
playing golf) 
Yes, limited a lot              
Yes, limited a little              
No, not limited at all 
 
B. Climbing several flights of stairs 
Yes, limited a lot              
Yes, limited a little              
No, not limited at all 
 
 
3. During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities as a result of your physical 
health? (Please answer Yes or No to each question) 
 
A. Accomplished less than you would like 
Yes                           No 
 
B. Were limited in the kind of work or other activities 
Yes                           No 
 
4. During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities as a result of any emotional 
problems (such as feeling depressed or anxious)? (Please answer Yes 
or No to each question) 
 
A. Accomplished less than you would like 
Yes                           No 
 
B. Didn't do work or activities as carefully as usual 






5. During the past 4 weeks how much did pain interfere with your normal work 
(including work both outside the home and housework)? (Please tick 
one box) 
Not at all       A little bit      Quite a bit      Moderately      Extremely 
 
 
6. These questions are about how you feel and how things have been with you 
during the past month. For each question, please indicate the one 
answer that comes closest to the way you have been feeling. (Please 
tick one box) 
 
How much time during the last month: 
       A. Have you felt calm and peaceful? 
            All of the time 
            Most of the time 
            A good bit of the time 
            Some of the time 
            A little of the time 
            None of the time 
 
B. Did you have a lot of energy? 
            All of the time 
            Most of the time 
            A good bit of the time 
            Some of the time 
            A little of the time 
            None of the time 
 
C. Have you felt downhearted and low? 
            All of the time 





A good bit of the time 
Some of the time 
A little of the time 
None of the time 
 
D. Has your health limited your social activities? 
All of the time 
Most of the time 
A good bit of the time 
Some of the time 
A little of the time 
None of the time 
This questionnaire is designed to help us know how you feel. Please give the 
reply which comes closest to how you have been feeling in the past 
week. Don't take too long over your replies: your immediate reaction to 
each item will probably be more accurate than a long thought out 
response. 
 
Is anyone helping you to complete the questions in this section? 
No, I am answering on my own                  
Yes, my carer/family/friend are helping me 
I am a carer/family/friend answering on his/her behalf 
 
1. I feel tense or 'wound up': 
most of the time      a lot of the time       occasionally           not at all 
 
2. I feel as if I am slowed down: 
nearly all the time    very often               sometimes             not at all 
 
3. I still enjoy the things I used to: 






4. I get a sort of frightened feeling like butterflies in my stomach: 
not at all                    occasionally           quite often            very often 
 
5. I get a sort of frightened feeling as if something awful is about to happen: 
very definitely and quite badly   yes, but not too badly 
a little, but it doesn't worry me   not at all 
 
6. I have lost interest in my appearance: 
definitely                 I don’t take as much care as I should 
I may not take as much care as I should      
I take just as much care as ever 
7. I can laugh and see the funny side of things: 
as much as I always could      definitely not so much now 
not quite so much now            not at all 
8. I feel restless as if I have to be on the move: 
very much indeed         quite a lot         not very much           not at all 
9. Worrying thoughts go through my mind: 
a great deal of the time  a lot of the time   
from time to time            only occasionally 
 
10. I look forward with enjoyment to things: 
as much as I ever did        definitely less than I used to 
rather less than I used to   hardly at all 
 
11. I feel cheerful: 
not at all            not often             
sometimes        most of the time 
 





very often indeed         quite often          
not very often               not at all 
 
13. I can sit at ease and feel relaxed: 
definitely                 usually                 not often                  not at all 
 
14. I can enjoy a good book or radio or TV programme: 






































Identification of all stroke-
related ICD-9 and ICD-10 
codes. 
Review of ONS data sent to 
SLSR from 1995-2011 to 
identify any stroke-related 
death codes. 
Does this individual live with 
the SLSR geographic area? 
          YES  
Is this stroke recurrence 
known already to the SLSR? 
NO 
Did this individual die within 21 
days of first stroke? 
YES 
Review patients medical 
records to ascertain if stroke 
recurrence (as defined by 
SLSR) occurred. 
NO 
Review patients medical 
records to ascertain if stroke 














































Appendix 5. Medication within each category of secondary prevention for analyses in Chapter 6 
  
Secondary prevention treatment variable Medication generic/trade name  


































































































































 APPENDIX 6: Number of cases remaining in studies undertaken as part of this thesis during follow-up 
period, by covariate 
 (1) Dataset used for analyses in Chapter 3 
(i)   0-1 years after first stroke 
(ii)  1-5 years after first stroke  
(iii) 5-10 years after first stroke  
 (2) Dataset used for analyses in Chapters 5 & 6  
(i) 0-1 years after first stroke – all strokes 
(ii) 1-5 years after first stroke – all strokes 
(iii) 5-12 years after first stroke – all strokes 
(iv) 0-1 years after first stroke – ischaemic strokes only  
(v) 1-5 years after first stroke – ischaemic strokes only 





 (3) Dataset used for analyses in Chapter 7 
(i) 0-1 years after first stroke 
(ii) 1-5 years after first stroke 
(iii) 5-10 years after first stroke 




 (1) Dataset used for analyses in Chapter 3 
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 2) Dataset used for analyses in Chapters 5 & 6  
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 (3) Dataset used for analyses in Chapter 7 
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